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Chapter 1 General introduction 
 
1.1 Introduction 
 
As a psychologist in an inpatient substance use disorder (SUD) treatment facility, I 
learned about the often burdened life-stories of many of the patients. Some patients 
had suffered from emotional neglect or physical abuse during childhood, others had 
experienced traumatic events later in life, such as sexual violence, traffic accidents or 
combat related experiences. The writing of one’s life-story was a standard part of the 
treatment program, which gave patients the opportunity to share these experiences with 
their therapy group and therapists.  
To my surprise, these life-stories were often the endpoint as far as the traumatic 
experiences were concerned and assessment of a possible posttraumatic stress disorder 
(PTSD) did not take place. Perhaps, because the possibilities regarding treatment for 
PTSD were very limited, it might have seemed like an unnecessary effort, as follow-up 
treatment could not be offered to the patients. In those cases where the traumatic 
experiences were further examined and PTSD was found to be present, external referral 
for PTSD treatment was the standard procedure. However, it would happen that the 
same patient was referred back to our clinic as PTSD could not be treated elsewhere if 
the patient was still using substances (which was often the case).   
Our clinic has struggled with this issue for some time and it has become even 
more pressing after the “Enschede fireworks disaster” in the year 2000, which affected 
many people. This event shifted the focus of mental health care institutions, including 
Tactus, towards the subject of trauma and PTSD, but it proved to be difficult to address 
the issue properly. For example, the regular interventions (Eye Movement 
Desensitization and Reprocessing) proved not to be as effective, especially in patients 
with complex PTSD. The question arose if there was more that could be done for our 
patients. Did we have the right tools (measures, timing, personnel) to assess PTSD as 
early as possible, did we have an idea about the number of patients who suffer from 
trauma and PTSD, and what did we have to offer them as treatment? To gain better 
insight in the problems related to PTSD in SUD patients and to find better methods to 
detect and possibly treat PTSD, a research project was initiated of which this dissertation 
is the result. 
In the past 20 years, there has been increasing interest in patients with SUD and 
comorbid PTSD. For instance, there is accumulating evidence that suggests a high 
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prevalence of PTSD in SUD patients (P. Brown, Recupero, & Stout, 1995; Driessen et al., 
2008; Gielen, Havermans, Tekelenburg, & Jansen, 2012; Najavits et al., 1998). A 
considerable proportion of SUD patients drop out of treatment (Palmer, Murphy, Piselli, 
& Ball, 2009) or relapse within months, weeks or even days after termination of 
treatment (Moos & Moos, 2006). The presence of PTSD is one of the factors that 
complicates SUD treatment and results in worse treatment outcomes compared to 
either disorder alone (P. Brown, Stout, & Mueller, 1996; Schäfer & Najavits, 2007). This 
may be especially true for complex PTSD (Ford, Hawke, Alessi, Ledgerwood, & Petry, 
2007). Unfortunately, PTSD is often overlooked and the absence of appropriate 
assessment, diagnosis and treatment remains a significant problem.  
The main aims of the dissertation are as follows: 1.To offer descriptive 
characteristics on the prevalence of trauma and PTSD in a sample of SUD inpatients. 2. 
To evaluate several instruments as screening tools for PTSD. 3. To determine the clinical 
added value of a traumatic experiences checklist. 4., To quantify and compare subjective 
suffering due to PTSD and SUD. 5. To describe a protocol for a randomized controlled 
trial (RCT) to study the efficacy of an integrated treatment for SUD and PTSD (“Seeking 
Safety”). In this introductory chapter the different concepts that are important in this 
dissertation are described: SUD, PTSD, comorbidity of SUD and PTSD, screening, 
assessment and treatment of PTSD. The introduction concludes with an overview of the 
studies conducted within the context of this thesis.  
 
1.2 Substance Use Disorders 
 
1.2.1 Background  
The use of psychoactive substances has occurred throughout history. Ancient 
civilizations used substances in the form of plants or extracts for medicinal reasons or 
religious ceremonies (Goodman, Lovejoy, & Sherratt, 2007; R. J. Sullivan & Hagen, 2002; 
Vetulani, 2001). Nowadays, some of these natural substances are still widely available, 
such as alcohol. In addition, an increasing number of synthetic drugs (e.g. 
amphetamines) are also available. Substance use can have some advantages in the 
perception of the person who uses them, such as increased focus, reduced anxiety and 
feelings of euphoria. However, there are also numerous disadvantages, mostly in the 
long term. Eventually, due to a combination of factors, regular substance use can lead 
to a substance use disorder (SUD).  
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Apart from the substance-induced psychiatric disorders, the DSM-IV-TR 
(Diagnostic and Statistical Manual of Mental Disorders) describes two SUDs, 
dependence and abuse. Substance dependence is described as a state in which a 
person is dependent from a substance (tolerance and withdrawal symptoms) and is not 
able or finds it very difficult to cease the substance use even in the presence of severe 
social consequences. Substance abuse, viewed as the less severe variant of substance 
dependence, is particularly related to the social and legal consequences of substance 
use. The differentiation between dependence and abuse has disappeared in the DSM 5, 
mainly because in many cases the criteria for substance abuse were relatively sere 
(being imprisoned for drug-related crimes and alienation from friends and family due to 
substance use) and did not fit well with the profile of an individual with mild substance 
use problems. In addition, factor analyses showed that the criteria of dependence and 
abuse formed one factor (Hasin, Muthuen, Wisnicki, & Grant, 1994) and as a result it will 
be possible to give a dimensional severity rating of addiction on a scale with mild, 
moderate and severe.  
Addiction is a popular term that is often used to describe the concept of 
substance dependence. However, it is generally regarded as a more general term that 
describes the loss of control over substance use or behavior (in the case of sex, 
gambling or shopping addiction) and the intense urge to use the substance (or perform 
the pathological behavior) despite adverse effects, a notion that was described early on 
by Jellinek in 1960 (Jellinek, 1960). It’s a chronic relapsing disorder associated with 
problems on multiple domains (physical, psychological, interpersonal, legal, 
professional). Here, the term SUD will be used to refer to the concept of addiction. 
Exposure to substances is a conditional factor, but insufficient in itself as a cause 
for the development of SUD. Extensive research has shown that SUD is caused by a 
combination of factors: biological (genetics), psychological and social factors (McLellan, 
Lewis, O’Brien, & Kleber, 2000). All of these factors contribute to the transition from 
sporadic recreational use, to intensified (escalated) use to a final state of dependence. 
Biological factors refer to the vulnerability some individuals have of developing a SUD 
based on their genetics and the neurobiological changes associated with the 
development of addiction (Koob, 2006). It is important to note that different stages in 
the development of SUD are associated with different and independent phenotypes 
(Kasanetz et al., 2010). This means that someone may be vulnerable to progress from 
sporadic use to intensified use (from stage I to stage II), but not necessarily from 
intensified use to dependence and loss of control (from stage II to stage III) (Piazza & 
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Deroche-Gamonet, 2013). Besides the genetic vulnerability (Kendler, Jacobson, Prescott, 
& Neale, 2003), social influences (e.g. social values or availability of substances) (Noll, 
Zucker, & Greenberg, 1990) and psychological factors such as impulsivity or negative 
affect (Pardini, Lochman, & Wells, 2004) each has its influence on the stages toward 
dependence.  
 
1.2.2 Prevalence of SUD 
Hasin, Stinson, Ogburn & Grant (2007) estimated the lifetime prevalence of alcohol 
abuse at 17.8% and alcohol dependence at 12.5%. The lifetime prevalence of any SUD 
is estimated at 14.6% (Kessler, Angermeyer, et al., 2005). More recent numbers from 
Substance Abuse and Mental Health Services Administration (2013) show that 9.4% of 
adult Americans (18+) have used an illicit drug in the past month and 56.4% are current 
drinkers of alcohol. 2.7% of the adult population could be diagnosed with a current 
drug use disorder and 7.2% with an alcohol use disorder. The prevalence of SUD is 
generally twice as high in men compared to women (Substance Abuse and Mental 
Health Services Administration, 2013). A review combining several prevalence studies 
estimated the 12-month prevalence of alcohol abuse at 6% in the general adult U.S. 
population and alcohol dependence at approximately 4% (Sussman, Lisha, & Griffiths, 
2011).  
In the Netherlands, the percentages of SUD are comparable, with 19.1% having 
a SUD in their lifetime and 5.6% during the past year (de Graaf, ten Have, & van 
Dorsselaer, 2010). In the European Union, alcohol dependence in the past year is 
estimated to be 3.4% and cannabis dependence at 0.3% for all ages and 1.8% for the 
14-17 age-group (Wittchen et al., 2011). 
In conclusion, substance use disorders affect a large proportion of the 
population, with approximately one in five people in the Netherlands developing SUD in 
their lifetime. Given its chronic and relapsing character, SUD poses a considerable 
challenge for mental health care to reach and aid people with SUD. 
  
1.2.3 Consequences of SUD 
SUD is a cause of severe suffering for substance users, their environment and society. 
For the substance user the consequences can be psychological (e.g. substance induced 
depression), financial, physical (e.g. liver cirrhosis) and/or social. For the environment the 
witnessing of deterioration of a loved one can be very painful and leave one feeling 
helpless. Economic costs of excessive drinking in the US is estimated to be over $223 
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billion dollar each year (Bouchery, Harwood, Sacks, Simon, & Brewer, 2011). In addition, 
illegal drug use results in $193 billion dollars of costs each year (national drug 
intelligence center: www.justice.com/ndic). These costs result from health- and crime-
related costs as well as loss of productivity. Unfortunately there are no recent data for 
the Netherlands, but in 2001, the costs of treatment for AUD, together with losses in 
productivity and traffic accident- and crime-related consequences, were estimated at 
2.6 billion euros annually (KPMG Bureau voor Economische Argumentatie, 2001).  
The overall burden of a disease can also be measured by disability adjusted life 
years (DALY), which is the number of years lost due to ill-health, disability, or early 
death. DALY’s are calculated based on incidence and duration of a specific disorder 
(World Health Organization, 2008). For men in Europe, the biggest contributor to 
disease burden among all mental disorders were alcohol use disorders (82.8 days per 
10,000 inhabitants) and drug use disorders 28.7 per 10,000 (Wittchen et al., 2011). For 
men and women combined the DALY was 48.9 for alcohol use disorders. A recent large 
study with data from 1990 to 2010 calculated 25.6 DALY’s per 10,000 in 2010 for 
alcohol use disorders and 29 per 10,000 DALY’s for drug use disorders, with opioid use 
disorder as the main contributor (13.3 DALY’s per 10,000) (Murray et al., 2012). The 
Global Burden of Disease study uses DALY’s to produce systematic and comprehensive 
estimates of the burden of diseases and injuries. However, there are still major gaps in 
epidemiological data regarding illicit drugs. Degenhardt, Whiteford & Hall (2014) 
reviewed data on the impact of illicit drugs and found that opioid dependence 
accounted for the highest proportion of the total burden. They also concluded that 
estimates of the burden of disease attributable to illicit drugs are most likely to be 
underestimated, for example because the effects of harmful use or abuse were not 
included in the estimates. 
According to the WHO, in 2012 approximately 3.3 million deaths (5.9% of all 
global deaths) were attributable to alcohol consumption (World Health Organization, 
2014). Although SUD has severe consequences for the substance user and his or her 
environment, it has been estimated that only a small proportion receives treatment. 
Approximately 24% (Hasin et al., 2007) to 30% (Substance Abuse and Mental Health 
Services Administration, 2013) of those with alcohol dependence in the U.S. reported 
receiving treatment or counselling. These numbers, in combination with the high 
prevalence of SUD, stress the importance of improving prevention and treatment, 
thereby reducing societal costs as well as individual suffering. 
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1.3 Stress, trauma and posttraumatic stress disorder 
 
1.3.1 Background and definition 
Stress can be described as a reaction to an experience that is emotionally (or physically) 
challenging. It can follow from an event where a sense of control may be lacking or an 
event that is perceived as dangerous. The response to stress originates in the brain, 
more specifically in the amygdala. This structure can activate the hypothalamus-
pituitary-adrenal gland axis (HPA axis), leading to a cascade of the release of several 
hormones, ending with cortisol, which in turn inhibits the release of hormones secreted 
by the hypothalamus and the pituitary. This system is essential for a person’s health as 
well as survival as it enables quick decision making in dangerous situations and prepares 
the body for this reaction (“fight-or-flight” response) (McEwen, 2007). However, acute 
and chronic stress can lead to dysregulation of the HPA axis, as well as alterations in 
other brain systems. For example, acute stress has been linked to working memory 
dysfunction (Qin, Hermans, van Marle, Luo, & Fernández, 2009) and chronic stress 
results in a reduction of prefrontal cortex functioning (top-down control) (Ansell, Rando, 
Tuit, Guarnaccia, & Sinha, 2012) and increase of amygdala functioning (Vyas, Mitra, Rao, 
& Chattarji, 2002). 
The experience of a traumatic event often leads to a stress reaction in the 
victim, which is regarded as a normal reaction to possible life-threatening events in most 
circumstances. What constitutes as a traumatic event, or trauma, has changed over 
time. The difference between a traumatic event and other regular “unpleasant” events, is 
that a traumatic event is paired with threats against the life or integrity of the body, or a 
confrontation with death or violence. In the DSM-IV-TR a definition of a traumatic event 
is given as part of PTSD (criterion A). In previous versions of the DSM (DSM-III and 
DSM-III-TR) a traumatic event was conceptualized as a catastrophic stressor that was 
outside the range of usual human experience and would be distressing to almost 
everyone. In the DSM-IV the focus shifted from the traumatic event itself toward the 
subjective individual responses. The criterion for trauma is defined as an event that 
involves threat (or reality) of death, serious injury, or damage to physical integrity, and 
inspires intense fear, helplessness, or horror. The definition in DSM-5 is exposure to 
death, threatened death, actual or threatened serious injury, or actual or threatened 
sexual violence. In this definition, exposure can be direct (being victim or direct witness) 
or indirect (learning that a close relative was exposed to trauma). 
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 PTSD is a psychiatric disorder that is characterized by re-experiencing of the 
traumatic event, avoidance or emotional numbing and hyperarousal. It was included in 
the DSM in 1980. However, knowledge of the pattern of symptoms and the long-lasting, 
devastating effects of trauma have been known long before 1980 and the DSM-I (1952) 
even described the “gross stress reaction”, a precursor to PTSD that shows many 
similarities with its current definition (Najavits, n.d.). The first structural observations of 
PTSD-like patients occurred during the end of th
e 
19th century and were focused 
around the term “hysteria”. Hysteria was an illness characterized by a great number of 
often unexplainable (somatic) symptoms and was found only in women. The disease 
was thought to be caused by disturbances of the uterus (from the ancient Greek word 
ὑστέρα “hystera”). After some research, Freud among others discovered that hysteria 
was almost always caused by psychological trauma, in most cases childhood sexual 
abuse. The unbearable emotional feelings that accompany the trauma were assumed to 
be the cause of the typical change in consciousness alongside the other observed 
symptoms (Breuer & Freud, 1895). This change in consciousness was what Janet later 
would call “dissociation” (Perry & Laurence, 1984). A few years later, Freud would 
abandon his theory of sexual abuse as a cause for hysteria; he encountered major 
resistance from professional colleagues and it was considered incomprehensible (and 
also unacceptable) that childhood sexual abuse was so widespread (Herman, 1992). 
The period of systematic study of hysteria was thus short-lived, but the theme 
of disorders caused by traumatic events came back into focus during the first World 
War. During this period, symptoms of hysteria were observed in soldiers that returned 
from the battlefield as is described in “Hysterical disorders of warfare” by Yealland 
(Yealland, 1918). Most prominent were the hyperarousal and startle response that was 
cued by loud noises. It was believed that in these patients the disorder was caused by 
the shocking effect of exploding grenades, hence the term “shell shock” (Myers, 2012). 
Although it was recognized at the time that acts of war could have severe psychological 
consequences for individuals, little was done to prevent or treat it, except for attempts 
to heal soldiers just enough so to re-enter the war, something quite common also 
during WW II (Grinker & Spiegel, 1945). During WW I there have even been reports of 
men being executed on grounds of “cowardism”, while it has later been recognized that 
these men most probably suffered from PTSD. It was not until after the war in Vietnam 
that a systematic approach to studying long-term psychological effects of war was 
obtained (Herman, 1992). This tradition has moved forward since then and has led to a 
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clear description of clustered symptoms in response to a traumatic event, thus leading 
to the term posttraumatic stress disorder in the DSM in 1980. 
One of the symptoms of PTSD is the re-experiencing of the traumatic 
experience(s). This often occurs as recurring intrusive and frightening memories, 
nightmares or flash-backs, which can result in an (maladaptive) avoidance strategy 
towards activities, places, feelings or persons that are associated with the trauma. The 
avoidance of emotions can also lead to more general emotional numbing. Finally, 
hyperarousal, a strong startle response and hypervigilance are characteristic of patients 
who suffer from PTSD. 
 
1.3.2 Prevalence of trauma and PTSD 
Traumatic experiences are common in the general population, although numbers vary, 
often as a result of different definitions of what constitutes as a traumatic event and the 
subjective nature of the appraisal of an event. Most studies use criterion A from the 
DSM-IV, which has recently been updated to the DSM-5 and now describes criterion A 
as being exposed to death, threatened death, actual or threatened serious injury, or 
actual or threatened sexual violence by direct exposure, witnessing, indirect exposure, or 
repeated or extreme indirect exposure to aversive details of the event(s). Other authors 
have used some kind of traumatic experiences checklist to determine whether or not 
someone has experienced a traumatic event. These events, however, do not always 
meet the definition of the DSM description of a traumatic event (e.g. neglect). 
Epidemiological data show that 61% of all males and 51% of females report at least one 
lifetime traumatic event (Kessler, Sonnega, Bromet, Hughes, & Nelson, 1995). In a study 
by Breslau et al. (1998) an even higher prevalence rate was found: 89.6% of the sample 
experienced a traumatic event. It should be noted that in that study the definition of 
trauma was broadened to “learning about traumas that happened to others” and 
“sudden death of a close friend or relative”. In a sample of adolescents in Germany a 
prevalence rate of 21.4% was found (Perkonigg, Kessler, Storz, & Wittchen, 2000). The 
authors suggest this difference with prevalence rates in the U.S. is probably caused by 
the relative young age of the sample in Germany and other sociodemographic 
differences. For example, natural disasters, combat and threat with weapons are more 
common in the US. A recent study in the Netherlands showed that 52.5% of the 
population reported at least one lifetime traumatic event (this study included “death of a 
loved one” and “severe illness” as traumatic events) (Bronner, 2009). Another Dutch 
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study, using a list of 36 potential traumatic experiences, found a prevalence of 80.7% 
(de Vries & Olff, 2009). 
A number of epidemiological studies on the prevalence of PTSD in the general 
population have been conducted, most of which reported on the lifetime prevalence of 
PTSD, i.e. at least one episode of PTSD during lifetime. Percentages differ considerably 
among studies, ranging from 1.3% to 12.3% (Davidson, Hughes, Blazer, & George, 
1991; Kessler, Chiu, Demler, Merikangas, & Walters, 2005; Perkonigg et al., 2000; 
Resnick, Kilpatrick, Dansky, Saunders, & Best, 1993). Differences arise due to the use of 
different diagnostic instruments, gender of the population (the prevalence of PTSD is 
approximately two times higher in women compared to men) and country. In the 
Netherlands, the prevalence of PTSD has been estimated in three separate 
epidemiological studies yielding a lifetime prevalence of 7.4% (de Vries & Olff, 2009), 
12-month prevalence of 2.6% (Darves-Bornoz et al., 2008) and current prevalence of 
3.8% (Bronner et al., 2009). 12-month prevalence of PTSD in the European Union was 
estimated at 2.3% (Darves-Bornoz et al., 2008). 
 
1.3.3 Consequences of PTSD 
PTSD is often associated with physical health problems, impaired functioning and a 
general lower quality of life. Significant associations between PTSD and stress-related 
health problems such as arthritis, asthma and ulcers have been found (Lauterbach, Vora, 
& Rakow, 2007; Weisberg et al., 2002), as well as other physical disorders, including 
diabetes, kidney/liver disease, lupus and epilepsy (Lauterbach et al., 2007) and general 
health (Zayfert, Dums, Ferguson, & Hegel, 2002). These results are further supported by 
a recent meta-analysis that demonstrates a large effect size for general health 
symptoms, a moderate effect size for medical conditions and small effect sizes for 
quality of life and gastrointestinal health (Pacella, Hruska, & Delahanty, 2013). Veterans 
with PTSD have a higher risk of impaired functioning (bed days, not working, diminished 
well-being) compared to veterans without PTSD (Zatzick et al., 1997). A rough estimate 
based on a study on work impairment caused by psychiatric disorders (Kessler & Frank, 
1997) is that there is an annual productivity loss of $3 billion dollar in the US as a result 
of PTSD (Brunello et al., 2001). Furthermore, research on quality of life consistently 
shows lower scores on quality of life related measures in persons with PTSD compared 
to persons without (Berger et al., 2007) with an average effect size across studies of 1.46 
(Olatunji, Cisler, & Tolin, 2007). Compared to persons without PTSD, PTSD patients have 
a 40% elevated odds of high school and college failure (Kessler, Foster, Saunders, & 
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Stang, 1995), 30% elevated odds of teenage child-bearing (Kessler et al., 1997) and 60% 
elevated odds of marital instability (Kessler, Walters, & Forthofer, 1998). Suicidal ideation 
is also elevated in PTSD patients (Panagioti, Gooding, & Tarrier, 2009), as well as 
completed suicide (Gradus et al., 2010). Those with PTSD have 5.3 times the suicide rate 
compared with those without PTSD, adjusted for confounders such as gender, age, 
depression and marital status. The DALY for PTSD is estimated at 5.9 per 10,000 
inhabitants in the US (Wittchen et al., 2011) and 5.4 per 10,000 inhabitants in the 
Netherlands (World Health Organization, 2008).  
 
1.4 Comorbidity of SUD and trauma/PTSD 
 
1.4.1 Background and definition 
The term ‘comorbidity’ refers to the concept of two or more distinct clinical entities that 
are present in a patient at the same time (Feinstein, 1970). Although originally only used 
in medical science, the term has become popular in psychiatric epidemiology since the 
1990s, describing the co-occurrence of two or more psychiatric diagnoses in one 
patient (Maj, 2005). The comorbidity between two psychiatric disorders is very common 
as many studies have reported (Kessler, Chiu, et al., 2005; Merikangas et al., 2010). 
However, because of this high prevalence, it has been argued that the theoretical 
concept may be invalid in the case of psychiatric disorders as they may not be two 
distinct entities (Maj, 2005). Clinically, however, the concept is very useful as it allows 
researchers and clinicians to study and discuss the different clinical aspects of 
psychopathology. 
 
1.4.2 Prevalence of comorbid SUD and PTSD 
Epidemiological studies have repeatedly found that persons seeking treatment for PTSD 
often also meet the criteria for a SUD. In the United States, among men who develop 
PTSD, 52% develop alcohol use disorder and 35% develop a drug use disorder. Among 
women, the percentages are 28% and 27% respectively (Kessler, Sonnega, et al., 1995). 
In a study in the Australian general population, 34.4% of the persons with PTSD also had 
a SUD, most commonly alcohol use disorder (24.1%) (Mills, Teesson, Ross, & Peters, 
2006). 
The relationship between SUD and PTSD is also evident in SUD patients. The 
prevalence of PTSD in SUD patients varies between 11% to 61% (P. J. Brown & Wolfe, 
1994; Najavits, Weiss, & Shaw, 1997; Ouimette, Read, & Brown, 2005). This large variety 
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in prevalence numbers is caused by the different populations under study and which 
diagnostic instrument is used. In women, for example, the prevalence rate of PTSD is up 
to four times higher than in men (Deykin & Buka, 1997; Najavits et al., 2003). A current 
episode of PTSD was found in 20.5% of cocaine dependent patients (Najavits et al., 
1998) and in 25% of alcohol use disorder outpatients (Dragan & Lis-Turlejska, 2007). 
Driessen et al. (2008) also studied the differences regarding substances of abuse and 
PTSD. The authors found that the prevalence of comorbid PTSD was 34% in patients 
with both alcohol dependence and drug dependence, 29% in patients with drug 
dependence and 15% in patients with alcohol dependence. Recently, current PTSD has 
been assessed in SUD outpatients during intake procedures in the Netherlands, 
revealing a prevalence of 14.8% (van Dam, Ehring, Vedel, & Emmelkamp, 2010). 
Prevalence studies in inpatient populations generally result in higher percentages of 
comorbid PTSD and SUD compared to outpatient settings. In a clinical sample of SUD 
patients in Great Britain a prevalence rate of 38.5% current and 51.9% lifetime PTSD was 
found (Reynolds et al., 2005). 
 
1.4.3 Associations between SUD and PTSD 
Several explanations have been put forward to explain the high level of co-occurrence 
of PTSD and SUD. One of the explanations is based on the notion that PTSD often 
precedes SUD. In this pathway, the use of substances is a form of self-medication, hence 
the name to describe this theory: the self-medication hypothesis (Khantzian, 1997). For 
example, it was suggested that alcohol, cannabis, opiates and benzodiazepines alleviate 
PTSD symptoms because of their depressant effects on the nervous system, thereby 
diminishing the burden of PTSD symptoms, especially in the re-experiencing and 
hyperarousal clusters. Other substances with an excitant working mechanism may be 
used to counteract symptoms from the avoidance cluster (Brady et al., 2005). 
Unfortunately, these assumptions have not held up based on empirical testing. For 
example, treatment seeking women with alcohol dependence and PTSD evidenced 
significantly greater avoidance and arousal symptoms compared to women with cocaine 
dependence (Back, Sonne, Killeen, Dansky, & Brady, 2003). Also, Sullivan & Holt (2008) 
found no difference between drug users (primarily cannabis and cocaine, SUD not 
assessed) and alcohol users on re-experiencing, more avoidance symptoms in drug 
users compared to alcohol and no difference on the arousal scale.  
A second hypothesis suggests that substance abuse precedes and increases the 
chance of PTSD. Substance abusers often place themselves in dangerous situations to 
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sustain their habit (Cottler, Compton, Mager, Spitznagel, & Janca, 1992) or are 
vulnerable to experiencing trauma due to the direct effects of the substance (e.g. 
incapacitated rape) (Kaysen, Neighbors, Martell, Fossos, & Larimer, 2006). This results in 
a higher number of traumatic experiences which each may lead to PTSD. The 
hypothesis has been partly supported by findings that substance use problems lead to 
an increased risk for assaultive violence exposure, but not overall risk for trauma 
exposure (Haller & Chassin, 2014). Moreover, SUD patients may be at increased risk for 
PTSD after trauma due to neurobiological changes resulting from repeated substance 
use or withdrawal (Stewart & Conrod, 2003) (Chilcoat & Breslau, 1998)and due to poor 
coping strategies and other addiction related problems (Bonin, Norton, Asmundson, 
Dicurzio, & Pidlubney, 2000; Stewart, Conrod, Samoluk, Pihl, & Dongier, 2000). 
A third explanation for the high co-occurrence of PTSD and SUD is that the 
development of both disorders is influenced by shared predispositions. One of these 
predispositions is a shared genetic vulnerability which influences the development of 
both disorders, or it can be another pre-existing factor (e.g. major depression or 
antisocial personality disorder) that might predispose an individual to both PTSD and 
SUD.  
For most people, PTSD precedes substance use (Chilcoat & Breslau, 1998; 
Haller & Chassin, 2014; Mills et al., 2006; Najavits et al., 1997). This is sometimes 
interpreted as supporting the self-medication pathway, although order of onset is not 
the same as a causal pathway. For other people, SUD precedes PTSD or the onset of 
both disorders is more or less simultaneous. As described above, these pathways have 
also shown to be valid. However, many questions remain to be answered, especially 
regarding the influence of neurobiological changes and the overlapping 
neuropathology (Enman, Zhang, & Unterwald, 2014). 
 
1.4.4 Consequences of PTSD and SUD 
An important general notion is that patients with comorbid SUD and PTSD have a more 
severe clinical profile than patients with either disorder alone. For example, patients SUD 
and PTSD report worse physical health (Ouimette, Goodwin, & Brown, 2006), more 
interpersonal problems (Lubman, Allen, Rogers, Cementon, & Bonomo, 2007), earlier 
onset of substance abuse and greater severity of current drug use (Driessen et al., 
2008). Also, they have more comorbid psychopathology, such as mood and anxiety 
disorders (Read, Brown, & Kahler, 2004) and personality disorders (Najavits et al., 1998). 
In contrast to other psychiatric disorders (e.g. generalized anxiety disorder, clinical 
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depression), patients with PTSD may worsen with abstinence from substances (Jacobsen, 
Southwick, & Kosten, 2001) because the use of substances no longer masks the PTSD 
symptoms. In turn, PTSD symptoms (re-experiencing of trauma, hyperarousal) are a 
common trigger for substance use (Ouimette, Coolhart, Funderburk, Wade, & Brown, 
2007), so an increase of symptoms in one can change the symptoms in the other (P. 
Brown, Stout, & Gannon-Rowley, 1998).  
 These characteristics result in a difficult-to-treat population of patients. As a 
consequence, a patient may be withheld from PTSD treatment because clinicians are 
hesitant to start assessment or treatment when current substance use may interfere. 
Patients in SUD treatment are often encouraged to delay any focus on their PTSD 
problems until abstinence has been achieved. Clinicians perceive these patients as more 
difficult to treat than those with either disorder alone (Najavits, 2002a). Even when 
patients reach treatment services, they have difficulty completing treatment, are more 
likely to be readmitted and have a higher use of services (Schäfer & Najavits, 2007). 
 
1.5 Assessment of PTSD 
 
Recognition of the fact that PTSD and SUD are often co-occurring, does not 
automatically mean that both disorders are adequately recognized and diagnosed in 
patients in clinical practice. Research suggests that PTSD is often underdiagnosed in 
SUD patients and when diagnosed, treatment that is focused on these problems is often 
not provided (Kimerling, Trafton, & Nguyen, 2006)(Gielen, Krumeich, Havermans, 
Smeets, & Jansen, 2014). One of the best strategies to increase the detection of SUD 
patients with possible PTSD is by means of screening procedures. Screening is generally 
used to identify patients who may have a particular disease or disorder, even when they 
do not show apparent symptoms. Also, it is often difficult for patients to describe 
specific subjective symptoms spontaneously without being asked. Screening procedures 
can thus be used in an early stage (although it can be beneficial during all stages of 
treatment) to identify disorders and hereby enable early assessment and treatment 
intervention. These procedures are of great value for the field of SUD treatment as PTSD 
is highly prevalent and underdiagnosis of PTSD is a problem. Standard and regular 
screening has shown to be effective in increasing the chance of detecting PTSD in SUD 
patients by four times (Kimerling et al., 2006).  
A number of screening instruments for PTSD have been validated in SUD 
populations, such as the Impact of Events Scale (Weiss & Marmar, 2004), the PTSD 
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Symptom Scale Self-Report (Coffey, Dansky, Falsetti, Saladin, & Brady, 1998), the Penn 
Inventory (Harrington & Newman, 2007) and the Primary Care PTSD screening 
questionnaire (PC-PTSD) (Kimerling et al., 2006). The PC-PTSD is currently the only 
instrument that has been validated in a Dutch population of SUD patients (van Dam et 
al., 2010). A more extensive description of screening instruments is available in Chapter 
2 and Chapter 3. When a patient screens positive, further assessment is needed to 
establish a clinical diagnosis of PTSD and symptom severity. For this purpose, a semi-
structured interview can be used, for example, the PTSD module of the Structured 
Clinical Interview for DSM-IV disorders (SCID-I) (First, Spitzer, Gibbon, & Williams, 2001) 
or the Clinician-Administrated PTSD Scale (CAPS) (Weathers, Keane, & Davidson, 2001). 
Assessment of PTSD in SUD patients is most reliable when a patient has been abstinent 
from substances for several weeks, thus minimizing the effects of withdrawal symptoms 
(Coffey, Schumacher, Brady, & Cotton, 2007). Most of the core symptoms of PTSD 
(recurrent memories, re-experiences and avoidance), however, can also be detected 
when a patient is not yet abstinent from substances. This is an important notion as 
patients frequently drop out of treatment before they have achieved abstinence and 
because integrated treatments for comorbid PTSD and SUD are available (Najavits & 
Hien, 2013; Torchalla, Nosen, Rostam, & Allen, 2012).  
In conclusion, an increasing number of PTSD screening instruments are 
available, but few have been validated in SUD populations and only one in the 
Netherlands. These instruments are important as it is extremely difficult to assess each 
patient for PTSD with an elaborate clinical interview. Therefore, research that focuses on 
finding the best instruments for this purpose are of great importance, from patients’ and 
also economic perspective. 
 
1.6 Perceived suffering from illness  
 
The severity of an illness, or distress, can be expressed in terms of the number and 
severity of the symptoms or associated problems. The goal of treatment is often to 
alleviate distress from illness by means of a decrease in physical or psychological 
symptoms. However, a decrease in symptoms is not always associated with a decrease 
in distress. Distress can also be expressed in terms of perceived suffering. It may 
therefore be important to pay attention to perceived suffering from illness in patients. 
The concept of suffering has often been linked to “quality of life” and that the larger the 
functional impairments, the larger the suffering (Zatzick et al., 1997). It may even be 
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more related to the quality of life of a patient than direct illness-related variables, such 
as disease activity, fatigue or other clinical symptoms (Gladman, Urowitz, Ong, Gough, & 
MacKinnon, 1996). The individual experience of an illness and its perceived impact play 
an important role in addition to clinical symptoms. 
 Although the concept is hard to define, Büchi, Sensky, Sharpe & Timberlake 
(1998) developed a quantitative measure to determine the perceived extent of threat of 
an illness (or symptoms) to a person’s sense of Self, which is a conceptualization of 
suffering (Wittmann, Schnyder, & Stefan, 2012). The measure is called the Pictorial 
Representation of Illness and Self Measure (PRISM). The PRISM is a visual measure that 
assesses the subjective position of one’s illness in relation to the self, which is measured 
in millimeters. The usefulness of this instrument in measuring suffering has been 
demonstrated in different settings and patient populations (Büchi et al., 2002; Reinhardt, 
Bischof, Grothues, John, & Rumpf, 2006; Rumpf, Löntz, & Uesseler, 2004). Because of 
the high prevalence of PTSD in SUD patients, it is interesting to study perceived 
suffering from both disorders and the relation with each other. This could be clinically 
relevant as it may be expected that a patient would want to receive treatment for the 
disorder he or she is suffering from the most. With the PRISM we have a tool to 
compare the severity of PTSD and SUD related problems using the “common currency” 
of suffering. 
 
1.7 Treatment/Seeking Safety 
 
Effective treatments for PTSD are available and evidence-based treatments are 
described in several guidelines (Benedek, Friedman, Zatzick, & Ursano, 2009; Foa, 
Keane, Friedman, & Cohen, 2008). Treatments that are most often used when SUD is 
not present and have been extensively studied in non-SUD samples are exposure 
therapy, Eye Movement Desensitization and Reprocessing (EMDR) and cognitive 
reprocessing therapy. However, the literature on the treatment of comorbid PTSD and 
SUD is more recent. Interventions that have been shown to be effective for PTSD, 
cannot automatically be used successfully in SUD patients with PTSD. In some cases the 
exposure to the traumatic event may exacerbate substance use, induce relapse or lead 
patients to drop out of treatment, or the high-risk environment leads to re-
traumatization. Clinicians and researchers have held different perspectives on the 
sequencing of treatments, where some argue that PTSD should only be treated after a 
period of abstinence, some that PTSD should be treated first, and yet others stating they 
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should be treated simultaneously. The latter is the current consensus (Foa et al., 2008; 
Ouimette & Read, 2013); due to the interconnectedness of both disorders and 
experiences in clinical practice, consensus has been achieved in the notion that both 
disorders should be treated using an integrated approach, i.e., both disorders need to 
be treated simultaneously.  
Research on the effectiveness and efficacy of these integrated treatments have 
progressed gradually over the past decades, but more outcome studies are needed 
(Torchalla et al., 2012). The majority of the studies that have been conducted have 
focused on Seeking Safety. This treatment has been developed by dr. Lisa M. Najavits as 
a flexible, present-focused coping skills model that addresses trauma and substance 
abuse (Najavits, 2002b). It is intended for use across genders, trauma types, substance 
use types, treatment settings and clinicians. Further characteristics of the treatment are 
that it is an integrated, early-stage intervention (focused on stabilization) and is 
designed to restore hope (idealistic approach). The model consists of up to 25 topics, 
divided among four domains: cognitive, behavioral, interpersonal and case 
management. The central goal of Seeking Safety is to help patients attain safety from 
both PTSD and SUD.  
There have been 28 studies so far on Seeking Safety: 18 pilots, 3 controlled 
studies and 7 RCT’s. Most often, these studies were conducted in open-group format 
with different Seeking Safety doses (Najavits & Hien, 2013). The first RCT was published 
in 2004 (Hien, Cohen, Miele, Litt, & Capstick, 2004), which found that both Seeking 
Safety and an active comparison treatment, Relapse Prevention, outperformed TAU (a 
non-randomized control) on both PTSD and substance use variables at end of 
treatment, with gains sustained through 9-month follow-up. An RCT by Najavits, Gallop 
& Weiss (2006) focused on adolescents also found that Seeking Safety outperformed 
the control condition (TAU) on both PTSD and substance use variables with gains 
sustained at 3 month follow-up. An RCT comparing a partial dose of Seeking Safety (12 
sessions) plus sertraline versus Seeking Safety plus pill placebo found positive outcomes 
on both PTSD and SUD, with gains sustained at 1 year follow-up (Hien et al., 2015). In 
an RCT on military veterans comparing Seeking Safety to TAU, Seeking Safety 
outperformed TAU on drug use, active coping, attendance and satisfaction, with both 
Seeking Safety and TAU showing positive outcomes on PTSD and alcohol use (although 
the study was underpowered). An RCT by Hien et al. (2009, 2010) using a partial dose of 
Seeking Safety showed that both Seeking Safety and Women’s Health Education (WHE) 
showed positive outcomes on both PTSD and SUD, but that on a wide variety of 
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secondary analyses, including an analysis on heavy drug users, Seeking Safety 
outperformed WHE on all but one variable. Thus far, Seeking Safety is the only model 
for PTSD/SUD that has outperformed a control on both PTSD and SUD by end of 
treatment (Najavits & Hien, 2013). A recent meta-analyses aimed to evaluate the 
effectiveness of Seeking Safety and found medium effect sizes for decreasing PTSD 
symptoms and modest effect sizes for decreasing substance abuse (Lenz, Henesy, & 
Callender, 2016). 
Seeking Safety has been implemented in other countries and cultures and the 
treatment manual is available in numerous languages. To better serve SUD patients with 
comorbid PTSD, v has been introduced in the Netherlands where the manual was 
translated in 2010. Thus far all studies in other countries have shown positive outcomes 
and strong satisfaction including pilot studies in Germany (Schäfer et al., 2010), Canada 
for both adults (Daoust et al., 2012) and adolescents (Daoust, Najavits, Juéry, Biyong, & 
Krause, 2014), Australia (Barrett et al., 2015); and France (Freyd-Harleaux & Strentz, 
2014). However, they have not used control groups and most did not provide effect 
sizes. In this dissertation an elaborate protocol of a RCT is described. 
 
1.8 Aims, research questions and outline of the thesis 
 
The main aims of this thesis are to examine the prevalence of trauma and PTSD in SUD 
patients in the Netherlands, to determine which PTSD screening instruments have the 
best psychometric properties, whether or not an inventory of traumatic events is of 
added value during screening procedures, to investigate the difference in subjective 
suffering due to PTSD and SUD and to develop a research protocol of an RCT to test 
the efficacy of Seeking Safety. The following table provides an overview of the research 
questions and in which chapter they are discussed: 
 
 
Research question Chapter and procedure 
1) Which traumatic experiences are most 
prevalent and what is the prevalence of 
current and lifetime PTSD in an inpatient 
SUD population? 
 
Using the Clinician-Administered PTSD 
Scale the prevalence of current or lifetime 
PTSD and traumatic experiences were 
assessed in 197 SUD patients in inpatient 
treatment. The results are presented in 
chapter 2. 
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2) Are the Self-Report Inventory for PTSD 
and the MINIplus (PTSD section) reliable 
screening instruments for PTSD? 
 
In chapter 2, two screening instruments 
were tested for their psychometric 
properties in predicting PTSD in a sample 
of 197 SUD inpatients. 
3) Can the Depression, Anxiety and Stress 
Scale (DASS), a non-trauma-related 
measure, be used as a convenient 
screener for PTSD? 
 
Chapter 3 describes how a depression, 
anxiety and stress checklist can be used to 
screen for PTSD, also when it is used 
during intake procedures. 
4) What is the added value of an inventory 
of traumatic events, the Traumatic 
Experiences Checklist, in addition to a 
PTSD screener? 
 
In chapter 4, we examined the added 
value of traumatic experiences checklist in 
an early stage of treatment. A model was 
created to test the influence of 
(characteristics of) traumatic experiences 
on current substance use severity, 
independent of current PTSD (symptoms). 
 
5) What is the difference in subjective 
suffering from SUD and PTSD in SUD-
PTSD patients? 
 
In chapter 5, the main topic is subjective 
suffering from PTSD and SUD and how this 
differs between patients with and without 
PTSD. The concept of suffering was 
quantified using the PRISM, a visual 
measure. 
 
6) How can we study the efficacy of a new 
integrated therapy for SUD and PTSD in 
the Netherlands? 
Chapter 6 describes the design of a 
randomized controlled trial of 108 patients 
to evaluate “Seeking Safety”: an integrated 
treatment for trauma/PTSD and SUD. The 
effects of Seeking Safety on substance use 
and PTSD symptoms will be investigated, 
as well as the cost-effectiveness of Seeking 
Safety compared to an active substance 
use treatment program. 
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In the general discussion, chapter 7, the major findings of this thesis are summarized 
and discussed. The clinical relevance of the results are also discussed, as well as the 
limitations and suggestions for future research.  
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Abstract 
Posttraumatic stress disorder (PTSD) is highly prevalent in substance use 
disorder (SUD) populations. Because resources for extensive and thorough diagnostic 
assessment are often limited, reliable screening instruments for PTSD are needed. The 
aim of the current study was to test two short PTSD measures for diagnostic efficiency in 
predicting PTSD compared to the Clinician-Administered PTSD Scale (CAPS). The 
sample consisted of 197 SUD patients receiving residential substance use treatment who 
completed questionnaires regarding substance use and trauma-related symptoms, all 
abstinent from substance for four weeks. The PTSD section of the Mini International 
Neuropsychiatric Interview plus (MINIplus) and the Self-Report Inventory for PTSD (SRIP) 
are compared to the CAPS. Results showed low sensitivity (.58) and high specificity (.91) 
for the PTSD section of the MINIplus. The SRIP showed high sensitivity (.80) and 
moderately high specificity (.73) at a cut-off score of 48. The prevalence of PTSD as 
measured with the CAPS was 25.4% current and 46.2% lifetime. Results indicate that the 
MINIplus, a short clinical interview, has insufficient quality as a screener for PTSD. The 
SRIP, however, is a reliable instrument in detecting PTSD in a SUD inpatient population 
in the Netherlands. Screening for PTSD is time efficient and increases detection of PTSD 
in SUD treatment settings. 
 
Keywords: Substance use disorder; Substance abuse; Posttraumatic stress disorder; 
Screening; Assessment; Co-morbidity 
 
1. Introduction 
 
Research has yielded important information on the prevalence of posttraumatic stress 
disorder (PTSD) among substance use disorder (SUD) samples. Lifetime prevalence of 
PTSD in the general population ranges from 3.4% in Europe (Darves-Bornoz et al., 
2008) to 6.8% in the United States (Kessler, Chiu, Demler, Merikangas, & Walters, 2005). 
Among treatment-seeking samples of SUD patients, the rate of co-occurring PTSD 
ranges from 11% to 51% current and 33% to 75% lifetime PTSD (Brown, Recupero, & 
Stout, 1995; Najavits, Weiss, & Shaw, 1997). In SUD inpatients, the prevalence rate of 
PTSD ranges from 25% to 51% (Driessen et al., 2008; Kimerling, Trafton, & Nguyen, 
2006; Ouimette, Read, & Brown, 2005; Reynolds et al., 2005). In outpatient settings, 
prevalence rates between 8% and 27% have been found (Clark, Masson, Delucchi, Hall, 
& Sees, 2001; Driessen et al., 2008; Najavits et al., 2003, 2007). Addiction severity in 
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patients with SUD and PTSD is higher than in patients with SUD alone (Driessen et al., 
2008). Furthermore, patients with comorbid SUD and PTSD show worse treatment 
outcomes (Brown & Wolfe, 1994; Hien, Nunes, Levin, & Fraser, 2000). Therefore, 
assessment of PTSD is essential for the purpose of treatment planning and providing 
appropriate care (Brown et al., 1995; Read, Brown, & Kahler, 2004). 
One of the most widely used measures of PTSD is the Clinician-Administered 
PTSD Scale (CAPS) (Blake et al., 1995), a semi-structured interview that is often referred 
to as the “gold standard” measure for PTSD. Unfortunately, this diagnostic tool is 
lengthy (up to 90 minutes) and, moreover, requires substantial training. Many SUD 
programs do not have the staffing nor resources for such a measure. However, 
considering the high prevalence of PTSD in SUD patients and the impact on treatment, 
standard assessment of this disorder may be crucial. For this purpose, screening 
instruments may be a valuable first step in evaluating trauma-related problems in SUD 
populations (Kimerling, Ouimette, et al., 2006) (Najavits, 2004).  
A number of questionnaires have been evaluated as screening measures for 
PTSD in SUD samples. A summary is given in Table 1. Thus far, the PC-PTSD is the only 
instrument that has been validated in the Netherlands (van Dam, Ehring, Vedel, & 
Emmelkamp, 2010), but results are not yet convincing. Changing the original cut-off 
score of the PC-PTSD from 3 to 2 resulted in a high sensitivity (.86), but low specificity 
(.57). The rationale for validating measures in SUD samples when they are already 
validated in samples of the general population is that in general, the cut-off scores for 
screening measures are lower in SUD samples, as can be seen in the PC-PTSD study as 
well as with the PTSD Checklist-Civilian version (PCL-C) and the Penn Inventory. It has 
been suggested too that female substance users minimize PTSD symptoms, which may 
justify a lower cut-off score (Harrington & Newman, 2007). 
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Table 1. Validated screening instruments for PTSD in SUD 
Instrument No. 
items 
Gold standard Sensitivity Specificity Sample 
PTSD Symptom Scale 
Self-Report (Coffey, 
Dansky, Falsetti, Saladin, 
& Brady, 1998) 
 
17 DIS
1
 (modified) 
 
.89 .65 118 SUD in- 
and 
outpatients 
Addiction Severity Index 
(Najavits et al., 1998) 
 Combination of 
THQ
2
 and PCL
3
 
.91 .46 110 cocaine 
dependent 
outpatients 
 
Penn Inventory 
(Harrington & Newman, 
2007) 
26 CAPS
4
 .82 .64 44 inpatient 
substance 
users 
 
Primary Care PTSD 
screening questionnaire 
(Kimerling, Trafton, et 
al., 2006) 
 
4 SCID-I
5
 .91 .80 97 SUD 
veteran 
inpatients 
Primary Care PTSD 
screening questionnaire 
(van Dam et al., 2010) 
4 SCID-I .86 .57 142 Dutch 
SUD patients 
1
DIS = Diagnostic Interview Schedule 
2
THQ = Trauma History Questionnaire 
3
PCL = PTSD Checklist 
4
CAPS = Clinician Administrated PTSD Scale 
5
SCID = Structured Clinical Interview for DSM Disorders 
 
There are two different types of instruments that can be used for screening and 
diagnosis of psychiatric disorders: interviews (structured or semi-structured) and self-
report questionnaires. Each has advantages and disadvantages (Eaton, Neufeld, Chen, & 
Cai, 2000; Wilson & Keane, 2004). In the current study, one short structured interview, 
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the Mini International Psychiatric Interview plus (MINIplus) (Sheehan et al., 1998), and 
one self-report questionnaire, the Self-Report Inventory for PTSD (SRIP) (Hovens et al., 
1994), were tested as PTSD screens. 
The MINIplus is a structured diagnostic interview that is already used regularly 
within SUD programs. The MINI has been proposed as a screening instrument in 
previous research (Black, Arndt, Hale, & Rogerson, 2004) and the PTSD section of the 
MINIplus could be used as a potentially helpful PTSD screen. The MINIplus closely 
follows the DSM criteria and is therefore expected to show good reliability. Furthermore, 
assessment time is short because the measure allows for skip-outs as soon as it is clear 
that the patient does not meet criteria for the disorder, sometimes in just one to two 
questions per disorder. However, there are doubts about the quality of this measure for 
diagnosing psychiatric disorders (Black et al., 2004). The PTSD module of this 
instrument, in particular, may be too brief to be useful. 
The second measure that is tested in this study is the SRIP. The SRIP is an 
assessment tool that has been developed to be used as a screening instrument in the 
Netherlands. It is a self-report questionnaire containing 22 items and takes 
approximately five minutes to complete. Subscores can be obtained for the DSM-IV 
PTSD clusters. The items do not require the patient to name a particular trauma, which 
may be an important advantage for patients who may be hesitant or unable to disclose 
their traumatic experiences. Men, for example, may underreport some traumatic 
experiences, such as sexual or physical abuse, if they perceive these to violate their 
image of masculinity (Lisak, 1994). The scale has been validated in a Swedish sample of 
psychiatric outpatients, treatment seeking and non-treatment seeking traumatized 
veterans,and a Dutch sample of elder people (Al-Saffar, Borgå, & Hällström, 2002; Van 
Zelst et al., 2003). The fact that the measure has already been validated in Dutch makes 
this measure preferable over other international screening instruments for our work. 
However, the scale has not yet been validated in a SUD population. Routine screening 
for PTSD in SUD patients has long been recommended to ensure that SUD patients who 
are suffering from PTSD symptoms are recognized and treated accordingly (Najavits, 
2004). Also for this reason, high sensitivity of an instrument will be preferred over 
specificity, so that patients suffering from PTSD will not be overlooked. 
 In sum, the primary aim of this study was to test the psychometric properties of 
the MINIplus and the SRIP in screening for PTSD in an inpatient SUD population. 
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2. Methods 
 
2.1 Participants 
The study participants were 197 patients admitted to one of four different inpatient 
addiction treatment facilities
1
 in the Netherlands between 2008 and 2011. All 
participants met DSM-IV-TR criteria for SUD. Participants were selected according to the 
following inclusion criteria: 1) current substance use disorder (alcohol or drug abuse or 
dependence) per DSM-IV criteria; and 2) capable of understanding and speaking the 
Dutch language. Exclusion criteria were the following: 1) severe cognitive impairment; 2) 
severe self-destructive behaviour, defined as patients who are known to self-mutilate or 
have suicidal tendencies as assessed during intake; and 3) patients who were considered 
inappropriate to participate according to his or her clinician. Of the 263 eligible patients, 
eight did not meet inclusion criteria, 53 refused to participate and five did not complete 
all the interviews and were therefore excluded from the analyses (Figure 1).  
 
Figure 1. Flowchart of enrolment of participants 
 
                                                 
1
 Tactus Verslavingszorg, Iriszorg, GGZ Noord-midden Limburg, Novadic Kentron 
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2.2 Measures 
Clinician-Administered PTSD Scale. The CAPS (Blake et al., 1995) has been previously 
translated into Dutch and validated by Hovens, Luinge and Van Minnen (Hovens, 
Luinge, & Van Minnen, 2005). It is considered the gold standard for assessing PTSD 
severity. The original CAPS has good psychometric properties and the Dutch translation 
appears to have excellent properties as well, with inter-rater reliability between.92 and 
1.00 and internal consistency of.89 (Hovens et al., 1994; Weathers, Keane, & Davidson, 
2001). The interviewer determines which traumatic events the individual has experienced 
and assesses the 17 symptoms of PTSD in relation to a specific trauma, using DSM-IV-
TR criteria. Each symptom is rated on a 0-4 scale for frequency and intensity (e.g., 
distress or functional impairment). A diagnosis of PTSD is given when a patient meets 
the necessary number of symptoms in criterion B (re-experiencing), C (avoidance) and D 
(increased arousal). In our project, all research assistants received training in 
administration, scoring and interpretation of the CAPS.  
 Mini International Neuropsychiatric Interview Plus. The MINI plus is a brief 
structured interview consisting of questions with ‘yes’ or ‘no’ answers to detect present 
and past DSM-IV-TR and ICD-10 Axis I disorders. It explores 26 disorders and is a more 
detailed version of the MINI (which explores 17 disorders). In the present study, only the 
PTSD section was used. This section assesses current PTSD and starts with criterion A 
(“experienced a traumatic event involving actual or threatened death or serious injury, 
or a threat to the physical integrity of oneself or others”), followed by the DSM-IV-TR 
criteria B, C, D, E and F. Inter-rater reliability analysis for this section revealed a kappa of 
0.95 (Sheehan et al., 1998). It must be noted, that although the original version has 
been validated and found to be a reliable diagnostic instrument (Bohnen, De Winter, & 
Hoencamp, 2011), the Dutch translation of the MINIplus is currently being studied for 
validation purposes (van Vliet & De Beurs, 2007). 
 Self-Report Inventory for PTSD. The SRIP (Hovens, Bramsen, & van der Ploeg, 
2002) is a Dutch self-report questionnaire that was developed to measure PTSD. The 
scale contains 22 items that are rated on frequency on a 4-point scale. The questions 
are divided into three categories based on the DSM criteria, namely re-experience (B), 
avoidance (C) and hyperarousal (D), for which subscores can be obtained. Criterion A is 
not assessed in this measure. The questionnaire takes five minutes to complete, which 
makes it very time-efficient. The internal consistency has been found to be.92. 
Convergent validity has also been tested, comparing the SRIP to the results of the 
Mississippi PTSD Scale (Keane, Caddell, & Taylor, 1988) and the Impact of Events Scale 
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(IES) (Horowitz, Wilner, & Alvarez, 1979). Intercorrelation with the Mississippi PTSD Scale 
was high (.82) and somewhat lower with the IES (.69). The moderate correlation with the 
IES may be explained by the fact that there are no items incorporated in the IES that 
measure hyperarousal. For criterion validity the Dutch version of the CAPS was used, 
which resulted in an optimal cut-off score of 52 and sensitivity and specificity of.86 
and.71, respectively. 
 
2.3 Procedure 
All research assistants were psychologists with a bachelors’ or masters’ degree. 
They visited treatment centres at consecutive points in time to inform all current patients 
about the purpose of the study. The SRIP was administered to all patients in the facility 
during the research period. Subsequently, patients could voluntarily choose to 
participate in the remainder of the study. The filled out SRIP questionnaires of the non-
participating patients were used to compare them with the results of the participating 
patients regarding PTSD related symptoms to control for selection bias. If these patients 
met the inclusion criteria, an appointment was scheduled. A minimum of four weeks of 
abstinence was required before the actual interviewing took place to control for 
withdrawal symptoms. Before the interview, written informed consent was obtained. The 
duration of the assessment was approximately two hours, in which all measures were 
administered. The study has been approved by the local medical ethical committee 
(METC\11270.haa). 
 
2.4 Analyses 
Descriptive statistics were used to describe the sociodemographic characteristics of the 
sample and to determine prevalence of PTSD according to the CAPS. T-tests were used 
to compare the age and the mean scores on the SRIP between the participants and 
non-participants. To compare gender between these two groups, chi-square was 
calculated. Mean scores and standard deviations were calculated for scores on the SRIP 
and CAPS for the total sample. Correlational analyses were used to test the 
psychometric properties of the SRIP and its subscales compared to the CAPS. Finally, for 
the MINIplus and the SRIP, sensitivity, specificity, positive predictive power (PPP), 
negative predictive power (NPP) and overall efficiency were calculated. To determine 
the optimal cut-off score for the SRIP, receiver operator characteristic curve (ROC) 
analyses were conducted.  
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3. Results 
 
Socio-demographic characteristics of the subjects are shown in Table 2. The prevalence 
of PTSD according to the CAPS was 25.4% current and 46.2% lifetime. Comparison of 
participants and non-participants yielded no significant differences for gender, age or 
total score on the SRIP, 46.7 (SD=13.3) versus 46.4 (SD=13.2) respectively, nor on the 
subscales of the SRIP (Table 3).  
 
Table 2. Characteristics of the study population 
Socio-
demographics 
 Total 
sample 
PTSD-
positive 
PTSD-
negative 
(n=197) (n=50) (n=146) 
       
Gender (% male)  75.1 74 75.3 
       
Mean age (sd)  38.7 (12.6) 38.7 (10.7) 38.8 (13.2) 
       
Marital status (%) Married/cohabitating 19 12 21 
  Single 63 64 63 
  Divorced/widowed 18 24 16 
       
Education (%) No education, primary school 7.7 12 6.3 
  Secondary school, lower level 31.4 30 31.2 
 Secondary school, higher level 46.9 44 48.3 
 Postsecondary 13.9 14 14 
      
Substance Alcohol 46.6 45.8 46.9 
 Cocaine/Amphetamines 22.5 27.1 21.0 
 Cannabis 10.5 8.3 11.2 
 Opiates 3.1 2.1 3.5 
 Polysubstance 8.4 10.4 7.7 
 Other 8.9 6.3 9.8 
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The mean CAPS total score for patients that did not meet criteria for PTSD was 
23.4 (SD=17.6) and the mean CAPS total score for those who did meet criteria was 63.8 
(SD=19.3). Mean SRIP score was 46.6 (SD=13.3, range 22-85). Participants who met 
criteria for PTSD according to the CAPS had higher mean scores on the SRIP (59.0, 
SD=12.1) when compared to participants that did not meet the criteria (42.3, SD=10.7), 
t(1,191)=9.151, p<0.001.  
 
Table 3. Comparison of participants and non-participants 
 Participants 
(n=197) 
Non-participants 
(n=58) 
 
Gender (% men) 73.5 81.3 X2=1.235, p=0.35 
Age, mean (SD) 38.7 (12.6) 37.3 (13.5) t(1,234)=0.54 
SRIP total, mean (SD) 46.8 (13.3) 45.7 (14.0) p = 0.58 
SRIP intrusion 11.9 (4.4) 11.4 (5.3) p = 0.48 
SRIP avoidance 19.8 (5.9) 19.0 (5.6) p = 0.39 
SRIP hyperarousal 15.2 (4.6) 15.3 (4.5) p = 0.83 
 
The correlation between the total scores on the CAPS and the SRIP was high 
[r(192)=.69 ( p<.001)]. Correlations for the subscales were moderate to high (Table 4). 
Results from the PTSD section of the MINIplus showed that according to this instrument, 
a total of 42 (21.4%) patients are diagnosed with PTSD. Overall efficiency was relatively 
high with.83, but this was mainly because of the high specificity of.91. The sensitivity 
was.58, meaning that 42% of the patients that were diagnosed with PTSD according to 
the CAPS were missed as such by the MINIplus. 
The standard cut-off score of the SRIP is 52 (Hovens et al., 1994). When 
applying this cut-off score, the sensitivity was.76 and the specificity was.85. Other 
diagnostic efficiency results were evaluated using different cut-off scores. The sensitivity, 
specificity, positive predictive power, negative predictive power and efficiency of the 
SRIP at different cut-off scores are shown in Table 5. ROC-analyses yielded an area 
under the curve (AUC) of.84 and an optimal cut-off score of 48. For this cut-off score, 
sensitivity was.80 and specificity was.73. 
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Table 4. Pearson correlations for subscales of the SRIP and CAPS 
 CAPS intrusion CAPS avoidance CAPS hyperarousal 
SRIP intrusion .647** .460** .485** 
SRIP avoidance .523** .631** .499** 
SRIP hyperarousal .450** .427** .688** 
**significant at a level of p<.001 
 
Table 5. Diagnostic efficiency of the SRIP at different cut-off scores 
SRIP cut-off score Sensitivity Specificity PPP NPP Efficiency 
43 0.90 0.47 0.37 0.93 0.58 
45 0.86 0.61 0.43 0.93 0.67 
47 0.80 0.69 0.48 0.91 0.72 
48 0.80 0.73 0.51 0.91 0.75 
50 0.76 0.78 0.55 0.90 0.78 
52 0.76 0.85 0.63 0.91 0.82 
53 0.72 0.87 0.65 0.90 0.83 
54 0.72 0.88 0.68 0.90 0.84 
55 0.68 0.88 0.67 0.89 0.83 
57 0.64 0.91 0.71 0.88 0.84 
59 0.52 0.92 0.68 0.85 0.81 
SRIP = Self-report Inventory for PTSD 
PPP = Positive Predictive Power 
NPP = Negative Predictive Power 
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Figure 2. Receiver operating characteristic (ROC) curve SRIP prediction score sensitivity and 
specificity estimates against the CAPS.  
  
4. Discussion 
 
The purpose of this study was to test two possible screening instruments to detect PTSD 
in a Dutch sample of SUD inpatients for diagnostic accuracy compared to the CAPS. The 
MINIplus is very successful in excluding false-positives (specificity of.91) but this strict 
screening process results in a high percentage of PTSD-positive patients that are missed 
(sensitivity of.53) and therefore remain undetected. One possibility to increase the 
sensitivity of this instrument is to change the diagnostic scoring rules by making them 
less stringent. A positive score for each of the first three criteria (A, B, C) for example 
yields a sensitivity of.70 and specificity of.87. However, the MINIplus does not reach the 
sensitivity score of the SRIP (.80), and therefore the SRIP is a better screener for PTSD 
positives in an inpatient SUD-population. While information from the MINIplus can be 
used when the measure is administered in addiction treatment settings, this is limited to 
information from the first question only; namely, whether or not the patient has 
experienced a traumatic event. This results in a relatively reliable estimate of patients at 
risk for PTSD. As can be expected, this leads to many patients in the “at risk” group that 
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do not suffer from PTSD. In our sample, 85% of the patients answered “yes” to the 
question about a traumatic event, of which 28.7% had a current episode of PTSD. A 
reliable screening instrument is therefore necessary, and for that purpose, the SRIP 
shows better properties than the MINIplus. 
Correlation between the SRIP and the CAPS showed evidence for convergent 
validity of the scale. Correlations of the three subscales, measuring the three symptom 
clusters of PTSD, were significant. For intrusion the correlation was.65, for avoidance it 
was.63 and for hyperarousal.69. The original proposed cut-off point of 52 yielded a 
sensitivity of.76 and specificity.85. Efficiency of the instrument is higher at higher cut-off 
scores, but this will be at the expense of the sensitivity. Especially in a population where 
PTSD has a great influence on treatment outcome, it can be argued that high sensitivity 
is preferred over high specificity in order to ascertain that a minimal number of cases 
will be overlooked (Baldessarini, Finkelstein, & Arana, 1983). At a cut-off score of 32 the 
screener showed a sensitivity of 1.00, meaning that all PTSD-positives will be detected; 
however, the associated specificity dropped to.19 when using this threshold. This results 
in a large number of false-positives, which leads to a subsequent investment in largely 
unnecessary follow-up diagnostics.  
The lack of assessment of criterion A in the SRIP could potentially pose a 
problem, because it could be expected that the number of false-positives increase if 
criterion A is missed. In total, there were 39 false-positives. A review of the data showed 
that 4 of these patients did not meet criterion A on the CAPS. If these patients would 
have been correctly classified as not meeting current PTSD criteria, for example by 
including a question concerning criterion A in the SRIP, the overall efficiency would 
increase with 1.2%. However, including such a question increases the risk for false-
negatives, as can be seen from the results of the MINIplus. 
It is important to note that screening is only the first step and further 
assessment of PTSD is necessary when screening results for PTSD are positive. For this 
purpose, the CAPS can be used as well as an assessment of trauma history conducted 
by a therapist. However, a careful trade-off should be considered between extra time 
for diagnosing PTSD or extra time for treating patients without PTSD. For example, 
when using the SRIP as a diagnostic tool, of all the patients that test positive for PTSD, 
49 percent will not actually have PTSD (low positive predictive power) and will be 
treated unnecessarily. When a thorough assessment of PTSD can reduce the number of 
patients that are treated unnecessarily, it seems that this would be worth the time 
investment of an hour for assessment using the CAPS. In a sample of 200 subjects, this 
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would mean that 82 will screen positive on the SRIP when using a cut-off score of 48. To 
be certain of the diagnosis for PTSD, all of these patients should be assessed further 
with the CAPS, leading to a subsequent time investment of approximately 82 hours. 
Another option is to offer treatment for all patients that screen positive on the SRIP. 
When treating all these screen-positives, 40 will be treated unnecessarily. The extra 
effort and resources this may cost can be estimated, but are also dependent on which 
treatments are available, as cost and duration may vary between different treatments. 
Note however that when the optimal cut-off score is used, 20 percent of the patients 
that suffer from PTSD will still be missed during the screening procedure. It is therefore 
important to remain alert for signs of PTSD that may emerge later during treatment.  
This study is the first to report the prevalence of PTSD in a SUD inpatient 
population in the Netherlands. The prevalence of 25.4% current and 46.2% lifetime 
PTSD is comparable to the percentages found in previous studies in other European 
countries (Reynolds et al., 2005; Schäfer & Najavits, 2007) and the United States (Brown 
et al., 1995; Jaycox, Ebener, Damesek, & Becker, 2004; Kimerling, Trafton, et al., 2006). 
The high number of patients with comorbid PTSD and SUD indicates the need for 
reliable and valid screening and assessment instruments for PTSD. Our study provides 
valuable information on screening in clinical practice. We advise to use information from 
the MINIplus, only when this is already available, and to use this as a first step in 
determining which patients are at risk for PTSD. For patients that have indicated to have 
experienced a traumatic event on the MINIplus, the SRIP should be used to assess PTSD 
symptoms and to estimate reliably whether or not PTSD is present. When information 
from the MINIplus is not available, the SRIP could be used for all patients. All patients 
that score 48 or above should be assessed further by means of the CAPS to affirm the 
PTSD diagnosis.  
A limitation of this study is that there was a relatively high rate of patients that 
refused to participate. External validity was controlled by means of collecting data from 
these patients as well, but this information was limited to age, gender and PTSD 
symptoms as measured by the SRIP. The participating patients and the patients that 
refused to participate did not differ significantly on these factors. It should be noted, 
however, that other factors that were not measured, such as depression or anxiety, may 
also have influenced the results.  
Another limitation is that the measurements were assessed in an inpatient 
population after a minimum of four weeks abstinence. While this is a good way of 
establishing the theoretical strength of the screening instruments, the practical 
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implications are only valid for this subpopulation of SUD patients. This is relevant 
because a considerable number of the patients in substance use treatment centres often 
drop out within the first three weeks. The average length of stay for patients that drop 
out of residential treatment has been found to be 13.9 days (SD=7.2) (McKellar, Kelly, 
Harris, & Moos, 2006). Ideally, screening should therefore take place as soon as 
possible, especially since effective integrated treatments for comorbid PTSD and SUD 
are becoming increasingly available (Riggs & Foa, 2008). Replication of our findings in 
patients within the first three weeks of treatment should provide insight into the validity 
of the SRIP in that instance.  
This study has focused on a population of inpatients in SUD treatment. This 
limits the generalizability to other populations (e.g. outpatient settings). The cut-off 
score for the SRIP that was found differed from the one proposed in previous research 
in samples of the general population and other psychiatric populations (Hovens et al., 
2002). Replication of the cut-off score of 48 in a comparable population of SUD patients 
in residential settings would strengthen the generalizability of the current findings. 
Furthermore, future research is needed to test the validity of the SRIP in outpatient 
settings. 
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Chapter 3 
 
Screening of current PTSD in substance use disorder patients with the Depression, 
Anxiety and Stress Scale (DASS-21): a reliable and convenient measure. 
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Abstract 
 Background: Several instruments have been developed and validated as 
screens for posttraumatic stress disorder (PTSD) in substance use disorder (SUD) 
patients. Unfortunately, many of these instruments have one or several disadvantages 
(e.g. low specificity, low sensitivity or high costs). No research has been conducted on 
instruments that screen simultaneously for other psychiatric disorders, which would be a 
potentially time-saving and cost-effective approach. In the current study we tested the 
psychometric properties of the Depression Anxiety and Stress Scale (DASS) as a screen 
for PTSD. Methods: The DASS was assessed in an inpatient facility during intake with 58 
patients and again four weeks after admission. Another 138 patients were assessed four 
weeks after admission only. The results were compared to the Clinician-Administered 
PTSD Scale (CAPS) that was also administered after four weeks of abstinence. Results: 
ROC curve analyses showed an area under the curve of 0.84 for the DASS at intake and 
0.78 for the DASS after four weeks abstinence. Conclusion: The DASS is therefore a 
reliable and convenient measure to use as a screen for PTSD in SUD patients.  
 
Key words: Screen - Assessment - Posttraumatic stress disorder - PTSD - Substance Use 
Disorder - Depression Anxiety and Stress Scale (DASS) 
 
1. Introduction 
 
The high rate of co-occurrence of posttraumatic stress disorder (PTSD) with substance 
use disorder (SUD) is well established (Ouimette & Read, 2013). In SUD inpatients, the 
prevalence rate of current PTSD ranges from 25% to 51% (Driessen et al., 2008; 
Kimerling, Trafton, & Nguyen, 2006; Ouimette, Read, & Brown, 2005; Reynolds et al., 
2005). In SUD outpatients, prevalence rates between 8% and 27% have been found (H. 
W. Clark, Masson, Delucchi, Hall, & Sees, 2001; Najavits et al., 2007; van Dam, Ehring, 
Vedel, & Emmelkamp, 2013).  
Although highly prevalent, the detection rate of PTSD in SUD treatment settings 
is low (Kimerling et al., 2006). Assessment of PTSD has long been the domain of general 
mental health care, with SUD treatment professionals reluctant to assess PTSD for fear 
of opening “Pandora’s box”, i.e., evoking intense emotion associated with trauma (Hien, 
Cohen, Miele, Litt, & Capstick, 2004). Additional difficulties in the assessment of PTSD in 
SUD patients include the influence of active substance use or withdrawal on PTSD 
symptoms and patients' hesitance to discuss trauma-related subjects due to shame and 
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guilt (Najavits, 2004). Men, for example, may underreport some traumatic experiences, 
such as sexual or physical abuse, if they perceive these to violate their image of 
masculinity (Lisak, 1994).  
Also, in general, there seems to be a greater focus on co-occurring psychiatric 
diagnoses in SUD patients for which effective pharmacotherapy is available, or in which 
the relationship with SUD is better understood than for PTSD (e.g. major depression) 
(Najavits, 2004). The low level of detection of PTSD and therefore the lack of proper 
treatment has important clinical implications as SUD patients with concurrent PTSD 
show worse treatment outcomes than patients with either disorder alone (P. Brown & 
Wolfe, 1994; Hien, Nunes, Levin, & Fraser, 2000; Najavits et al., 2007), and addiction 
severity in patients with SUD and PTSD is higher than in patients with SUD alone 
(Driessen et al., 2008).  
 Screening instruments have been developed to increase the detection rate of 
PTSD in SUD patients. Examples of these are the Primary Care PTSD questionnaire 
(Kimerling et al., 2006; van Dam, Ehring, Vedel, & Emmelkamp, 2010), the PTSD 
Checklist (PCL) (Blanchard, Jones-Alexander, Buckley, & Forneris, 1996), the Impact of 
Events Scale (Horowitz, Wilner, & Alvarez, 1979), the Trauma Screening Questionnaire 
(TSQ) (Brewin et al., 2002) and the Self-report Inventory PTSD (SRIP) (Hovens et al., 
1994). The choice of which instrument to use can be based on a variety of attributes, for 
example, the psychometric properties, ease of use (such as length of assessment time), 
and the availability in the public domain. Thus far, three screening instruments for PTSD 
have been validated in SUD patients in the Netherlands: the SRIP, the PTSD section of 
the MINIplus and the PC-PTSD. The SRIP and the MINIplus have been validated in an 
inpatient population after a few weeks abstinence. The SRIP showed good psychometric 
properties (Area Under the Curve, AUC, of 0.84; sensitivity of 0.80 and specificity of 0.73) 
(Kok et al., 2012). The MINIplus did not perform well as a screen and showed a 
sensitivity of 0.58 and specificity of 0.91 (Kok et al., 2012). The assessment time of both 
instruments is relatively short: approximately 5 minutes. The SRIP, however, is not 
available in the public domain and each assessment costs money. The PC-PTSD has 
been validated in a Dutch SUD-population during outpatient intake procedures which 
yielded a sensitivity of 0.86 and specificity of 0.58 (van Dam et al., 2010). Furthermore, it 
has recently been altered, leading to better diagnostic efficiency; sensitivity 0.87 and 
specificity 0.75 (van Dam et al., 2013). However, although there are several instruments 
that could be used in clinical practice, reality is that time and resources become more 
and more limited due to budget cuts and reorganizations. Thus, the idea of a screening 
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instrument that is free to use, short in assessment time and can be used to screen for 
more than one disorder is appealing. In the current study we investigated the 
performance of the DASS-21, the screening instrument by default for depression, 
anxiety and stress symptoms in SUD patients in the Netherlands (Lovibond & Lovibond, 
1995b; Schippers, Broekman, Buchholz, Koeter, & van den Brink, 2010).  
Symptoms of PTSD show at least some overlap with depression, anxiety and 
stress (e.g. a diminished sense of the future, conditioned fear of situations, hyperarousal) 
(Borsboom, Cramer, Schmittmann, Epskamp, & Waldorp, 2011). Furthermore, 
depression and anxiety are often part of the symptom profile of complex PTSD (De 
Bellis, 2002; Herman, 1992; Najt, Fusar-Poli, & Brambilla, 2011). Therefore, a quick 
assessment of depression, anxiety and stress symptoms could be a convenient and 
reliable way to assess the risk of PTSD in SUD patients. The DASS is free to use, relatively 
short (21 items) and has good internal consistency, construct validity and criterion 
validity (de Beurs, van Dyck, Marquenie, Lange, & Blonk, 2001; Nieuwenhuijsen, de Boer, 
Verbeek, Blonk, & van Dijk, 2003). In addition, a major advantage is that it can 
simultaneously screen for anxiety and depression. 
 In the current study we tested the psychometric properties of the DASS-21 as a 
screen to determine which patients are at risk for current PTSD in a sample of SUD 
patients during intake procedures and a larger sample of SUD inpatients four weeks 
after their admission. This last group was thus at least four weeks abstinent from 
substances. The DASS was compared with the gold standard measure for PTSD, the 
Clinician-Administrated PTSD Scale (CAPS) (Blake et al., 1995). A second objective was 
to determine whether screening for PTSD at two consecutive time points might increase 
the detection rate of SUD patients with comorbid PTSD.  
 
2. Methods  
 
2.1 Design 
Our objective is to validate the DASS as a screen for PTSD, using both cross-sectional 
and longitudinal approaches. The data are drawn from a larger prevalence study for 
PTSD that addressed the psychometric properties of the SRIP and the MINIplus as PTSD 
screening tools (Kok et al., 2012).  
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2.1 Participants 
The study was conducted from 2008 to 2010, and was approved by the local medical 
ethical committee (METC\11270.haa). Study participants were 263 patients admitted 
consecutively to one of four different inpatient SUD treatment facilities in the 
Netherlands between 2008 and 2011. Inclusion criteria were: 1) current substance use 
disorder per DSM-IV criteria, and 2) capable of speaking Dutch. Exclusion criteria were: 
1) severe cognitive impairment, 2) severe self-destructive behaviour, defined as patients 
that are known to self-mutilate or have suicidal tendencies as assessed during intake, 
and 3) his or her practitioner did not approve the patient's participation. Of the 263 
eligible patients, 8 were excluded based on exclusion criteria, 53 refused to participate 
and 5 did not complete all the interviews and were therefore excluded from the 
analyses. These patients will be referred to as the non-participants (n=66). The DASS 
was also administered at admission in one of the treatment centres. These data were 
collected for the patients in this treatment centre (n=58). 
 
2.2 Measures 
Depression, Anxiety and Stress Scale (DASS-21). The DASS-21 is a 21-item self-report 
questionnaire designed to measure the severity of depression, anxiety and stress 
symptoms. It was derived from the original 42 item DASS (Lovibond & Lovibond, 
1995b). Each subscale consists of 7 items that are scored from 0 (did not apply to me at 
all) to 3 (applied to me very much, or most of the time) for the week preceding the 
interview. The item scores are summed and then multiplied by 2 to obtain total scores 
that can be compared to the original DASS-42 (Lovibond & Lovibond, 1995a). In 
nonclinical samples, the internal consistency, reliability and validity were found to be 
strong (Lovibond & Lovibond, 1995b). The three subscales have been supported by 
factor analysis and internal consistency in a psychiatric clinical group (T. Brown, 
Chorpita, Korotitsch, & Barlow, 1997). Strong support for an underlying model of 
negative emotionality has recently been found in the short version of the DASS in a 
sample of adolescents (Willemsen, Markey, Declercq, & Vanheule, 2011). The Dutch 
version of the DASS has been validated in an occupational health setting, showing high 
internal consistency of the subscales with Cronbach’s alphas of 0.94 (depression), 0.88 
(anxiety) and 0.93 (stress). Construct validity was supported by moderately high 
correlations of the DASS with indices of divergent validity ranging from -0.22 to 0.07 
(Nieuwenhuijsen et al., 2003). It has also been validated in a population of students and 
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psychiatric patients in which support was found for convergent and divergent validity 
(de Beurs et al., 2001).  
Clinician-Administered PTSD Scale. Hovens, Luinge and Van Minnen (Hovens, 
Luinge, & Van Minnen, 2005) translated the CAPS (Blake et al., 1995) into Dutch. It is the 
most widely used and rigorous structured interviews for the diagnosis and severity of 
PTSD. Both the original and the Dutch CAPS have strong psychometric properties, with 
interrater reliability between 0.92 and 1.00 and internal consistency of 0.89 (Hovens et 
al., 1994; Weathers, Keane, & Davidson, 2001). The interview identifies a trauma and 
ratings of the 17 symptoms of PTSD in relation to it (using DSM-IV-TR criteria). Each 
symptom is rated on a 5-point scale for frequency of the symptom’s occurrence and 
intensity (e.g., distress or functional impairment). 
 Self-Report Inventory for PTSD. The SRIP (Hovens, Bramsen, & van der Ploeg, 
2002) is a Dutch self-report questionnaire of PTSD symptoms. Twenty-two items are 
rated on a 4-point frequency scale, with three subscales per the DSM-IV symptom 
clusters re-experiencing (B), avoidance (C) and hyperarousal (D). The internal 
consistency has been found to be 0.92 (Hovens et al., 2002). Convergent validity has 
also been tested, comparing the SRIP to the results of the Mississippi PTSD Scale (Keane, 
Caddell, & Taylor, 1988) and the Impact of Events Scale (IES) (Horowitz et al., 1979). 
Intercorrelation with the Mississippi PTSD Scale was high (0.82) and moderate with the 
IES (0.69). For criterion validity the Dutch version of the CAPS was used, which resulted 
in a recommended cut-off score of 52, and sensitivity and specificity of 0.86 and 0.71, 
respectively, in a psychiatric population (Hovens et al., 2002), and a cut-off score of 48 
in a SUD inpatient population (Kok et al., 2012). 
 
2.3 Procedure 
The study was performed in inpatient settings. Before the interview, written informed 
consent was obtained. All research assistants had a bachelor's or master's degree in 
psychology. For patients, four weeks of abstinence was required before the interview to 
control for withdrawal symptoms. Therefore, the interview took place four weeks after 
admission. The SRIP was administered to all patients in the participating facilities during 
the research period. The SRIP of non-participating patients was used to compare them 
with the study participants to evaluate possible selection bias. The data from the DASS 
that was administered during intake were collected after inclusion.  
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2.4 Analyses 
Chi-square and t-tests were used to compare baseline characteristics between 
participants and non-participants. Descriptive statistics were conducted on 
sociodemographic variables and PTSD prevalence on the CAPS.  
Mean scores and standard deviations were calculated for the DASS and its 
subscales assessed during intake (DASS 1) and four weeks after admission (DASS 2) for 
the 58 participants for whom these data were available. The DASS 2 scores for the 58 
participants were compared to the scores of the other 138 participants that only filled in 
the DASS 2 with a t-test.  
Correlational analyses were then used to evaluate the association between the 
DASS and its subscales with the CAPS. To determine a cut-off score for the DASS, 
receiver operator characteristic (ROC) analyses were conducted for the two different 
time points, i.e. during intake and after four weeks of abstinence with 58 study 
participants. In case there were no significant differences between the 58 participants 
and the other participants at the second time point, a ROC curve was also produced for 
the whole sample at the second time point. Finally, sensitivity, specificity, positive 
predictive power (PPP), negative predictive power (NPP) and overall efficiency were 
calculated for the DASS 1 and DASS 2 for different cut-off points. Sensitivity and 
specificity for the two time-points combined were calculated as follows: If a patient 
screened positive on either time-point, he or she was considered PTSD positive for the 
combined analysis of the two time-points. If a patient screened negative on both time-
points, he or she was considered PTSD negative. High sensitivity will be preferred over 
high specificity, because a positive screening will be followed by assessment with a 
clinical interview.  
 
3. Results 
 
We were able to collect the data for the SRIP from 59 of the 66 non-participants. 
Comparison of participants and non-participants yielded no significant differences on 
gender, age, SRIP total score or its subscales (Table 1). Socio-demographic 
characteristics of the study participants are shown in Table 2. PTSD prevalence per the 
CAPS was 25.4% current and 46.2% lifetime. All patients diagnosed with PTSD had the 
disorder prior to intake and none developed a new PTSD diagnosis between the two 
assessments.  
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Table 1. Comparison of participants and non-participants 
 Participants 
(n=196) 
Non-participants 
(n=59) 
 p 
Gender (% men) 75.1 81.3 X
2
=1.235 0.353 
Age, mean (SD) 38.7 (12.6) 37.3 (13.5) t=0.598 0.551 
SRIP total, mean (SD) 46.8 (13.3) 45.7 (14.0) t=0.540 0.589 
SRIP intrusion 11.9 (4.4) 11.4 (5.3) t=0.697 0.486 
SRIP avoidance 19.8 (5.9) 19.0 (5.6) t=0.882 0.38 
SRIP hyperarousal 15.2 (4.6) 15.3 (4.5) t=-0.208 0.836 
SRIP = Self-report Inventory for PTSD 
 
Table 2. Characteristics of the study population 
Socio-demographics  (n=196) 
    
Gender (% male)  75.1 
    
Mean age (SD)  38.7 (12.6) 
    
Marital status (%) Married/cohabitating 19 
  Single 63 
  Divorced/widowed 18 
    
Education (%) No education, primary school 7.7 
  Secondary school, lower level 31.4 
 Secondary school, higher level 46.9 
 Postsecondary 13.9 
   
Primary substance of 
abuse
1
 (%) Alcohol 46.6 
 Cocaine/Amphetamines 22.5 
 Cannabis 10.5 
 Opiates 3.1 
 Polysubstance 8.4 
 Other 8.9 
1
 Measured by EuropASI 
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Mean scores for the DASS and its subscales for the 58 patients at the two time 
points are presented in Table 3. The scores of these 58 patients compared to the other 
138 patients at the second time point are presented in Table 4. There were no 
significant differences between the two groups.  
 
Table 3. DASS scores at intake (DASS 1) and after 4 weeks abstinence (DASS 2) 
 DASS 1 (n=58) 
Mean (SD) 
DASS 2 (n=58) 
Mean (SD) 
t p 
Total score 53.6 (26.9) 41 (24.6) 3.144 0.003 
Depression subscale 20.3 (11.9) 13.6 (10.6) 3.55 0.001 
Anxiety subscale 13.4 (10.1) 10 (8) 2.476 0.016 
Stress subscale 19.9 (9.6) 17.4 (10.1) 1.581 0.119 
DASS = Depression, Anxiety and Stress Scale 
 
Table 4. Comparison of DASS 2 scores for patients assessed at both time points versus 
those assessed only at time 2  
 DASS 2 (n=58) 
Mean (SD) 
DASS 2 (n=138) 
Mean (SD) 
t p 
Total score 41 (24.6) 41.5 (28.2) 0.125 0.901 
Depression subscale 13.6 (10.6) 12.6 (11.1) 0.576 0.565 
Anxiety subscale 10 (8) 11.1 (9.7) 0.771 0.442 
Stress subscale 17.4 (10.1) 17.9 (10.9) 0.242 0.809 
DASS = Depression, Anxiety and Stress Scale 
 
Correlational analyses showed that the strongest relationship existed between 
the total score for current PTSD symptoms on the CAPS and the total score on DASS 2. 
See Table 5 for all correlations.  
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Table 5. Association between the DASS and CAPS (Pearson’s r) 
 Current PTSD  
symptoms (CAPS) 
DASS 1 total  0.50 (p<0.001) 
DASS 1 depression 0.41 (p=0.001) 
DASS 1 anxiety 0.34 (p=0.009) 
DASS 1 stress  0.54 (p<0.001) 
DASS 2 total 0.55 (p<0.001) 
DASS 2 depression 0.46 (p<0.001) 
DASS 2 anxiety  0.53 (p<0.001) 
DASS 2 stress  0.45 (p<0.001) 
CAPS = Clinician Administered PTSD Scale 
DASS = Depression, Anxiety and Stress Scale 
 
ROC-analyses were calculated for the DASS administered during intake (n=58) 
and four weeks after admission (n=58). This yielded an area under the curve (AUC) of 
0.837 (BI: 0.719 - 0.955) for the DASS during intake, and an AUC of 0.759 (BI: 0.618 - 
0.900) for the DASS after four weeks of abstinence (Figure 1). A third ROC curve for all 
the 196 patients at DASS 2 showed an AUC of 0.793 (BI: 0.708 - 0.878) (Figure 2).  
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Figure 1. Receiver operating characteristic (ROC) curve illustrating the ability of the DASS to 
discriminate patients with PTSD from patients without PTSD. DASS_1 is assessed at intake (n=58), 
DASS_2 is assessed after four weeks abstinence (n=58). 
 
72 
 
 
Figure 2. Receiver operating characteristic (ROC) curve illustrating the ability of the DASS_2 
(n=196) to discriminate patients with PTSD from patients without PTSD.  
 
 Several cut-off scores were tested for the total DASS 1 score using the presence 
of PTSD at the second time-point as a reference (Table 6). The best cut-off score was 
66, with a sensitivity of 0.79 and specificity of 0.78. With this cut-off score the overall 
efficiency was 0.78. The same analyses were performed with the data from the DASS 2. 
A cut-off score of 44 resulted in the highest overall efficiency and the best balance 
between sensitivity (0.80) and specificity (0.70). Of the 58 patients who completed the 
DASS during intake, 14 met the criteria for PTSD. A total of 11 were correctly classified 
as such with the DASS 1. When the score on the DASS 2 was also used two more 
patients were classified correctly. Using both the DASS 1 and DASS 2 to screen for PTSD 
yields a sensitivity of 0.93 and a specificity of 0.71. 
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Table 6. Diagnostic efficiency of the DASS at intake (DASS 1) (n=58) and after four 
weeks of abstinence (DASS 2) (n=138) compared to the CAPS 
 cut-off score Sensitivity Specificity PPP NPP Efficiency 
DASS 1 50 0.93 0.56 0.39 0.96 0.64 
 66 0.79 0.78 0.52 0.92 0.78 
 68 0.71 0.80 0.52 0.9 0.78 
DASS 2 38 0.86 0.61 0.42 0.93 0.67 
 40 0.86 0.65 0.45 0.93 0.70 
 42 0.84 0.68 0.47 0.92 0.72 
 44 0.80 0.70 0.48 0.91 0.73 
 46 0.71 0.72 0.47 0.88 0.72 
CAPS = Clinician Administered PTSD Scale 
DASS = Depression, Anxiety and Stress Scale 
PPP=Positive Predictive Power 
NPP=Negative Predictive Power 
 
4. Discussion 
 
We evaluated the psychometric properties of the DASS as a screen for PTSD in a sample 
of SUD inpatients (n=196, of whom a subsample of 58 completed the DASS at both 
intake and four weeks after admission). Results indicate that the DASS has good 
psychometric properties in screening for PTSD in SUD. The psychometric properties are 
comparable to those of a PTSD screen, the SRIP, that was recently studied (Kok et al., 
2012). The AUC in case of the SRIP (see introduction) was slightly higher than the AUC 
of the DASS. However, the differences between the DASS and the SRIP as screening 
measures for PTSD are very small. 
The DASS that was administered during intake yielded slightly better results 
than the DASS that was administered after a period of abstinence. To obtain these 
results, the cut-off score had to be raised. This means that patients suffer from more 
depression, anxiety and stress symptoms, and also PTSD symptoms during intake. Only 
the difference in stress symptoms did not reach statistical significance (Table 3). As can 
be seen in Figure 1, the AUC for the DASS during intake is larger than the second 
measurement with the DASS. This provides support for the possibility of early detection 
of PTSD, which is important because detoxification and the first steps towards 
abstinence are difficult for patients that suffer from PTSD, as their PTSD symptoms may 
worsen during this period (Jacobsen, Southwick, & Kosten, 2001). Accurate identification 
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of these symptoms as early as possible may help prevent dropout and guide treatment 
planning.  
The DASS has several other advantages compared to the PTSD screens that 
were mentioned in the introduction. First, with the DASS it is also possible to screen for 
depression and anxiety disorders, which makes it a time-efficient and therefore cost-
effective approach. Second, the DASS is in the public domain, so there are no financial 
costs. Third, the DASS is already being used in many treatment facilities in the 
Netherlands and could thus be a convenient measure. 
The DASS 1 was administered at least four weeks before the CAPS was 
assessed, which makes it more difficult to draw firm conclusions about the relation 
between the two measures. It could be argued, for example, that during the time 
between the two measurements, a patient may have developed PTSD. We know this 
was not the case, however, as all patients had developed PTSD prior to intake. 
Therefore we conclude that it is useful to screen for PTSD during intake to determine an 
“at-risk” population. Furthermore, screening again during a later stage increases the 
detection rate of PTSD considerably. We would thus advise to always screen for PTSD 
with the DASS during outpatient intake procedures and, if the score is high (>65), 
consider assessing PTSD with a structured interview. When the score is lower than 66, it 
is suggested to screen again after a few months or when the patient has been abstinent 
for at least four weeks as several false-negatives can subsequently be detected.  
A limitation of this study is that our results regarding the possibility of reliable 
screening during intake were obtained from only 58 patients of the 196 who 
participated in the study. Although we did not find a systematic bias, replication of our 
findings with a larger sample would be a useful next step. Another limitation is that 
other psychiatric disorders in the mood and anxiety domain were not assessed. These 
disorders often co-exist with PTSD and also have some symptom overlap (L. A. Clark & 
Watson, 1991). It would be interesting to study which specific symptoms from the DASS 
differentiate between PTSD, anxiety and stress symptoms related to intoxication and/or 
withdrawal versus symptoms of mood, and anxiety disorders. Hierarchical models of 
anxiety and depression posit that each anxiety disorder can be differentiated from the 
others by one or more specific components (T. Brown, Chorpita, & Barlow, 1998; 
Mineka, Watson, & Clark, 1998) and it has been suggested that intrusions probably 
represent such a specific component for PTSD (Simms, Watson, & Doebbelling, 2002). 
This notion also offers possibilities for improving the DASS as a screening instrument for 
PTSD, for example by adding one or more items relating to intrusion. Although the SRIP 
75 
 
does incorporate items regarding this domain it does not outperform the DASS as a 
screen for PTSD; thus it would be interesting to test an adjusted version of the DASS 
with items related to intrusion. 
   
Conclusion 
 
The DASS-21 can be used as a reliable screen for PTSD during intake and after four 
weeks of abstinence in SUD patients. The best results are obtained when the DASS is 
administered twice: at intake and after a period of abstinence (which in our study was 
one month). Because the DASS is already being used in many facilities in the 
Netherlands, it is a convenient measure. Its potential to screen for depression and 
anxiety disorders, short assessment time, and public-domain availability also make it an 
appealing instrument for clinical and research use.  
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Abstract 
Traumatic experiences have been linked with substance use disorders (SUD) 
and may be an important factor in the perpetuation of SUD, even in the absence of 
posttraumatic stress disorder (PTSD) symptoms. The purpose of the current study was to 
examine the relationship between childhood trauma and substance use severity in 192 
SUD inpatients. Childhood trauma was assessed using the Traumatic Experiences 
Checklist (TEC). With variables derived from this measure in addition to PTSD symptoms, 
two regression models were created with alcohol use or drug use severity as dependent 
variables. Alcohol severity was explained by PTSD symptoms as well as the age of 
trauma. Drug severity was explained solely by PTSD symptoms. The clinical value of 
assessing childhood trauma in determining the addiction severity appears to be limited 
in comparison with PTSD symptoms. 
 
Key words: substance use disorder; childhood trauma; child abuse; assessment; 
posttraumatic stress disorder. 
 
1. Introduction 
 
Substance use disorders (SUD) are responsible for a large burden on society (Office of 
National Drug Control Policy, 2004). This burden is often expressed in financial costs, 
such as those related to hospitalizations, law enforcement, and criminal activities, but 
SUD can also lead to a large psychological burden on substance users and their 
environment (Gossop et al., 1998). Effective treatments for SUD are therefore important. 
The presence of posttraumatic stress disorder (PTSD) is a complicating factor in the 
treatment of SUD, and high rates of comorbidity of the two disorders are well-
documented (Ouimette & Read, 2013). In SUD inpatients, the current prevalence of 
PTSD ranges from 25% to 51% (Driessen et al., 2008; Kimerling, Trafton, & Nguyen, 
2006; Kok et al., 2012; Ouimette, Read, & Brown, 2005; Reynolds et al., 2005). In 
outpatient SUD settings, prevalence rates of current PTSD between 8% and 27% have 
been found (Clark, Masson, Delucchi, Hall, & Sees, 2001; De Bellis, 2002; Driessen et al., 
2008; Graybill, Mackie, & House, 1985; Mills et al., 2006; Najavits et al., 2007; Schneider, 
Baumrind, & Kimerling, 2007). In comparison, epidemiological studies in the general 
population found a lifetime prevalence of PTSD ranging from 1.3% to 12.3% (Davidson, 
Hughes, Blazer, & George, 1991; Kessler, Chiu, Demler, Merikangas, & Walters, 2005; 
Perkonigg, Kessler, Storz, & Wittchen, 2000; Resnick, Kilpatrick, Dansky, Saunders, & 
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Best, 1993). A large proportion of SUD patients experience trauma, but do not develop 
PTSD. It has been estimated that approximately 90% of SUD patients experienced at 
least one lifetime trauma (Farley, Golding, Young, Mulligan, & Minkoff, 2004; Najavits, 
Weiss, & Shaw, 1997; Triffleman, Marmar, Delucchi, & Ronfeldt, 1995). A descriptive 
study compared alcohol dependent patients with non-SUD patients and found that 
trauma was much more prevalent in the alcohol dependent patients (Mirsal, Kalyoncu, 
Pektaş, Tan, & Beyazeyürek, 2004). Moreover, SUD patients experience more severe 
trauma and are traumatized more often than people in the general population (Khoury, 
Tang, Bradley, Cubells, & Ressler, 2010). The impact of trauma on SUD, in the absence 
of PTSD, is inconsistent. Some studies show that exposure to trauma increases the risk of 
SUD (Kilpatrick, Saunders, & Smith, 2003; Sartor et al., 2007). Also, SUD patients with 
more severe histories of trauma seem more prone to substance use relapse (Hyman et 
al., 2008; Westermeyer, Wahmanholm, & Thuras, 2001) and show worse treatment 
outcomes compared to patients with less severe trauma (Brown & Wolfe, 1994; Hien, 
Nunes, Levin, & Fraser, 2000). However, a longitudinal study by Chilcoat and Breslau 
(1998) showed that exposure to trauma in the absence of PTSD did not increase the risk 
of SUD.  
Given the potential importance of trauma and PTSD on SUD treatment, it is 
important to have reliable screenings instruments. Integrated treatments, for example, 
that focus on SUD, trauma-related symptoms and preventing re-traumatization have 
been shown to produce positive outcomes in both PTSD and SUD symptoms (Cocozza 
et al., 2005; Gil-rivas, Prause, & Grella, 2009; Hien, Cohen, Miele, Litt, & Capstick, 2004; 
Najavits & Hien, 2013; Najavits, Schmitz, Gotthardt, & Weiss, 2005; Zlotnick, Najavits, 
Rohsenow, & Johnson, 2003). An issue of clinical importance is “how” and “when” to 
assess the trauma characteristics. Some suggest that information about trauma is 
necessary for treatment planning with few adverse events when asking about trauma 
(Larsen & Berenbaum, 2014; McHugo et al., 2005). However, others mention ethical 
considerations and adverse reactions that may play a role when asking about trauma 
too early (Newman & Kaloupek, 2009). Patients may be unwilling to disclose traumatic 
experiences at the beginning of treatment, because they do not trust the interviewer, 
feel ashamed, or are afraid of experiencing intense emotions associated with their 
memories (Lisak, 1994). Screening for PTSD can still be done using a brief self-report 
inventory for PTSD symptoms in which trauma is not assessed (Kok et al., 2012). 
Alternatively, a trauma inventory may be used or added to assess trauma characteristics 
in addition to PTSD symptoms.  
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  Thus, the aim of the current study was to determine the value of a childhood 
trauma inventory in addition to a self-report inventory of PTSD symptoms in relation to 
substance use severity. We hypothesize that both PTSD symptom severity and trauma 
play a role in substance use severity in SUD patients. 
 
2. Methods 
 
2.1 Participants 
The study was conducted from 2008 to 2010 and was approved by the local medical 
ethical committee (METC\11270.haa). Participants were 192 SUD inpatients in the 
Netherlands selected for the following inclusion criteria: 1) admitted to inpatient SUD 
treatment; and 2) capable of speaking Dutch. Exclusion criteria were: 1) severe cognitive 
impairment; 2) severe self-destructive behaviour, defined as patients that are known to 
self-mutilate or have suicidal tendencies as assessed during intake; and 3) his or her 
practitioner did not approve the patient's participation. Of the 263 eligible patients, 8 
did not meet the inclusion criteria, 53 refused to participate and 10 did not complete all 
assessments and were therefore excluded from the analyses. All participants were 
Caucasian. 
 
2.2 Measures 
 
2.2.1 Traumatic Experiences Checklist 
The Traumatic Experiences Checklist (TEC) is a self-report questionnaire, developed in 
the Netherlands to collect information on 29 potentially traumatic experiences, asked as: 
“Did this happen to you?”. For “yes” responses, additional questions are the age(s) the 
event happened and the degree of psychological stress it caused (scale 1-5, where 
1=not at all, 2=only slightly, 3=moderately, 4=severely and 5=extremely traumatized). 
The total number of traumas ("yes" answers) ranges from 0-29, and separate counts can 
be obtained for emotional, physical and sexual traumas (Dom, De Wilde, Hulstijn, & 
Sabbe, 2007). Age of first trauma is identified by the earliest trauma with a score of at 
least 3 on the 1-5 scale. The TEC has been validated in a sample of 153 psychiatric 
outpatients, including satisfactory internal consistency, test-retest reliability and criterion 
validity (Nijenhuis, Van der Hart, & Kruger, 2002). 
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2.2.2 Clinician-Administered PTSD Scale 
Hovens, Luinge and Van Minnen (Hovens, Luinge, & Van Minnen, 2005) translated the 
CAPS (Blake et al., 1995) into Dutch. It is the most widely used and rigorous structured 
interview for the diagnosis and severity of PTSD. Both the original and the Dutch CAPS 
have strong psychometric properties, with interrater reliability between 0.92 and 1.00 
and internal consistency of 0.89 (Hovens et al., 1994; Weathers, Keane, & Davidson, 
2001). The interview identifies a trauma and ratings of the 17 symptoms of PTSD in 
relation to it (using DSM-IV-TR criteria). Each symptom is rated on a 5-point scale for 
frequency of the symptom’s occurrence and intensity (e.g., distress or functional 
impairment).  
 
2.2.3 European Addiction Severity Index (EuropASI)  
The EuropASI is the European adaptation of the fifth edition of the Addiction Severity 
Index (McLellan et al., 1992). It covers seven problem areas (medical, employment, 
alcohol, drug, legal, psychiatric, family and social) that are commonly affected by SUD. 
For the current study, only the drug and alcohol domains were used. A composite score 
(range 0 ‘not severe, no intervention necessary’ to 1 ‘very severe, intervention 
necessary) is obtained for each domain to indicate the level of severity. This score is 
based on the number days of each substance used in the past month, number of days 
the person experienced problems in the past month related to substance use, and the 
importance of treatment for substance use. Composite scores for the EuropASI are 
computed with a strategy similar to the one used in the ASI.  
 
2.2.4 Self-Report Inventory for PTSD 
The SRIP (Hovens, Bramsen, & van der Ploeg, 2002) is a Dutch self-report questionnaire 
of PTSD symptoms. Twenty-two items are rated on a 4-point frequency scale, with three 
subscales per the DSM-IV symptom clusters re-experiencing (B), avoidance (C) and 
hyperarousal (D). The internal consistency has been found to be 0.92 (Hovens et al., 
2002). Convergent validity has also been tested, comparing the SRIP to the results of the 
Mississippi PTSD Scale (Keane, Caddell, & Taylor, 1988) and the Impact of Events Scale 
(IES) (Horowitz, Wilner, & Alvarez, 1979). Intercorrelation with the Mississippi PTSD Scale 
was high (0.82) and moderate with the IES (0.69). For criterion validity the Dutch version 
of the CAPS was used, which resulted in a recommended cut-off score of 52, and 
sensitivity and specificity of 0.86 and 0.71, respectively, in a psychiatric population 
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(Hovens et al., 2002), and a cut-off score of 48 in a SUD inpatient population (Kok et al., 
2012). 
 
2.3 Procedure 
All research assistants had a bachelor's or master's degree in psychology. The SRIP was 
administered to all patients in the participating facilities during the research period. The 
SRIP of non-participating patients was used to compare them with the study participants 
to evaluate possible selection bias. Four weeks of abstinence was required for the 
participating patients before the other measures were administered in order to avoid 
potential influence of withdrawal symptoms. 
 
2.4 Analyses 
We calculated descriptive statistics on all variables. Patients without trauma were 
excluded from the remaining analyses. Two-tailed Pearson’s correlations were used to 
evaluate the association between substance use severity and trauma-related variables: 
number of traumas, age of traumas, type of traumas (TEC), presence of PTSD (CAPS), 
and severity of PTSD symptoms (SRIP) (Dragan & Lis-Turlejska, 2007). We used 
regression analyses to predict substance use severity, with PTSD symptoms as a 
predictor variable. After that, other trauma variables that showed a univariate correlation 
at p < 0.15 with either alcohol or drug- severity were entered one by one into the 
multivariate model. When the increase in explained variance was less than 10% for any 
variable, that variable was not included in the model. Two models were created: one for 
alcohol severity and one for drug severity. In each model, only patients that experienced 
at least some alcohol or drug severity were used in the analyses. This means that 
patients with a composite score of ‘0’ were excluded. Gender has also been described 
as a risk factor in the development of SUD in response to a trauma. Results, however, 
are contradictory and some researchers find a higher risk for men (Danielson et al., 
2009) and some a higher risk for women (Becker & Grilo, 2006). Therefore, gender will 
also be included in the regression models when there is a correlation with substance use 
severity of p < 0.15. 
 
3. Results 
3.1 Sample characteristics 
Characteristics of the sample are presented in Table 1. 37% of the sample had an 
alcohol use disorder, 30% had a drug use disorder and 33% was considered to have 
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both. For patients with at least some alcohol-related problems (not necessarily a SUD) 
(n=151), the mean alcohol severity on the EuropASI was 0.24 (SD=0.14). For patients 
with at least some drug-related problems (n=123), the mean drug severity 0.14 
(SD=0.07). 
 
Table 1. Sample characteristics of the total sample. Data are presented  
as Mean (SD) or percentages 
 Total sample (n=192) 
Age 38.6 (12.6) 
Gender (% men) 75 
Education (%)  
 No education/ primary school 6.9 
 Secondary school (lower level) 30.9 
 Secondary school (higher level) 47.9 
 Postsecondary 14.4 
Relationship status (%)  
 Single 63 
 Married/cohabiting 19 
 Divorced/widowed 18 
Country of birth (%)  
 Netherlands 96.4 
 Other 3.6 
Primary substance of abuse (%)  
 Alcohol 46.4 
 Cocaine 18.2 
 Cannabis 10.4 
 Amphetamines 4.2 
 Heroine 3.1 
 Multiple substances 13 
 Other 4.7 
Age at onset of substance use 23.6 (10.9) 
 
Overall, 95.8% of patients reported at least one trauma. See Table 2 (patients 
without trauma were excluded from the analyses) for TEC results. In the sample, 88 of 
the 192 patients (45.8%) met lifetime criteria for PTSD, and 25% met criteria for current 
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PTSD. Index trauma for current PTSD were life-threatening disease, human suffering and 
sudden death of family member or close friend (34%), sexual violence (26%), severe 
accident (18%), physical violence (16%) and other (6%).  
 
Table 2. Trauma variables derived from the TEC. Data are presented  
as Mean (SD) or (percentage) 
 Total sample 
(n=184) 
Age earliest traumatic event, yrs 11.3 (8.6) 
Total number of traumatic events 6.5 (4.2) 
Category of traumatic event  
 Emotional abuse 84 (43.8%) 
 Physical abuse 110 (57.3%) 
 Sexual abuse 52 (27.1%) 
 
3.2 Correlational analyses 
See Table 3 for correlations between trauma-related variables and substance use 
severity (among patients with at least one trauma). PTSD diagnosis and PTSD symptoms 
correlated with both alcohol and drug severity. Correlations with p < 0.15 were found 
between earliest age of trauma and alcohol severity, physical abuse and alcohol severity, 
and total number of traumas and drug severity.  
 
Table 3. Pearson’s R correlations for the EuropASI severity scores for alcohol and drugs, 
and trauma-related variables from the TEC, the CAPS and the SRIP. p-values are 
provided between brackets. 
 ASI Alcohol 
(n=144) 
ASI Drugs 
(n=120) 
Current PTSD (CAPS: dichotomous) 0.232* (0.005) 0.198* (0.031) 
PTSD-symptoms (SRIP) 0.327** (<0.001) 0.362** (<0.001) 
Age earliest trauma  0.163 (0.056) 0.035 (0.707) 
Emotional abuse 0.031 (0.717) 0.014 (0.88) 
Physical abuse -0.141 (0.103) 0.074 (0.440) 
Sexual harassment 0.036 (0.684) 0.097 (0.313) 
Sexual abuse -0.039 (0.657) 0.084 (0.384) 
Total number traumatic events 0.060 (0.462) 0.164 (0.069) 
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Gender -0.016 (0.82) 0.015 (0.83) 
 
3.3 Multivariate model for alcohol use severity 
In our model to predict alcohol severity, PTSD symptoms explained 10.7% of the 
variance (R
2
=0.107, p < 0.001). When the age-of-trauma variable was added, the 
explained variance increased to 14.2% (R
2
=0.142, p < 0.001). However, the addition of 
the physical abuse variable did not improve the model more than 10% and did not 
contribute significantly to the model (p = 0.10) and thus was not included in the final 
model (Table 4). 
 
Table 4. Multiple regression analysis predicting alcohol severity 
Factor β p R2 F change p 
Alcohol Severity (n=151)   0.142 10.91 <0.001 
Current PTSD-symptoms 0.328 <0.001    
Age earliest trauma  0.214 0.09    
 
3.4 Multivariate model for drug use severity 
PTSD symptoms explained a significant proportion of variance in drug use severity, 
R
2
=0.131, F(1,116)=17.395, p < 0.001. The number of traumas-variable contributed less 
than 10% and did not contribute significantly to the model. Thus the best model for 
drug use severity consisted of just one variable: current PTSD symptoms (Table 5). 
 
Table 5. Multiple regression analysis predicting drug severity 
Factor β p R2 F change p 
Drug Severity (n=123)   0.131 17.39 <0.001 
Current PTSD-symptoms 0.362 <0.001    
 
4. Discussion 
 
This study focused on the added value of assessing trauma in addition to the 
assessment of PTSD symptoms when the goal is to evaluate the impact on alcohol and 
drug severity in SUD patients. The results show that PTSD symptoms measured with the 
SRIP explained the highest proportion of variance in substance use severity and trauma 
related variables do not provide much additional information. For alcohol severity, age 
of trauma was significant, such that patients traumatized at a younger age experience 
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more severe alcohol use problems. Previous research has found mixed results, but there 
are indications that when traumatization occurs early during childhood, the chance of 
developing psychiatric disorders is larger than when they occur later in life (Lubit, 
Rovine, Defrancisci, & Spencer, 2003).  
Previous research has found that the number of lifetime SUDs was predicted by 
lifetime traumas and current PTSD symptoms, with an explained variance of 39% 
(Triffleman et al., 1995). The trauma variable in that study (total score on Trauma 
Antecedents Questionnaire) accounted for 12% of the variance, independent of PTSD. 
Although the dependent variable in the current study differs, we were unable to find 
comparable results with substance use severity as dependent variable. Interestingly, in 
the same study (Triffleman et al., 1995), the authors found null results for trauma 
variables as predictors of drug severity, as we also found. This is of clinical importance, 
because it means that there seems to be no need to obtain an inventory of childhood 
trauma per se during intake and that the assessment of current PTSD symptoms is 
sufficient to determine the relation between trauma-related variables and the severity of 
SUD, which may indicate a need for an integrated treatment for such patients. 
Assessment of current PTSD symptoms does require identification of a trauma that 
serves as the basis for such symptoms, but does not require the identification of all 
lifetime traumas. The disadvantages of lengthy lifetime trauma inventories should thus 
be taken into account, such as the extra time investment and possible increased stress 
for the patient. 
Strengths of the study include the large sample size and the use of valid 
instruments. However, this is a cross-sectional study and no conclusions can be drawn 
regarding causality. There are other limitations that should be noted. First, the 
retrospective nature of the data that were collected. Linking memories of events to 
symptoms in the present inevitably leads to bias (Bernard, Killworth, Kronenfeld, & Sailer, 
1984). Second, although the use of self-report measures is generally considered a 
reliable source of information concerning sensitive topics such as abuse and other 
traumas, there are several disadvantages, e.g. over-reporting (Eaton, Neufeld, Chen, & 
Cai, 2000; Wilson & Keane, 2004). Using both self-report measures and clinician 
administrated interviews, we tried to minimize these effects. A third limitation is that we 
used only one substance-related measure (substance use severity), which is not 
necessarily related to other clinically relevant variables such as dropout or relapse. 
Fourth, due to the fact that the study population consisted only of SUD patients, it was 
impossible to draw conclusions about the influence of childhood trauma on the 
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development of a SUD per se. Also, we cannot rule out the possible influence of 
multicollinearity and lack of power, although we did not find any evidence in that 
direction. Finally, it should also be noted that the data were collected from a population 
of inpatients. Typically, these patients present with high psychiatric comorbidity and 
secondary problems. Thus, the results cannot be generalized to other SUD populations.  
In conclusion, trauma is highly prevalent in this SUD inpatient population. In 
SUD patients the earliest age of trauma appears to be related to the current severity of 
alcohol use but not drug severity. We conclude that traumas play a marginal role in 
predicting current substance use severity. Current PTSD symptoms, measured with the 
SRIP, were predictive of both alcohol and drug severity in our models. Thus, such a brief 
questionnaire is both more efficient and more likely to yield clinically important 
information for treatment planning compared to an (added) inventory for trauma.  
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Abstract 
Objective: In a sample of people with substance use disorder (SUD) who had 
experienced psychological trauma, this study aimed to quantify differences in perceived 
suffering due to addiction related problems and to trauma related problems. Methods: 
The sample comprised 146 inpatients with SUD. 25% had posttraumatic stress disorder 
(PTSD), 21% had subthreshold PTSD; the remainder constituted the trauma-only group. 
PTSD, SUD, and suffering were assessed using validated instruments. Suffering was 
measured using the Pictorial Representation of Illness and Self Measure (PRISM). Results: 
No differences were found between the PTSD, subthreshold PTSD and trauma-only 
group in the suffering attributed to addiction related problems. Those in the PTSD 
group appraised their suffering due to trauma related problems as greater than the 
other groups. In the PTSD group but not the subthreshold PTSD group, suffering due to 
trauma related problems was appraised as greater than that due to addiction related 
problems. Conclusions: This is the first study to demonstrate quantitative comparisons 
between different health problems using the ‘common currency’ of suffering. Our results 
indicate that even among those on an inpatient SUD treatment program, comorbid 
PTSD may be more personally salient and cause greater suffering, with implications for 
therapeutic interventions available on SUD treatment programs.  
 
Key words: PRISM; substance use disorder; comorbidity; PTSD; illness perception; 
suffering 
 
1. Introduction 
  
Patients with substance use disorder (SUD) often have a history of traumatic 
experiences. The lifetime prevalence of traumatic experiences in patients with SUD is 
high compared to the general population. Percentages of up to 95% have been found 
(Farley, Golding, Young, Mulligan, & Minkoff, 2004; Mills, Teesson, Ross, & Peters, 2006; 
Najavits, Weiss, & Shaw, 1997; Triffleman, Marmar, Delucchi, & Ronfeldt, 1995), whereas 
in the general population percentages vary around 70% (Darves-Bornoz et al., 2008; 
Elliott, 1997; Resnick, Kilpatrick, Dansky, Saunders, & Best, 1993). Sometimes the 
experience of a traumatic event can result in a posttraumatic stress disorder (PTSD). The 
risk of developing PTSD after a traumatic event ranges from 6% in traffic accidents to 
21% in assault victims (Chapman et al., 2012; Kessler, Sonnega, Bromet, Hughes, & 
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Nelson, 1995). The prevalence of current PTSD in patients with SUD is highly dependent 
on the population under study, but is estimated to be approximately 25% (Kimerling, 
Trafton, & Nguyen, 2006; Kok et al., 2013; Najavits et al., 2007; Ouimette, Read, & 
Brown, 2005). Research indicates that SUD and PTSD are related to each other (Brown & 
Wolfe, 1994; Najavits et al., 1997). Patients with PTSD often self-medicate their PTSD 
symptoms with substances and patients with SUD have a higher risk of experiencing a 
traumatic event because of their unsafe environment and behaviours (Khantzian, 1997). 
Furthermore, the severity of PTSD symptoms is correlated with alcohol use problems 
(Shipherd, Stafford, & Tanner, 2005; Stewart, Conrod, Pihl, & Dongier, 1999) and drug 
use (Clark, Masson, Delucchi, Hall, & Sees, 2001; Ullman, Relyea, Peter-hagene, & 
Vasquez, 2013), such that higher current PTSD symptoms and the presence of PTSD is 
associated with higher substance use severity.  
The severity of SUD or PTSD is usually expressed in terms of the number of 
symptoms or associated problems. Patients with comorbid SUD and PTSD have a more 
severe clinical profile than patients with either disorder alone. For example, patients SUD 
and PTSD report worse physical health (Ouimette, Goodwin, & Brown, 2006), more 
interpersonal problems (Lubman, Allen, Rogers, Cementon, & Bonomo, 2007), earlier 
onset of substance abuse and more severe current drug use (Driessen et al., 2008). Also, 
they have more comorbid psychopathology, such as mood and anxiety disorders (Read, 
Brown, & Kahler, 2004) and personality disorders (Najavits et al., 1998). However, this 
reveals little about the person’s subjective illness experience. Quality of life measures can 
give information relevant to the impact of illness or symptoms on the person, but these 
often show only a weak correlation with ‘disease’ variables. In the presence of 
comorbidities, even generic quality of life instruments are difficult to interpret, because it 
is impossible to attribute impairments in quality of life to one or the other of the 
comorbid conditions. Thus neither symptom inventories nor quality of life measures can 
be expected to discriminate different aspects of the illness experience of a person. 
Psychological and emotional factors mediate the experience of an illness, including the 
perceived impact of the disease. Understanding the patient’s appraisal of his or her 
illness, and attributions about different aspects of the illness experience, is important in 
negotiating suitable foci for treatment and thereby reducing the risks of early dropout 
(Büchi, Straub, & Schwager, 2010; Sensky, 1990).  
A different approach is to consider different aspects of the illness experience in 
terms of the suffering they cause the person. In his seminal conceptualisation, Cassell 
defined suffering as “the perceived extent of threat of an illness or symptoms to a 
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person’s sense of self”(Cassell, 1982). According to this conceptualisation, suffering is 
expected to be influenced by factors such as the intrusiveness of the symptoms, their 
controllability, and the distress they cause the individual. Büchi et al (Büchi, Sensky, 
Sharpe, & Timberlake, 1998) developed a novel measure called the Pictorial 
Representation of Illness and Self Measure (PRISM). This is an essentially visual task in 
which patients are asked to map the place of their illness in their present life, in relation 
to their ‘Self’. In validation studies, the PRISM performed exactly as expected of a 
measure of suffering according to Cassell’s conceptualisation, with diverse clinical 
conditions, including rheumatological disorders, pulmonary disorders, and alcohol use 
disorder (Sensky & Büchi, 2016). A systematic review (Krikorian, Limonero, & Corey, 
2013) concluded that PRISM is a valid measure of suffering in palliative care settings. In 
a study by Wittmann et al. ( 2012) the PRISM has been validated as a measure of 
trauma-related suffering and the authors found that the instrument could be used to 
discriminate between patients with full, subthreshold and no PTSD diagnosis. In this 
study, PRISM was also found to be sensitive to change, showing predicted changes 
during the course of treatment. 
In the present study, we aimed to examine whether the findings of Wittmann et 
al. ( 2012) could be replicated, to demonstrate that perceived suffering is greater among 
patients with posttraumatic stress symptoms warranting the diagnosis of PTSD than 
among those with subthreshold PTSD (who have symptoms but do not warrant a 
diagnosis of PTSD). A further aim was to compare suffering due to addiction related 
problems and due to the experience(s) of trauma related problems in a sample of 
inpatients with SUD.  
 
 
2. Methods 
 
2.1 Procedure 
The data presented in this paper were collected as part of a larger cross-sectional study, 
aimed at describing the prevalence of PTSD in patients with SUD and validating 
screening instruments for PTSD (Kok et al., 2013). The study was performed in an 
inpatient setting. The Self-Report Inventory for PTSD (SRIP) (Hovens, Bramsen, & van 
der Ploeg, 2002) was administered to all patients in the participating facilities during the 
research period. The SRIP of patients that refused to participate in this study was used to 
compare them with the study participants to evaluate possible selection bias. Before the 
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interview, in which the other measures were administered, written informed consent was 
obtained. The assessment took place after a minimum of four weeks abstinence to 
control for withdrawal symptoms. The interviews were conducted by psychologists with 
a bachelor’s or master’s degree and trained in the study procedure and clinical 
interviews. The study has been approved by the local medical ethical committee 
(METC\11270.haa). 
 
2.2 Participants 
Eligible participants were 263 patients admitted consecutively to one of four different 
inpatient SUD treatment facilities in the Netherlands between 2008 and 2011. 
Participants were selected according to the following inclusion criteria: 1) current alcohol 
or drug dependence or abuse diagnosis as determined by the DSM-IV criteria and 2) 
capable of understanding and speaking the Dutch language. Exclusion criteria were: 1) 
severe cognitive impairment, 2) severe self-destructive behaviour, defined as patients 
that are known to self-mutilate or have active suicidal tendencies as assessed during 
intake, and 3) patient is considered incapable of participating by his or her clinician. Of 
the 263 eligible participants, 2 were known to have suicidal tendencies and 6 were 
considered incapable of participating because of problems adjusting to the clinical 
setting after admission. Another 53 patients refused to participate and 5 did not 
complete all the interviews and were therefore excluded. Reasons for refusal were most 
often insufficient time or lack of interest to participate. The PRISM was added to the test 
battery after the inclusion of 44 study participants. Of the final 153 participants, 7 did 
not experience a traumatic event, leaving 146 participants for the final analyses. 
 
2.3 Measures 
Pictorial Representation of Illness and Self Measure (PRISM). In the PRISM task, modified 
from Büchi et al (Büchi et al., 1998), patients were shown a rectangular paper sheet, 7.2 
cm wide and 6 cm high, with a circle in one corner of the rectangle. Patients were told 
that the rectangle represents their life and the circle represents the “Self”. They were 
then asked to draw an “x” to represent where their illness was in relation to their ‘Self’ in 
their life (see Appendix for the exact instructions). A systematic review of previous 
research using PRISM has indicated that the distance between the centre of the Self 
circle and the illness “x” (the Self-Illness Separation) is inversely correlated with the 
severity of the person’s suffering, meaning that the lower the score (recorded in 
millimetres), the higher the perceived suffering (Sensky & Büchi, 2016). Test-retest 
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reliability of the PRISM is high with r=0.95. Convergent and divergent validity have been 
established for three patient groups (Büchi et al., 2002). A systematic review of 52 
published studies reporting data using PRISM showed that PRISM has yielded consistent 
results in a wide variety of settings, and concluded that PRISM works as a visual 
metaphor, eliciting information that is personally salient for each patient (Sensky & 
Büchi, 2016). Consistent with Cassell’s conceptualisation of suffering, Self-Illness 
Separation is inversely correlated with the extent to which the individual appraises the 
illness (or symptoms being assessed) as intrusive or uncontrollable. In the current study 
we presented the patients with two separate PRISM tasks. In the first task, patients were 
instructed that ‘x’ represented their addiction related problems, yielding Self-Illness 
Separation for addiction related problems (this will be described as Self-Addiction 
Seperation). In the second task, ‘x’ represented patients’ trauma related problems, 
yielding Self-Illness-Separation for trauma related problems (this will be described as 
Self-Trauma Seperation).  
Clinician-Administered PTSD Scale. The CAPS (Blake et al., 1995) was translated 
into Dutch and validated by Hovens, Luinge and Van Minnen (Hovens, Luinge, & Van 
Minnen, 2005). It is the most widely used and most elaborate structured interview for 
detecting and investigating the severity of PTSD. The original CAPS has good 
psychometric properties and the Dutch translation appears to have excellent properties 
as well, with interrater reliability between.92 and 1.00 (Cohen’s kappa) and internal 
consistency of.89 (Hovens et al., 1994; Weathers, Keane, & Davidson, 2001). The 
interview determines which traumatic events the individual has experienced and the 17 
symptoms of PTSD according to the DSM-IV-TR. Every symptom is rated on frequency 
and intensity on a 5-point scale (ranging from 0 to 4). A diagnosis of PTSD is given 
when a patient meets the DSM-IV-TR criteria by having the necessary number of 
symptoms in Criterion B (re-experiencing), C (avoidance) and D (increased arousal). 
Each symptom is assessed using two questions: one measuring frequency of the 
symptom’s occurrence, and the other, its intensity (e.g., distress or functional 
impairment). Assessment time is approximately 60 minutes. All research assistants 
received training in administration, scoring and interpretation of the CAPS.  
Traumatic Experiences Checklist (TEC). The TEC is a questionnaire that has been 
developed in the Netherlands to collect information about traumatic experiences. It has 
been validated among a sample of 153 psychiatric outpatients (Nijenhuis, Hart, & 
Kruger, 2002). The TEC is a self-report questionnaire that inquires about 29 types of 
potentially traumatic events. For the purpose of the current study the TEC is used to 
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confirm that the participant had experienced a traumatic event in the past. A traumatic 
event is defined as the experience of an event that was significantly disturbing to the 
person. 
 Composite International Diagnostic Interview - Substance Abuse Module (CIDI-
SAM). The CIDI-SAM is a structured interview that was used to determine the presence 
of a substance use disorder for each substance during the past year. It has been found 
to have good to excellent interrater reliability (Cottler et al., 1991) and test-retest 
reliability. 
European Addiction Severity Index (EuropASI) The EuropASI (Kokkevi & 
Hartgers, 1995) is the European adaptation of the fifth edition of the Addiction Severity 
Index (McLellan et al., 1992). It covers seven problem areas (medical, employment, 
alcohol, drug, legal, psychiatric, family and social) that are commonly affected by SUD. 
For the current study the EuropASI was used to determine the primary substance of 
abuse. 
 
2.4 Analyses 
Descriptive statistics were used to describe the sociodemographic characteristics of the 
participating sample, the trauma exposure and characteristics, and to determine 
prevalence of current PTSD (including subthreshold PTSD). The diagnostic criteria for 
subthreshold PTSD proposed in the literature differ considerably. We have chosen to 
adapt a method that is used most often in the literature, defined as meeting the 
symptom criteria of DSM-IV for the re-experiencing cluster and for either the avoidance 
cluster or the hyperarousal cluster (Blanchard, Hickling, Taylor, Loos, & Gerardi, 1994). 
Mean scores and standard deviations were calculated for the two Self-Illness Separation 
scores from the PRISM and compared between the three groups (PTSD, subthreshold 
PTSD, psychotrauma only) using ANOVA with Bonferroni post-hoc analysis. Finally, a 
paired samples t-test was used for each of the three groups to determine the difference 
between the Self-Illness Separation for trauma related problems and the Self-Illness 
Separation for addiction related problems.  
 
3. Results 
 
3.1 Background variables 
Socio-demographic characteristics of the study participants are shown in Table 1. 
Comparison of participants and non-participants yielded no significant differences 
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regarding gender, age, SRIP total score or its subscales. The prevalence of PTSD 
according to the CAPS was 24.7%. Subthreshold PTSD was found in 20.5% of the 
participants and 54.8% experienced psychotrauma but did not develop PTSD even at 
the subthreshold level.  
 
Table 1. Characteristics of the study population 
Sociodemographics  (n=146) 
    
Gender (% male)  76.5 
    
Mean age (sd)  37.1 (12.1) 
    
Marital status (%) Married/cohabitating 22 
  Single 64 
  Divorced/widowed 14 
    
Education (%) No education, primary school 8.6 
  Secondary school, lower level 31.6 
 Secondary school, higher level 44.7 
 Postsecondary 15.1 
   
Primary substance of 
abuse
1
 (%) Alcohol 44.5 
 Cocaine/Amphetamines 26.7 
 Cannabis 12.3 
 Opiates 2.1 
 Polysubstance 9.5 
 Other 4.8 
1
 Measured by EuropASI 
 
3.2 Between group comparisons of addiction and trauma related problems 
There were significant differences between the three groups on Self-Trauma Separation 
(Figure 1). Bonferoni post-hoc analyses for the Self-Trauma Separation indicated that 
the score for the PTSD group (M=13.9, SD=11.2) was significantly lower than the 
trauma-only group (M=41.7, SD=27.9) (p<0.001), and the score for the subthreshold 
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group (M=24.4, SD=20.9) was also significantly lower than the trauma-only group 
(p=0.003). The differences between the three groups on addiction related problems did 
not reach statistical significance.  
 
 
Figure 1. Mean scores and confidence intervals for the Self-illness Separations (SIS) on the two 
PRISM tasks, compared between the three trauma groups with ANOVA. Y-axis represents mm. 
ARP = Addiction Related Problems, TRP = Trauma Related Problems. 
 
3.3 Within group comparisons of addiction and trauma related problems 
The correlations between the two Self-Illness Separation scores were significant but low 
(highest pearson’s r=0.3). In the PTSD group the mean Self-Illness Separation for 
addiction related problems was 24.0 (SD=22.7) and the Self-Illness Separation for 
trauma related problems for addiction related problems was 13.9 (SD=11.2). A paired 
samples t-test revealed that this difference reached statistical significance with 
t(1,35)=3.185, p=0.003. In the subthreshold PTSD group the difference between the 
Self-Illness Separation for addiction related problems, 21.2 (SD=22.7),and the Self-Illness 
Separation for trauma related problems, 24.4 (SD=20.9), was not significant, 
t(1,31)=0.375, p=0.71. In the trauma-only group the Self-Illness Separation was 
significantly smaller for addiction related problems compared to trauma related 
problems, 29.7 (24.6) versus 41.7 (27.9) respectively, t(1,71)=-3.1, p<0.003. There were 
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no significant differences in any of the Self-Illness Separation scores by gender, 
education, age and family (data not shown). 
4. Discussion 
This study is the first to examine the experiences of patients with SUD who have also 
experienced trauma from the perspective of their suffering, rather than focusing on 
psychological symptoms or generic measures of quality of life. Strengths of the study 
include the large sample size and the use of well validated measures. However, the fact 
that all those recruited to the study came from an inpatient treatment centre for people 
with SUD raises questions regarding the generalizability of the results. 
The study confirmed previous reports that comorbid PTSD (including also 
subthreshold PTSD) is widely prevalent among patients with SUD. Also, the high rate of 
traumatic experiences in this population is in line with previous research (Jaycox, Ebener, 
Damesek, & Becker, 2004; Triffleman et al., 1995). As expected, perceived suffering due 
to trauma-related problems was highest in the PTSD group, and lowest in the group 
which failed to meet even sub-threshold PTSD. This is consistent with the results of 
Wittmann and colleagues ( 2012) in that perceived suffering due to trauma was greatest 
in the PTSD group and least in the trauma-only group.  
In our sample, those with PTSD considered that this caused greater suffering 
than did their addiction related problems. The greater suffering attributed to trauma 
related problems compared with addiction related problems was present only in the 
PTSD group, and not shown by the sub-threshold PTSD group. Among patients with 
PTSD symptoms (but without comorbid SUD), Zlotnick et al. (2002) found that social and 
work impairment was similar in those with full or subthreshold PTSD, supporting the 
clinical value of the concept of subthreshold PTSD. However, the desire for treatment 
was significantly greater in the patients with full PTSD compared with the subthreshold 
group. Our results support a distinction between these two groups regarding perceived 
suffering.  
In terms of their perceived suffering due to addiction related problems 
(measured as the inverse of Self-Trauma Separation), patients with PTSD or 
subthreshold PTSD did not differ from those who had experienced trauma but had no 
PTSD symptoms. Although this is surprising in light of the extensive research showing 
that the occurrence of PTSD related symptoms was associated with drug and alcohol 
abuse severity (Clark et al., 2001; Stewart et al., 1999), this is perhaps another example 
of the difference between measures based on clinical/epidemiological symptoms 
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(number of SUDs, years of substance use) and variables that are based on perceived 
suffering from illness such as the PRISM. 
Our results have potentially important implications for treatment. The findings 
that PTSD is widely prevalent among patients with substance use disorders, and that a 
subgroup of patients (those with PTSD) attribute greater suffering to trauma than to 
their SUD suggests that interventions for PTSD should be available in SUD treatment 
programs. Our results indicate that patients with SUD who also have PTSD appraise the 
latter as causing greater suffering than the former. It may be that they regard alleviation 
of the PTSD symptoms as more pressing than managing their SUD, but at any rate, 
clinicians should be aware of the potential different appraisals of SUD and PTSD when 
negotiating a treatment plan. Moreover, because patients with these comorbidities are 
generally more vulnerable to stress than those without comorbid PTSD (McLaughlin, 
Conron, Koenen, & Gilman, 2010), they may also be more vulnerable to other stressors. 
Such vulnerability may manifest itself in stressful situations associated with treatment, 
such as inpatient admission or detoxification. Especially this subgroup may benefit from 
trauma-focused interventions while in SUD treatment. Several evidence-based 
treatments for co-occurring PTSD and SUD have become available over the past years. 
Most treatments show positive results in pilot studies and also in randomised controlled 
studies, although often the control condition improved similar on various outcomes 
(Najavits & Hien, 2013). In spite of positive results, the translation to clinical use is not 
always clear. One important issue is that almost all of the treatments that are studied in 
controlled trials suffer from high dropout rates (Roberts, Roberts, Jones, & Bisson, 2016). 
In our study we have addressed at least one potential target to reduce drop-out from 
treatment, but it would be necessary to study the effect of measuring suffering on drop-
out in future research.  
A major strength of using the PRISM in this study is that, because diverse 
conditions can be measured in terms of the suffering that the individual attributes to 
them, these conditions are therefore open to comparison in the extent of the suffering 
attributed to them. In our study, we compared patients’ appraisals of suffering due to 
substance misuse and that attributed to posttraumatic stress. Such a direct comparison 
is of course impossible using symptom inventories, and generic measures, of quality of 
life for example, are probably too insensitive to yield meaningful differences in this 
context, and cannot discriminate between effects due to comorbidities. Previous work 
has highlighted the use of PRISM with individual patients to discriminate between 
different symptoms or problems (Büchi & Sensky, 1999). However, to our knowledge, 
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this is the first study to use PRISM to measure a quantitative comparison between 
different symptoms among groups of patients.  
Suffering, as measured by the PRISM, gives a measure of the person’s appraisal 
of the intrusiveness and lack of controllability of the condition(s) being assessed. This is 
probably more relevant to the person’s perceived need for intervention or support than 
the number of symptoms experienced, or their duration. Our results indicate that it may 
not be appropriate to assume that people who engage with inpatient SUD programs 
would choose their substance use as the main focus of intervention. Shared decision-
making, in which patient and clinical team systematically collaborate to set treatment 
priorities and goals, has shown to improve treatment results (Joosten, De Jong, De 
Weert-Van Oene, Sensky, & Van Der Staak, 2009). Pilot work (Büchi et al., 2010) has 
provided preliminary support for the use of PRISM to support shared decision-making 
and to measure progress towards agreed treatment goals. To further evaluate the utility 
of the PRISM it needs to be included in future treatment evaluation studies to assess 
how the PRISM scores change during interventions on SUD and PTSD and whether 
these changes match the scores on PTSD and SUD symptom questionnaires. 
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Appendix 
Instructions for the first PRISM (addiction related problems):  
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We would like you to imagine that your addiction is your “weak spot”. Take a look at the 
rectangle below and imagine that this is your current life and you are the circle in the 
bottom right-hand corner. Please mark with an “x” where in the rectangle you would 
place your addiction. For example, if you would place the “x” close to the circle, this 
would indicate that your addiction is currently very present in your life. 
 
Instructions for the second PRISM (trauma related problems): 
Now imagine that your trauma-related problem is your “weak spot”. Take a look at the 
rectangle below and imagine that this is your current life and you are the circle in the 
bottom right-hand corner. Please mark with an “x” where in the rectangle you would 
place your trauma-related problem. For example, if you would place the “x” close to the 
circle, this would indicate that your trauma-related problem is currently very present in 
your life. 
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Abstract 
Background: Traumatic experiences and, more specifically, posttraumatic stress disorder 
(PTSD) are highly prevalent among substance use disorder (SUD) patients. This 
comorbidity is associated with worse treatment outcomes in substance use treatment 
programs and more crisis interventions. International guidelines advise an integrated 
approach to the treatment of trauma related problems and SUD. Seeking Safety is an 
integrated treatment program that was developed in the United States. The aim of the 
current study is to test the efficacy of this program in the Netherlands in an outpatient 
SUD population. 
Methods/Design: A randomized controlled trial (RCT) will be used to test the efficacy of 
Seeking Safety compared to Cognitive Behavioral Therapy (CBT) in a population of SUD 
outpatients. Each treatment will consist of 12 group sessions. The primary outcome 
measure will be substance use severity. Secondary outcome measures are PTSD and 
trauma symptoms, coping skills, functioning, and cognitions.Questionnaires will be 
administered at the start of treatment, at the end of treatment (three months after the 
start of treatment) and at follow-up (six months after the start of treatment). 
Discussion: This study protocol presents a RCT in which the efficacy of an integrated 
treatment for comorbid PTSD and SUD, Seeking Safety, is evaluated in a SUD outpatient 
population compared to CBT. It is expected that the intervention group will show 
significantly more improvement in substance use severity compared to the control 
group at end-of-treatment and at follow-up. Furthermore, a lower drop-out rate is 
expected for the intervention group. If the intervention proves to be effective, it can be 
implemented. A cost-effectiveness analysis will be conducted to evaluate the two 
treatments.  
Trial registration: The protocol for this study is registered with the Netherlands Trial 
Register with number NTR3084 and approved by the local medical ethical committee 
(METC\11270.haa). 
 
Keywords: Seeking Safety; Randomized Controlled Trial; CBT; Substance use; PTSD; 
Comorbidity 
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Background 
 
A history of traumatic experiences is very common among substance use disorder (SUD) 
patients, with estimates ranging from 55% - 99% (Driessen et al., 2008; Najavits, 
Gastfriend, et al., 1998). Furthermore, high rates of posttraumatic stress disorder (PTSD) 
have been found among SUD patients. The rate of drug and/or alcohol dependence in 
veteran populations varies from 40% to 75% (Kasprow & Rosenheck, 1998; Kulka et al., 
1990). In civilian populations with lifetime PTSD prevalence of SUD’s, ranges from 22% 
to 43%, compared with 2% to 15% in persons without PTSD (Breslau & Davis, 1992). 
Among SUD patients the rate of PTSD varies between 11%-60% for current PTSD and 
33%-75% for lifetime PTSD (Driessen et al., 2008; Najavits, Weiss, & Shaw, 1997; 
Reynolds et al., 2005). 
 These high rates of comorbidity suggest that PTSD and SUD are functionally 
related. Several pathways have been described in which these two disorders relate to 
one another, such as the “self-medication hypothesis” in which PTSD precedes SUD 
(Bremner, Southwick, Darnell, & Charney, 1996). When SUD precedes PTSD, a likely 
explanation is that substance users often risk hazardous situations to sustain their habit, 
and therefore experience high levels of physical and psychological trauma. This in turn, 
increases the chance of developing a PTSD (Cottler, Compton, Mager, Spitznagel, & 
Janca, 1992). Finally, there is accumulating evidence that both disorders share 
neurobiological systems, so that continued substance use may increase an individual’s 
susceptibility to developing PTSD following a trauma and, vice versa, that PTSD 
increases the vulnerability for developing SUD (Brady, Back, & Coffey, 2004). 
The association between SUD and PTSD is clinically significant, as well as the 
association with traumatic experiences in general, because trauma exposure and related 
PTSD symptoms have the potential to affect SUD treatment. These symptoms include 
re-experiencing the trauma, avoidance, and increased anxiety or hyperarousal. In 
addition to related symptoms of depression, they interfere with patients’ abilities to 
adhere to and benefit from substance abuse treatment (Ouimette, Brown, & Najavits, 
1998; Ouimette, Finney, & Moos, 1999). International guidelines advise to integrate the 
treatment of SUD and trauma related disorders such as PTSD (Best practices. 
Concurrent mental health and substance use disorders., 2002; Foa, Keane, Friedman, & 
Cohen, 2009; Posthuma, Vos, & Kerkmeer, 2003).  
Seeking Safety is a therapy that was developed in the United States as an 
integrated treatment for PTSD and SUD (Najavits, 2002). It has also been found a 
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feasible treatment for patients who are subthreshold on these disorders or who have 
just one or just the other disorder. The treatment is cognitive-behavioral, as well as 
addressing interpersonal and case management domains. It is present-focused and 
designed to help patients learn coping skills to attain safety from trauma/PTSD and 
substance abuse. Seeking Safety has had over 20 published studies (see (Najavits & 
Hien, 2013), for a comprehensive review). It has shown to reduce substance use and 
PTSD symptom severity in comparison with a control group in female patients (Hien, 
Cohen, Miele, Litt, & Capstick, 2004), female adolescents (Najavits, Gallop, & Weiss, 
2006), incarcerated women with SUD and PTSD (Zlotnick, Johnson, & Najavits, 2009) 
and in veterans in outpatient treatment (Boden et al., 2012), for example. Various quasi-
experimental and non-controlled studies show positive outcomes for Seeking Safety 
(Cook, Walser, Kane, Ruzek, & Woody, 2006; R A Desai, Harpaz-Rote, Najavits, & 
Rosenheck, 2009; Rani A Desai, Harpaz-Rotem, Najavits, & Rosenheck, 2008; Gatz et al., 
2007; Hien et al., 2009, 2010; Lynch, Heath, Matthews, & Cepeda, 2012; Morrissey et al., 
2005; Najavits, Weiss, Shaw, & Muenz, 1998; Zlotnick, Najavits, Rohsenow, & Johnson, 
2003). The treatment has shown positive results in the United States and is the only 
model for PTSD/SUD thus far to impact both PTSD and SUD (Najavits & Hien, 2013). 
The French translation of Seeking Safety has had positive findings and satisfaction in a 
Canadian study (Daoust et al., 2012). The Dutch translation, however, has never been 
studied. Cultural differences in expectancies from health care providers, differences in 
communicating and general views may cause differences in adherence and efficacy. 
  
Aims 
 
The aim of this study is to test the efficacy of Seeking Safety versus standard CBT in a 
Dutch sample of outpatient SUD patients who have experienced at least one traumatic 
event. As the population under study consists of patients in treatment for substance use, 
the primary outcome measure is substance use severity. Secondary outcome measures 
are PTSD and trauma symptoms, coping skills, functioning, and cognitions. We will also 
assess drop-out and satisfaction.  
A second aim of the study is to perform a cost-effectiveness analysis to 
compare the two treatments.  
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Methods 
 
Study design 
 
For this study a randomized controlled design is used. Semi-structured interviews and 
self-report questionnaires will be used to measure change over time on variables at 
three time points: at the start of the treatment (t=0), at end of the treatment (t=1) and 
three months after the end of treatment (follow-up, t=2). These points in time are 
chosen to conform to standard evaluation procedures within our facility. Routine 
outcome monitoring is conducted at completion of treatment for the outpatients or at 
three months after the start of treatment. The administration of questionnaires for the 
study will be synchronized with this monitoring. Both Seeking Safety and CBT will consist 
of weekly group sessions of 1 3/4 hours for 12 weeks (12 sessions total). This design 
keeps dosage equivalent across the treatment conditions, and has been used 
successfully in a prior recent RCT of Seeking Safety (Boden et al., 2012). Both Seeking 
Safety and CBT will be offered in closed-group format, as this is the standard in the 
control condition. Participants will not be financially rewarded for their participation. The 
results of the study will be presented following the CONSORT guidelines (Moher, Schulz, 
& Altman, 2001). 
 
Participants 
 
 Recruitment. All patients that enter group-based weekly therapy are asked to 
participate during intake. They will receive a letter explaining the purpose of the study, 
what they can expect and the requirements to participate, and an informed consent. 
They are asked to read the information carefully and decide on participating within two 
days.  
 Inclusion criteria. Eligible participants for this study are both male and female 
patients that enter group-based outpatient substance use treatment. They have to be 
18 years of age or older and sufficiently fluent in the Dutch language. In this study we 
will include all patients who have experienced a traumatic event and have trauma-
related symptoms. These are assessed by asking the patients whether or not they have 
experienced a traumatic event, and have a score of at least 30 on the Self-report 
Inventory for PTSD (SRIP). Furthermore, patients meet current DSM-IV criteria for 
substance dependence or abuse and have active substance use in the previous 30 days. 
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 Exclusion criteria. Patients will be excluded at intake if they have current 
uncontrolled psychotic or severe bipolar disorder; or serious danger to self or others 
(defined as stated intent to commit suicide or an act of violence, with clear intent and 
plan). These will be determined by a psychologist or a psychiatrist.. 
Randomization. Randomization will be at patient level. The participants will be 
randomly appointed to either the control group or the experimental group. The care-
takers are blind for this randomization. Envelopes will be distributed to the treatment 
facility and these contain the questionnaires that will be administered at t=0. After 
completing the questionnaires patients will be randomized based on a predefined 
randomization schedule. Randomization will be performed in blocks of 4 and 8 (in 
random order). The research assistants that administer the questionnaires for t=1 and 
t=2 will be kept blind for this randomization.  
 
Sample size calculation 
 
The sample size for this study is calculated using a significance level of 95% (p<0.05), a 
power of 80% and the same number of patients in the intervention and control group 
(ratio=1). Primary outcome variable is substance use severity as measured with the 
EuropASI. In recent studies, conducted within the same institution (Joosten, de Jong, de 
Weert-van Oene, Sensky, & van der Staak, 2009) but with a population of inpatients, a 
mean baseline score of 5.2 was found for the alcohol domain and 4.0 for the drugs 
domain. We expect the mean baseline scores for the outpatients to be somewhat lower, 
however not considerably. For comparison of baseline scores on the EuropASI, see 
(Morrissey et al., 2005; Najavits, Weiss, et al., 1998). For practical reasons we are using 
the mean of both domains (alcohol and drugs) for the sample size calculation. Thus, the 
mean score for substance use severity will be somewhat lower than (5.2+4.0)/2=4.6 with 
a standard deviation of 2.7. For this sample size calculation we will use a baseline score 
of 4.0 with the same standard deviation. We expect the substance use severity to 
improve with 60% (Morrissey et al., 2005) to 1.6 (SD=2.0) at end-of-treatment for the 
intervention group and 2.8 (SD=2.0) for the control group. We used PS – Power and 
Sample Size Calculation to calculate the sample size, which resulted in a sample size of 
45 patients in each group. Drop-out rates for this treatment are available for the past 
years from a management information system and are estimated around 20%. This 
drop-out rate may seem low compared to the numbers that are known from previous 
studies in SUD patients. However, we will use this percentage to calculate the number of 
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patients that are needed, but will perform an analysis on drop-out halfway through the 
study. When the drop-out rates turn out to be higher than expected, an amendment 
will be proposed to the medical ethical committee to continue including patients for an 
extended period of time. Because of the calculated drop-out rate, an extra 9 
participants will be included in both the intervention and the control group, yielding a 
total of 108 participants for the randomized controlled trial. Based on treatment entry 
numbers from previous years, approximately two years will be needed to include all 
patients. Furthermore, this number of patients seems plausible considering sample sizes 
in previous studies that show similarity in design (Boden et al., 2012; Najavits, Weiss, et 
al., 1998). 
 
Ethics 
 
The study was approved by the local medical ethical committee (METC\11270.haa).  
 
Treatment Program 
 
Intervention. Patients will be randomized to either Seeking Safety or to standard 
CBT. Seeking Safety was originally designed as an integrated model for patients that 
have both PTSD or trauma-related symptoms and SUD. The treatment manual has 
recently been translated into Dutch (Najavits, 2010). Seeking Safety consists of 25 
structured topics, which can be conducted in group or individual modality. In this study, 
it will be conducted in group modality. Topics are evenly divided among cognitive, 
behavioral and interpersonal coping skills, with a goal of helping patients attain safety in 
their lives. ‘Safety’ is defined as reduction in substance use and destructive behavior, 
establishment of a network of supportive people and self-protection from dangers 
associated with the disorders.  
There will be one Seeking Safety topic per session for the duration of three 
months, making it possible for patients to receive 12 topics. The topics to be used are: 
Safety; PTSD-Taking Back Your Power; When Substances Control You; Grounding; 
Healing from Anger; Honesty; Taking Good Care of Yourself; Compassion; Red and 
Green Flags; Asking for Help; Creating Meaning; and Life Choices.  
Patients that attend a minimum of 7 sessions will be considered "minimum dose 
completers" (Cohen & Hien, 2006). Every session is conducted according to a fixed 
structure, starting with a check-in to find out how each patient is doing and both 
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strengths and problems in coping since the last session. Second, a quotation is 
discussed followed by a discussion of the hand-outs in which the topic of the session is 
related to the patients’ life. This is also the place where coping skills are shared and 
discussed. Each session ends with a check-out where patients are encouraged to share 
one thing they have learned during the session and to formulate a commitment 
(homework) for the next session. The sessions will be facilitated by one therapist or 
social worker. The therapists and social workers all received a two-day training in 
Seeking Safety. Furthermore, all sessions will be videotaped and a random sample of 
20% will be selected for review. Thus, quality and adherence will be monitored and 
ongoing supervision will be provided.  
Comparison condition. Cognitive Behavioral Therapy (CBT) is an evidence-
based cognitive behavioral, manual-based model focused on reducing substance use. It 
includes relapse prevention and motivational interviewing in which positive 
reinforcement and enhancing self-efficacy among others, are used to attain behavioral 
change in the patient (Merkx & van Broekhoven, 2003). CBT is offered once a week for a 
period of three months in a closed group. 
 
Data collection 
 
Patients in both treatment conditions will be assessed identically: at the start of 
treatment (baseline), at the end of treatment (after three months) and at follow up (six 
months after start of treatment). Patients will be assessed by research assistants at these 
time points. Under their supervision patients will fill out most of the questionnaires in an 
online environment in which the data is linked to their electronic patient file.  
 
Instruments and outcome  
 
The primary outcome in this study is substance use severity at end of treatment as 
measured with the EuropASI. This measure will provide a composite score for alcohol 
and drugs which incorporates the number of days of use in the previous 30 days, 
amount of money spent on drugs or alcohol, perceived problems and burden of 
problems associated with substance use. The composite score for alcohol use severity 
will be used as the primary outcome measure for patients with alcohol use disorder and 
the composite score for drug use severity will be used for patients with substance use 
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disorder according to the DSM-IV. Secondary outcome measures are the other 
measures listed below.  
European Addition Severity Index (EuropASI) 
The EuropASI is the European adaptation of the fifth edition of the addiction severity 
index (Kokkevi & Hartgers, 1995). It is a semi-structured interview that gives a 
multidimensional profile of the substance-dependent individual and the severity of the 
addiction. It covers seven main problem areas (medical, employment, alcohol, drug, 
legal, psychiatric, and family and social) that are most commonly affected by substance 
abuse. Scoring is based on two indices for each problem area: firstly, the interviewer’s 
severity rating, in which the interviewer indicates the severity of the patient’s problems 
and his or her present need for additional treatment on a 9-point scale. Secondly, a 
composite score (range 0 - 1), an arithmetically based indicator of current (30 day) 
problem severity, is obtained. Composite scores for the EuropASI are computed with a 
strategy similar to the one used in the ASI (McLellan et al., 1992).  
 Obsessive Compulsive Drinking Scale (OCDS)  
The OCDS is a quick and reliable self-rating instrument that provides a score that 
measures cognitive aspects of craving of alcohol or drugs during the past seven days 
(Anton, Moak, & Latham, 1995). The short version of the scale (de Wildt et al., 2005) that 
is used in the current study consists of 5 items which can be scored on a 0-4 scale, 
where a higher score indicates higher obsessions and compulsions regarding drugs or 
alcohol.  
Self -Report Inventory PTSD (SRIP)  
The SRIP is a self-report measure of PTSD (Hovens, Bramsen, & van der Ploeg, 2002). 
The duration of this measure is five minutes, which makes it very time-efficient. The SRIP 
contains 22 items, based on the DSM-IV-TR criteria for PTSD. The items are scored on a 
4-point Likert scale, varying from 1 ‘not at all’ to 4 ‘often’, and indicates the intensity of 
the PTSD-symptoms in the past month. A total-score of 52 or higher indicates a PTSD-
diagnosis. The SRIP uses the three subscales described in de DSM-IV-TR criteria: 
‘Intrusion’, ‘Avoidance’, and ‘Hyper arousal’. Besides this, the 22 items are subdivided in 
four factors: ‘Emotional numbing’, ‘Avoidance’, ‘Intrusion’, and ‘Sleeping problems’. The 
test does not contain trauma-specific items, therefore the SRIP is suitable for any 
population. Research provides evidence for a high reliability of this measure. Hovens 
(Hovens et al., 1994) found, with the Clinician Administered PTSD Scale (CAPS) (Blake et 
al., 1995) as criterion, an internal consistence reliability of the total score between.90 
and.94. 
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 Trauma Symptom Checklist (TSC-33) 
The TSC-33 is a research measure that evaluates symptomatology in adults associated 
with childhood or adult traumatic experiences. It measures aspects of posttraumatic 
stress and other symptom clusters found in some traumatized individuals. It does not 
measure all 17 criteria of PTSD, and should not be used as a complete measure of that 
construct (Briere & Runtz, 1989). It is included in the current study to measure the 
aspects of psychological effects of traumatic experiences in addition to the standard 
DSM-IV criteria of PTSD.  
Utrecht Coping List (UCL) 
The UCL (Schreurs, Willige, Brosschot, Tellegen, & Graus, 1993) is a self-report 
instrument to measure the way people deal with problems or stressful situations. The 
questionnaire consists of 47 items divided into 7 subscales measuring seven different 
coping strategies: 1. ‘Active problem solving’, 2. ‘Palliative responses’, 3. ‘Avoidance and 
passive expectancy’, 4. ‘Seeking social support’, 5. ‘Depressive reaction pattern’, 6. 
‘Expressing emotions’ and 7. ‘Comforting cognitions’. Each item can be answered with 
‘seldom or never’, ‘sometimes’, ‘often’ and ‘very often’. A total score is obtained by 
adding the scores of all items together. 
 It is important to note, that although Seeking Safety emphasizes coping skills, 
we do not expect the scores of all patients to improve on every subscale of the UCL. 
Some of the ideas behind Seeking Safety are actually aimed at helping patients to avoid 
certain situations or feelings. This is not considered to be good or bad. The purpose of 
this study is to explore changes in coping styles and relate these changes to Seeking 
Safety.  
EuroQol-5D (EQ-5D) 
For the overall quantification of health status as a single index we will use the standard 
EQ-5D classification system developed by the EuroQol Group (Brooks, 1996). The EQ-
5D is one of the three widely used multi-attribute systems available to determine health 
state preferences (utilities). The EQ-5D classification describes health status according to 
five attributes (five questions): mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Each attribute has three levels, i.e., ‘no problems’ (1), ‘some 
problems’ (2) and ‘severe problems’ (3). Health state descriptions are constructed by 
taking one level for each attribute (e.g., 11111 represents the highest health status). 
Theoretically this set of attributes and the levels of the EuroQol-5D instrument allow for 
243 (35) different health-status descriptions. Based on the descriptive classification of 
the EQ-5D system a preference index (utility) can be estimated that expresses the 
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overall preference of the classified health status. These utility figures are required to 
calculate Quality-Adjusted Life Years (QALYs) for the cost-utility analysis (Torrance & 
Feeny, 1989). 
 Sheehan Disability Scale (SDS) 
The SDS (Sheehan, Harnett-Sheehan, & Raj, 1996) is a brief self-report measure that was 
developed to assess functional impairment in three inter-related domains: work/school, 
social and family life. The patient rates the extent to which problems in these areas are 
present on a 10 point visual analogue scale and can thus be used to measure 
functioning.  
 
Statistical analyses 
 
All analyses will be executed using SPPS for Windows version 18.0. Frequency tables will 
be provided for all baseline, end of treatment and follow-up variables. Descriptive 
statistics will include mean, median, interquartile range, numbers and percentages of 
patients, as appropriate. If applicable, 95% confidence intervals will be given. To 
compare differences between groups (Seeking Safety vs CBT) t-test or Mann-Whitney U 
tests will be used in case of continuous variables, as appropriate. For categorical 
variables chi-squared tests will be used. Repeated measures analyses (mixed models in 
SPSS) will be used to test the differences between the treatment conditions over time in 
severity of substance use problems as measured by the EuropASI severity score (pre, 
post and follow-up). The data will be tested for normality and transformed as 
appropriate when the data are skewed. Analyses will be based on the intent-to-treat 
principle. Participants have to attend at least one session to be considered part of this 
group. Differences regarding gender will be analysed and when appropriate, gender will 
be included in the analyses as a confounder or effect modifier. Multiple Imputation will 
be used for missing data. Effect sizes will be calculated to facilitate comparison of 
improvement between the two groups. Linear regression analyses will be used to 
determine the predictors of change in substance use and trauma symptoms. Also, 
amount of prior psychiatric treatment will be used in the analysis as a covariate.  
 
Cost-effectiveness analysis 
 
To make a comparison between the two treatments, the cost of these treatments (total 
costs of staff and materials) will be related to the benefits of the treatment by 
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performing a cost-effectiveness analysis. A cost-effectiveness analysis requires a 
numerical estimate of the magnitude of the effects of an intervention on health 
outcomes. The primary outcome measure of this study will be used for this purpose. 
Cost will be divided by effects to calculate the cost-effectiveness ratio (C/E). The statistics 
of interest in the economic evaluation of health care interventions is the incremental 
cost-effectiveness ratio, which is defined as the difference in cost between Seeking 
Safety and CBT. To quantify uncertainty in the estimated incremental cost-effectiveness 
ratio, confidence intervals will be calculated. In addition, a special variant of economic 
analysis is planned, i.e., cost-utility analysis, to incorporate the preferences (utilities) of 
the participants considering their own health status at the start of treatment and after 
follow-up. Based on these preferences combined with life expectancy figures, calculation 
of so-called QALYs is applicable. A general measure to express the benefits of the two 
different treatment strategies will be calculated by subtracting the number of quality-
adjusted life years computed after follow-up from the number of QALYs computed at 
baseline. Subsequently, quality-adjusted life years can be combined with the cost of 
each treatment strategy to arrive at the cost per QALY gained (Drummond, O’Brien, 
Stoddart, & Torrance, 1997; Torrance & Feeny, 1989). 
 
Discussion 
 
 This study protocol presents the design of an RCT evaluating the efficacy of the Seeking 
Safety treatment program in the Netherlands. The goal of the treatment is to reduce 
substance use and PTSD-related symptoms. Recently Najavits and Hien have 
summarized the literature on Seeking Safety, which shows consistent improvements 
when Seeking Safety is used, even among highly complex and severe patients (Najavits 
& Hien, 2013). Therefore it can be expected that an integrated treatment approach for 
substance use and trauma-related problems can be very effective. Although Seeking 
Safety has already shown positive results and is considered to be the first choice of 
evidence-based treatment for comorbid SUD and PTSD, there are several reasons why 
this RCT should be conducted.  
Firstly, the studies from which the results have been used as evidence for the 
efficacy of Seeking Safety, are largely conducted in the United States. SUD populations 
in the United States and Europe or the Netherlands are very similar as general 
characteristics are concerned. However, communication styles differs between countries, 
because of cultural differences. Also, the Netherlands are known for its liberal policies 
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and views towards several issues, for example drugs. These differences could have 
influence on the way patients perceive and adhere to Seeking Safety. The treatment 
uses a book with handouts for patients and guidance for therapists. This book and its 
handouts have been translated into Dutch in 2010 (Najavits, 2010), however, it is 
important to test the efficacy of the Dutch version for reasons mentioned above. A 
natural choice for a comparison condition is CBT, which is considered the gold-standard 
treatment for SUD alone. 
 Secondly, the majority of studies focused on female populations of SUD 
patients. While this group in particular may benefit from Seeking Safety, studies on male 
subpopulations have emerged over the last few years (Najavits, Schmitz, Gotthardt, & 
Weiss, 2005). In general, there are approximately twice as many male patients than 
female patients in substance use treatment (Brady & Randall, 1999) and it is therefore 
interesting to see what the effect of Seeking Safety is on a population where men are 
the majority and Seeking Safety groups are mixed-gender. The effect of gender in 
response to PTSD-focused treatment has not yet been systematically studied (Foa et al., 
2009). Therefore, in the current study gender will be studied as a possible confounder or 
modifier of the effect of Seeking Safety.  
 Thirdly, while previous studies on Seeking Safety have mostly been focused on 
patients with PTSD, in this study patients will also be included if they have experienced a 
traumatic event and present with some PTSD symptoms, but not necessary with full-
blown PTSD. That way, the possible benefits of this treatment will be available for a 
substantial larger group of patients. A possible limitation of this procedure is that self-
reported PTSD-related symptoms will be used to include patients in the study. Because 
the sample will consist of SUD patients, a proportion of the symptoms they report, may 
be due to substance use or withdrawal (e.g. sleep problems, difficulties concentrating). 
The symptoms of hyperarousal could be independent of any traumatic experience. For 
the purpose of this study, however, this is not a problem. There may be instances where 
a patient is included in the study while his symptoms are primarily related to substance 
use, but we still expect this patients to benefit from Seeking Safety in alleviating his 
symptoms.  
 The aim of this RCT is to test the efficacy of Seeking Safety versus CBT in an 
outpatient population of SUD patients. The design of the study is based on the fact that 
both Seeking Safety and CBT are evidence-based models, but CBT does not address 
trauma or PTSD. We expect that a majority of the patients may benefit from a treatment 
that focuses on both trauma and substance use. If the intervention group is more 
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successful in reducing substance use and PTSD symptoms, it can be argued that 
Seeking Safety should be offered for patients presenting with trauma issues.  
If either treatment proves to be more effective, cost-effectiveness must also be taken 
into account because scarcity of resources is a permanent feature of mental health care 
and substance use treatment in particular. It is well documented that patients that 
experienced trauma are in general higher users of services in the health care system 
(McCauley et al., 1995). However, it is difficult to determine for each hospitalization or 
crisis whether or not underlying PTSD is its direct cause, which makes economic 
evaluations difficult. Domino et al. (Domino, Morrissey, Nadlicki-Patterson, & Chung, 
2005) attempted to shed light on this subject by analyzing total service costs of women 
with mental health and substance abuse disorders who have experienced trauma. One 
group of women was enrolled in an intervention condition, which provided 
comprehensive, integrated and trauma-informed services. The other women received 
care-as-usual. The results showed that the intervention modestly improved clinical 
outcomes, especially drug use and trauma outcomes, and that there were no 
differences in cost between the intervention and the comparison condition. This 
provides support for the notion that integrated and trauma-focused interventions can 
be effective treatments for SUD patients with traumatic experiences, with no significant 
extra cost.  
 
Implications for practice 
 
If Seeking Safety turns out to be an effective treatment for the population under study, it 
could be implemented broadly within the outpatient setting of addiction treatment 
facilities. Cost-effectiveness analyses will be used to inform policy makers about the 
possible advantages of implementing Seeking Safety versus CBT. 
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Chapter 7  
 
Summary and general discussion 
 
7.1 Introduction 
 
Posttraumatic stress disorder (PTSD) is a psychiatric disorder precipitated by a traumatic 
event, such as physical abuse, sexual violence or combat experience. Substance use 
disorder (SUD) is a condition characterized by clinically significant impairment due to the 
continuing and compulsive use of a substance, despite adverse consequences. Previous 
research has found a relationship between SUD and trauma, in which SUD patients 
experience more frequent and severe trauma than people in the general population 
(e.g., interpersonal violence, physical abuse, childhood abuse or neglect) (Khoury, Tang, 
Bradley, Cubells, & Ressler, 2010), as well as between SUD and PTSD (Breslau, Davis, & 
Schultz, 2003; Jacobsen, Southwick, & Kosten, 2001; Leeies, Pagura, Sareen, & Bolton, 
2010). Several hypotheses describe the relationship between SUD and PTSD: the self-
medication hypothesis (PTSD precedes SUD), the high-risk hypothesis (SUD precedes 
PTSD) and shared vulnerability. These are described in more detail in the first chapter of 
this thesis.  
The first topic of this thesis addresses the prevalence of trauma and PTSD in an 
inpatient population of SUD patients in the Netherlands. The aim was to determine 
which kinds of trauma are most prevalent, how many patients are suffering from PTSD 
and whether these numbers are comparable with what has been found in the U.S. and 
some other European countries. The second topic focuses on the psychometric 
properties of three screening measures for PTSD to determine which is the best one to 
use for SUD patients. The third topic addresses the clinical added value of a traumatic 
experiences checklist besides a PTSD symptoms checklist. The fourth topic focuses on 
quantifying subjective suffering due to PTSD and SUD so that direct comparisons 
between the two disorders can be made. The last aim is to develop a detailed research 
protocol to execute a randomized controlled trial (RCT) to study the efficacy of an 
integrated group therapy for patients with SUD and PTSD/trauma: “Seeking Safety.” This 
chapter will provide a summary of the most important findings of the thesis, followed by 
the limitations, suggestions for future research and the clinical implications of the 
findings. 
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7.2 Key findings 
 
7.2.1 Prevalence of trauma/PTSD in SUD patients 
To determine the prevalence of PTSD in an inpatient SUD population, PTSD was 
assessed in 197 patients who were at least four weeks abstinent. PTSD was assessed 
using the Clinician-Administered PTSD Scale (CAPS), a clinical interview that is 
considered the gold standard for diagnosing PTSD. The prevalence of current PTSD was 
25.4% and 46.2% of the patients had at least one episode of PTSD during their lifetime 
(Kok et al., 2012; chapter 2). The traumatic event that was reported most often was 
physical violence (56.3%), followed by sudden and unexpected death of a loved one 
(54.3%), and traffic accident (41.6%). Sexual violence was experienced by 25.4% of our 
sample and combat exposure by 3% of the patients.  
Many previous studies have reported on the prevalence of (current) PTSD in 
SUD patients. Percentages range from 8% in an outpatient population of cocaine 
abusers (Najavits et al., 2007) to 50% in an inpatient population of primarily alcohol use 
disorder patients (Read, Brown, & Kahler, 2004). In the Netherlands, numbers on 
prevalence have long been unavailable, although recently, studies have been conducted 
in outpatient settings that found high percentages of SUD patients with comorbid PTSD: 
37% (Gielen, Havermans, Tekelenburg, & Jansen, 2012), 17% (Langeland, Draijer, & van 
den Brink, 2004) and 15% (van Dam, Ehring, Vedel, & Emmelkamp, 2013). It should be 
noted that in the study by Gielen et al. no clinical interview was used to determine the 
presence of PTSD.  
Our study was the first to report the prevalence of PTSD in a SUD inpatient 
population in the Netherlands. The prevalence of 25.4% current and 46.2% lifetime 
PTSD is comparable to the percentages that were found in previous studies in other 
European countries (Reynolds et al., 2005; Schäfer & Najavits, 2007) and the United 
States (P. Brown, Recupero, & Stout, 1995; Jaycox, Ebener, Damesek, & Becker, 2004; 
Kimerling, Trafton, & Nguyen, 2006). There are two main implications of these results. 
First, the high prevalence in combination with a low detection rate (Dansky & Roitzsch, 
1997; Kimerling et al., 2006) indicates the need for the systematic use of reliable 
screeners in SUD treatment to minimize the risk of PTSD going undetected. Second, a 
large number of patients may benefit from trauma-focused interventions who are not 
receiving them currently. Therefore, addiction treatment settings should focus on 
developing or implementing existing treatments for PTSD for this population. 
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7.2.2 Screening for PTSD  
We determined the reliability and usefulness of three screening instruments for PTSD 
and concluded that the Self-Report Inventory for PTSD (SRIP) and the Depression, 
Anxiety and Stress Scale (DASS) are good screening instruments for PTSD in SUD 
patients. The DASS in particular is of strong clinical value as it is easy to administer, free 
to use, already widely used in some European countries, and it is possible to 
simultaneously screen for depression and anxiety disorders; however, its key weakness is 
that it does not address PTSD symptoms per se. The Mini International Neuropsychiatric 
Interview-plus (MINI-plus) did not perform well as a screener.  
There are currently many other screening instruments available, but only a few 
have been validated in SUD populations, e.g. the Impact of Events Scale (IES) (Weiss & 
Marmar, 2004), the PTSD Symptom Scale Self-Report (PSS-SR) (Coffey, Dansky, Falsetti, 
Saladin, & Brady, 1998), Primary Care PTSD screening questionnaire (PC-PTSD) 
(Kimerling et al., 2006) or the Penn Inventory (Harrington & Newman, 2007). Some 
instruments have also been translated into Dutch, but most of these have not been 
validated, let alone in SUD populations. In chapter 2, two of the above-mentioned 
screening instruments were investigated for their psychometric properties in a Dutch 
SUD population: the SRIP and the PTSD section of the MINI-plus. The MINI-plus is very 
successful in excluding false-positives, but this strict screening process results in a high 
percentage of patients with PTSD that are missed and therefore remain undetected 
(high specificity, but low sensitivity). The results for the SRIP show that it is a reliable 
instrument to use as a screener for PTSD. The best balance between sensitivity and 
specificity was found with a cut-off score of 48, with which a reliable estimation can be 
made of which patients are at risk for PTSD and may need further assessment using a 
clinical interview. With this cut-off score sensitivity was 0.80 and specificity was 0.73. 
The SRIP does not include an assessment of criterion A of PTSD and this could 
potentially pose a problem, because the number of false-positives may increase if 
criterion A is not assessed. From the total of 197 patients, there were 39 false-positives 
when the SRIP was used (19.8% of the sample). A review of the data showed that 4 of 
these patients did not meet criterion A on the CAPS. If these patients would have been 
correctly classified as not meeting current PTSD criteria, for example by including a 
question concerning criterion A in the SRIP, the overall efficiency would increase with 
1.2%. A possible downside of including such a question is that it can increase the risk for 
false-negatives, as can be seen from the results of the MINI-plus. There, the use of a 
stringent formulation of criterion A, leads to the exclusion of a lot of patients that 
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actually meet the criteria for PTSD. However, the inclusion of a question that collects 
information about the traumatic event is something that should be investigated further 
(see 7.4).  
In chapter 3, another screening instrument was tested for its psychometric 
properties: the Depression, Anxiety and Stress Scale (DASS). This instrument was chosen 
because it has several advantages compared to the previously described SRIP. The 
DASS is an instrument that is already often used in addiction treatment centers in the 
Netherlands and some other countries in Europe such as Germany. There are no costs 
associated with the use of the instrument and it is a broad screener, i.e., it can be used 
to screen for depression and anxiety disorders. Although it was not designed as a PTSD 
specific screener, there exists strong overlap between symptoms of PTSD with 
depression and anxiety symptoms (Borsboom, Cramer, Schmittmann, Epskamp, & 
Waldorp, 2011). Because the measure is standard during our intake procedures and 
most other addiction treatment centers in the Netherlands, we tested whether it was 
associated with the presence of PTSD. The DASS was assessed during intake in a 
subsample (n=58) and again in the whole sample when the patients were at least four 
weeks in treatment and had been abstinent for at least that amount of time. The 
presence of PTSD was measured with the CAPS also at least four weeks after admission 
to the clinic. We found that both during intake and later during treatment, the DASS 
was associated strongly with PTSD. The DASS that was administered during intake 
yielded slightly better results (sensitivity: 0.79, specificity: 0.80) than the DASS that was 
administered after a period of abstinence (sensitivity: 0.78, specificity: 0.70) (Kok, de 
Haan, van der Meer, Najavits, & De Jong, 2015; chapter 3). This finding was surprising as 
one might expect to find the opposite to be true; i.e. it’s better to assess for PTSD when 
abstinence has been obtained. It provides support for the possibility of early detection 
of PTSD, which is important because detoxification and the first steps towards 
abstinence can be difficult for patients that suffer from PTSD, as their PTSD symptoms 
may worsen during this period (Jacobsen et al., 2001). It also confirms the earlier 
observation by Najavits (2004) that a period of abstinence is not required to assess for 
PTSD, in contrast to other psychiatric disorders that could be confused with SUD 
symptoms or early withdrawal.  
Prior research has found that trauma per se is not predictive of substance use 
severity. Especially in men, childhood trauma is not significantly related to substance use 
(Hyman et al., 2008; Widom, Marmorstein, & Raskin White, 2006; Widom, Weiler, & 
Cottler, 1999). In women, a link is more often found, but the relation is almost always 
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(largely) mediated by other factors. The most important factor is the presence of PTSD, 
but also stressful life events in adulthood, criminal behavior and depression (Khoury et 
al., 2010; Ullman, Relyea, Peter-hagene, & Vasquez, 2013; White & Widom, 2008). Our 
study extended on previous studies by focusing on several trauma variables (age of 
trauma, number of traumatic experiences and type of trauma) as predictors and current 
substance use severity as outcome variable. We found that there was no clear 
relationship between the trauma variables and current substance use severity, when 
controlling for current PTSD symptoms. Only for alcohol use severity was age of trauma 
significantly related, such that patients traumatized at a younger age experienced more 
severe alcohol use problems. We concluded that screening for traumatic experiences, in 
the absence of also screening for PTSD, is not sufficient (Tim Kok, de Haan, van der 
Meer, Najavits, & de Jong, 2015; chapter 4). 
In the literature, but also in clinical practice, there has been an extensive debate 
on the extent to which trauma and/or PTSD should be assessed during intake or during 
an early stage of treatment. The clinical impression is that patients are sometimes 
hesitant to discuss these subjects, even when the clinician is empathetic and inviting to 
discuss this with the patient. The patient may be reluctant to discuss painful traumatic 
events that are accompanied with feelings of shame and guilt. However, it is always 
important to pay attention to possible trauma and PTSD. In all health care institutions a 
trauma-informed approach has been emphasized by organizations such as the 
SAMHSA National Center for Trauma Informed Care (http://www.samhsa.gov/nctic). 
Trauma-informed care means that each health care organization should be aware of 
the prevalence of trauma, recognize how trauma affects individuals that are involved in 
the organization and respond to the problem by putting knowledge into practice. 
Addiction treatment settings too should also be aware of the prevalence and impact of 
trauma and PTSD. 
It is evident that it is important to provide SUD patients with the best possible 
treatment, as soon as possible. Screening for trauma and PTSD is of great importance in 
the process of treatment planning. If a patient has a history of trauma and presents with 
symptoms related to trauma/PTSD, this needs to be considered in the diagnostics and 
treatment that follow. Screening for PTSD can be done using a short screening 
instrument that inventories PTSD symptoms, or even more general symptoms of anxiety 
and depression. The extent to which trauma histories are assessed during which stage of 
treatment is dependent on the clinical judgment of the therapist. However, the exact 
timing and to what extent should also be discussed with the patient, thereby serving two 
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purposes. First, the patient realizes that the subject is open for discussion. This is an 
important message as it breaks through the secrecy that is often associated with trauma. 
Second, the patient will have some feeling of being in control. The sense of control is 
often damaged to a large extent in patients who experienced trauma. In the end, the 
message should be that trauma needs to be addressed at some point during treatment, 
as it is impossible to view one’s trauma and addiction as separate entities. 
 
7.2.3 Subjective suffering due to trauma-related problems and addiction-related 
problems 
In chapter 5, we discussed the concept of subjective suffering from trauma-related 
problems (TRP) and addiction-related problems (ARP) and how we measured it with the 
PRISM. Suffering was defined as the perceived extent of the threat of the illness or 
symptoms to a person’s sense of Self (Cassell, 1982). We found that subjective suffering 
due to TRP was highest in the group of patients with PTSD. Furthermore, we were the 
first to find that this group considered that their TRP caused greater suffering than did 
their ARP. This was not the case in the sub-threshold PTSD group or the patients that 
only had experienced trauma but did not develop PTSD; an important clinical finding. In 
terms of perceived suffering due to ARP, patients with PTSD or sub-threshold PTSD did 
not differ from those who had experienced trauma but had no PTSD symptoms. 
Because we used the concept of suffering, we were able to compare separate 
conditions with each other. This is a different way of looking at the severity of a disorder 
compared to the use of clinical instruments that use the presence and severity of DSM-
IV symptoms to quantify the severity of a disorder.  
 A major strength of this study is that, because the severity of disparate 
conditions can be measured in terms of suffering, these conditions are open to 
comparison in the extent of the suffering attributed to them. Such a direct comparison is 
impossible using symptom inventories. From the results, we conclude that a large part 
of the patients, primarily those that meet the criteria for PTSD, attribute greater suffering 
due to trauma than addiction. This subgroup of patients may benefit more from 
treatment when trauma interventions are available during SUD treatment. Furthermore, 
the PRISM is an instrument that could be of use in settings with patients with other 
comorbid disorders (e.g., anxiety, depression). In many cases it may be difficult to 
determine focus during the course of treatment and, within the boundaries of 
professional care, it’s important to take the views of the patient into account. The PRISM 
may help to reveal the problem the patient considers to be the most intrusive, or close 
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to the “Self” at that particular moment. The recent work on “shared decision-making”, in 
which patient and clinical team collaborate to set treatment priorities and goals, has 
provided support for the effectiveness of incorporating the ideas and wishes of the 
patient in treatment planning. The PRISM is a promising tool to use for this purpose.  
 
7.2.4 Study protocol for a randomized controlled trial 
There is a great need for methodologically rigorous, pragmatic and clinically relevant 
studies on the efficacy of treatments for the dual diagnosis of SUD and PTSD (Najavits & 
Hien, 2013; Torchalla, Nosen, Rostam, & Allen, 2012). Several interventions have been 
developed, but few have been systematically evaluated. One of the most studied 
interventions is the Seeking Safety protocol, developed by Najavits (2002). In chapter 6, 
we described a detailed proposal for a RCT to study the efficacy of Seeking Safety in a 
Dutch outpatient population of SUD patients with at least some PTSD symptoms (Kok, 
de Haan, van der Meer, Najavits, & DeJong, 2013). The RCT will compare weekly 
Cognitive Behavioral Therapy (CBT) groups, with Seeking Safety. CBT is an evidence-
based cognitive behavioral, manual-based model that is focused on reducing substance 
use. It includes relapse prevention and motivational interviewing in which positive 
reinforcement and enhancing self-efficacy are important ingredients. The primary 
outcome variable will be substance use severity at end of treatment and three months 
after end of treatment. Secondary outcome variables are trauma and PTSD symptoms, 
craving and general health status. To make a comparison between the two treatments, 
the cost of these treatments (total costs of staff and materials) will be related to the 
benefits of the treatment by performing a cost-effectiveness analysis.  
There are several reasons for conducting this study. First, evidence for the 
efficacy of Seeking Safety comes from studies that are largely conducted in the United 
States. SUD populations in the United States and Europe or the Netherlands are very 
similar on general characteristics. However, communication styles differ between 
countries, because of cultural differences. It is therefore important to test the translated 
Dutch version of the treatment protocol as these differences could influence the way 
patients perceive and engage in Seeking Safety. Thus far, all existing studies outside of 
the US have found positive results in terms of both outcomes and satisfaction (Barrett et 
al., 2015; Daoust et al., 2012; Daoust, Najavits, Juéry, Biyong, & Krause, 2014; Freyd-
Harleaux & Strentz, 2014; Schäfer et al., 2010) and thus we anticipate similar results for 
this study.  
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 Secondly, the majority of studies focused on female populations of SUD 
patients. A review of the current studies on Seeking Safety reveals that 65% are studies 
in female populations. While this group in particular may benefit from Seeking Safety, 
mixed gender and/or studies on males have emerged over the last few years, with the 
first study with only men published in 2005 (Najavits, Schmitz, Gotthardt, & Weiss, 2005) 
and the first mixed-gender study in 2006 (Cook, Walser, Kane, Ruzek, & Woody, 2006). 
In general, the prevalence of SUD in men is 2.5 times higher than in women (De Graaf, 
Ten Have, Van Gool, & Van Dorsselaer, 2012) and there are approximately twice as 
many male patients than female patients in substance use treatment (Brady & Randall, 
1999). Some pilot studies with mixed-gender populations have been conducted, 
showing promising findings on trauma symptoms (Searcy & Lipps, 2012) as well as 
substance use (Daoust et al., 2012; Najavits et al., 2013). However, the number of 
participants in these studies were small and there were no control groups. A RCT could 
confirm the positive findings of Seeking Safety in a population where men are the 
majority and group sessions are mixed-gender. The effect of gender in response to 
PTSD treatment has not yet been systematically studied (Foa, Keane, Friedman, & 
Cohen, 2009). Therefore, in the current study gender will be studied as a possible 
confounder or modifier of the effect of Seeking Safety. 
 Thus, this study will be one of the first RCT’s to investigate the efficacy of 
Seeking Safety outside of the US and the first in the Netherlands. There have been pilot 
studies in Germany (Schäfer et al., 2010), Canada (Daoust et al., 2012; in press), Australia 
(Barrett et al., 2015) and France (Freyd-Harleaux & Strentz, 2014), but these were 
conducted in small samples and without a control group. The study will be incorporated 
into regular treatment and everyday practice as much as possible. Sample size 
calculations have been conducted to ensure adequate power. Primary outcome 
variables are substance use and PTSD symptoms, but coping, health status, trauma 
symptoms, adherence and drop-out will also be assessed. If the intervention proofs to 
be more successful in reducing substance use and PTSD symptoms than the control 
intervention, it can be argued that Seeking Safety should be offered for SUD patients 
who present with trauma issues. If both interventions prove to be effective, cost-
effectiveness must also be taken into account, because scarcity of resources is a 
permanent feature of mental health care and substance use treatment in particular.  
 
7.3 Limitations 
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We acknowledge some limitations in this study, which may provide directions for future 
research (see 7.4). First, the sample in our study consisted of SUD patients that were 
willing to participate. A number of patients refused to participate for various reasons. In 
theory, this could have influenced the results of prevalence and psychometric properties 
of the screening instruments. However, we collected data on PTSD symptoms with the 
SRIP from all the patients (including the non-participating patients), as well as general 
characteristics such as gender and age. Comparisons of these data did not reveal any 
significant differences. Because of the thorough comparison between the participating 
and non-participating patients, the results are easier to generalize to other inpatient 
populations.  
 Second, although the use of self-report measures is generally considered a 
reliable source of information concerning sensitive topics such as abuse and other 
traumatic experiences, there are several potential disadvantages such as over-reporting 
(Eaton, Neufeld, Chen, & Cai, 2000; Wilson & Keane, 2004). However, to determine the 
prevalence of PTSD, a clinician administered interview was used to minimize the risk of 
over- or under-reporting. Self-report measures were only used in an explorative way 
and for the purpose of screening. The DSM-IV criteria for SUD were also assessed with a 
structured interview (CIDI-SAM). 
Third, our study was conducted in a sample of SUD patients in a controlled 
environment. Although addiction runs a chronic course and is characterized by periods 
of stability, relapse and deterioration, patients that are admitted to inpatient treatment 
are generally in a phase of more severe symptoms and secondary problems than 
patients that are in outpatient treatment. Some of the results (prevalence and cut-off 
scores for screeners) can therefore be difficult to generalize to all SUD patient groups.  
Another limitation is that assessment took place at least four weeks after 
admission. This was done to ensure that the patients were stable and abstinent for at 
least four weeks. The average length of stay for patients that drop out of residential SUD 
treatment has been found to be 13.9 days (SD=7.2) (McKellar, Kelly, Harris, & Moos, 
2006). In addition, De Weert-Van Oene, Schippers, De Jong & Schrijvers (2001) found 
that 26% of the patients drop out of residential treatment within the first 30 days of 
treatment. Ideally, screening should therefore take place as soon as possible, as 
previously underlined by other authors (Mccauley, Killeen, Gros, Brady, & Back, 2012; 
Najavits, 2004), especially since effective integrated treatments for comorbid PTSD and 
SUD are becoming increasingly available (Ouimette & Read, 2013). These treatments 
are also applicable in these early stages of treatment and could be a valuable aid in 
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preventing dropout. Replication of our findings in patients within the first three weeks of 
treatment should provide insight into the validity of the screening instruments. We have 
partly succeeded in this with our study on the DASS (chapter 3) that was administered 
during outpatient intake procedures, but these results should be interpreted with 
caution, as only 58 patients were included in the analyses. 
Finally, it should be noted that we only assessed PTSD and no other Axis-I or 
Axis-II disorders. Therefore, it was impossible to control for the influence of these 
disorders on PTSD symptoms. Axis-II disorders co-occur frequently with PTSD. For 
example borderline personality disorder (BPD) is present in approximately 30% of the 
patients with PTSD (Pagura et al., 2010; Shea, Zlotnick, & Weisberg, 1999). In the case of 
BPD, one study found that the additional diagnosis of this disorder does not result in a 
more severe clinical profile or PTSD symptoms (Zlotnick, Franklin, & Zimmerman, 
2002b), but elevated suicide proneness and impulsiveness can be found (Zlotnick et al., 
2003). Disorders in the mood and anxiety domain also often co-exist with PTSD and 
show symptom overlap. Especially in the case of major depressive disorder (MDD) there 
has been discussion about the interpretation of the highly overlapping symptoms. At 
least a subset of PTSD symptoms (numbing, dysphoria, sleep problems) seems to be 
closely related to MDD symptoms (Gros, Price, Magruder, & Frueh, 2012) which makes it 
difficult to view PTSD symptoms as unique to PTSD and interpret PTSD symptoms in 
absence of information on mood disorders.  
 
7.4 Research implications 
 
In this section I will describe some directions for future research, based on the findings 
of the studies and taking into account the limitations. First, our sample consisted of 
patients in a controlled environment, which was important because it was possible to 
study patients during a controlled period of abstinence. However, replication of the 
findings in an outpatient population is an important next step, because the majority of 
SUD patients in the Netherlands are in outpatient treatment and represent a population 
that probably has less severe symptoms at that specific time compared to patients who 
are admitted in clinics. We have succeeded in replicating these results to some degree 
with the patients that were assessed during intake. However, as they were later admitted 
to an inpatient treatment facility, this may imply that they were already in the more 
severe spectrum of SUD.  
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  Future research should focus on the use of self-report measures and 
improving them. For example, it may be interesting to study what the effect would be of 
adding a question to the SRIP on criterion A for PTSD. In the current study, the 
impression was that patients were inclined to answer “no” to a direct question regarding 
a traumatic event. An explanation may be that the question in the MINI-plus only 
includes events that involve death or severe injury. Events that include a threat to the 
physical integrity, which is part of criterion A of PTSD in the DSM-IV-TR, has not been 
included. Another explanation may be that the question is too long and therefore not 
understood by some patients. Finally, it is possible that patients do not view some of 
their experiences as “severe”, because they learned to live with it and see them as “a 
part of life.” So, it will be interesting to see if the results of screening are improved if 
criterion A is added and what may be the best way to assess criterion A. 
 It would also be interesting to study which specific symptoms or items from the 
screeners, especially the DASS, differentiate between PTSD, mood disorders, anxiety 
disorders, intoxication or withdrawal symptoms. It is evident that during recovery from 
SUD, stress symptoms may either increase or decrease. Some of the items in the 
screeners may be more sensitive to these factors than others. If these items can be 
identified, deleting or modifying these items may improve the psychometric properties 
of the screening instruments. 
Within the field of mental health care, Routine Outcome Monitoring (ROM) is 
becoming increasingly important. It can be used to improve treatments based on 
regular feedback as the progress of patients is monitored. For this purpose it is most 
efficient to use short measures with good reliability and validity. In this dissertation I 
have described the psychometric properties of several short screening instruments and 
some of them may be suited as monitoring instruments. Future research should focus 
on the DASS and the PRISM in this context. In addition, other outcome variables than 
substance use severity need to be studied, such as general psychological functioning, 
social functioning and work impairment, as these can all be influenced by past trauma 
(Zlotnick, Franklin, & Zimmerman, 2002a). These variables may also be of use in 
monitoring the progress of treatment as ROM should not be limited solely to the 
assessment of PTSD or SUD symptoms. As it was shown in chapter 5, these symptoms 
do not always reflect the true burden the patient experiences. A promising instrument 
such as the PRISM should therefore also be tested in future research as a ROM 
instrument.  
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 We have described a protocol for a RCT to test the efficacy of Seeking Safety in 
an outpatient population in the Netherlands. If this proves to be successful, this will be 
an important first step in the treatment of patients with SUD and PTSD. However, the 
next step will be to determine which treatment is the best for which particular patient 
(population). For some patients present-focused therapy will not be sufficient to obtain 
an acceptable level of PTSD symptoms and adding past-focused therapy (EMDR or 
exposure) or medication might be needed. Some early attempts have been made to 
integrate these treatments and results are promising (S. H. Brown, Gilman, Goodman, 
Adler-Tapia, & Freng, 2015; Hien et al., 2015; Najavits et al., 2005). Future research 
should expand on these studies and also include EMDR and pharmacological 
interventions.  
 
7.5 Clinical implications 
 
Our results showed that the prevalence of PTSD in SUD patients is indeed high and this 
should be taken into account. Assessing PTSD is very important as it has considerable 
implications for treatment if a patient has concurrent PTSD (Mills, Teesson, Ross, & 
Peters, 2006; Ouimette, Finney, & Moos, 1999). Dansky et al. in the 1990s (Dansky & 
Roitzsch, 1997) and others (e.g., Gielen, Krumeich, Havermans, Smeets, & Jansen, 2014) 
have highlighted that many clinicians in SUD treatment facilities underestimate the 
prevalence of PTSD and they have insufficient expertise on the subject, and also in 
mental health settings, clinicians often neglect to assess or treat SUD. Because they 
underestimate the prevalence of PTSD, they often don’t think about assessing trauma or 
PTSD. Also, in my experience there are many treatment programs in the Netherlands 
that have little knowledge of specific interventions and do not implement integrated 
interventions due to lack of time, money or implementation skills.  
Our research has provided support for the use of two screening instruments for 
PTSD: the SRIP and the DASS. They are both easy to use and therefore potentially 
applicable in many settings. For the purpose of screening for PTSD in a SUD setting we 
recommend to use the SRIP for every patient that enters treatment, although the DASS 
can also be used. Both instruments have approximately the same sensitivity and 
specificity, are not trauma focused and have the same length. The choice for which 
instrument to use can depend on available resources and personal preference. 
Assessment of the severity of PTSD symptoms may be sufficient to make a fast decision 
regarding offering several early interventions to patients, such as psychoeducation and 
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coping skills training for PTSD symptoms. These interventions can play an important role 
in preventing dropout during the early stage of treatment, which is especially important 
in the PTSD field (Najavits, 2015).  
Although it is part of trauma-informed care to routinely ask about trauma early 
in treatment, some patients are unwilling to discuss the subject in further detail, because 
of feelings of shame and fear of intense emotions. It would therefore be preferable to 
prioritize quick screening for PTSD over a detailed inventory of trauma history, because 
the latter is not necessary to direct patients to the before mentioned early interventions 
and is more time consuming. Unfortunately, we were unable to study the effect of the 
timing of trauma assessment on adherence and treatment outcomes. After screening 
procedures it is important to assess PTSD in more detail and to determine whether or 
not the patient meets criteria for PTSD and to identify other DSM-IV disorders. This is 
necessary because some treatment services may not be available when a formal DSM-IV 
diagnosis is not present. The assessment should consist of a psychological evaluation of 
symptoms, thoughts, feelings and behavior, in combination with a structured interview. 
In our study we used the CAPS as a clinical interview and this instrument has been 
validated for use in clinical practice as well. Although it takes one hour, it is a valuable 
instrument for structured and reliable classification of PTSD. In the Netherlands, there is 
currently no instrument that is sufficiently validated to replace the CAPS for this purpose. 
During this stage of assessment, a more detailed inventory of traumatic experiences can 
be made with the Traumatic Experiences Checklist (TEC). The advantage of the TEC is 
that incorporates a comprehensive list of possible traumatic experiences and a 
quantitative measure of burden caused by each experience. The TEC can be used in 
addition to the CAPS.  
The results in chapter 5 emphasized the importance of assessing and paying 
attention to trauma-related issues in SUD treatment from a different perspective. It is 
noteworthy that patients with PTSD view their trauma-related problems (TRP) as 
currently more important (or closer to the “Self”) than their addiction related problems 
(ARP). The focus of treatment should therefore be open to discussion, perhaps in the 
tradition of “shared decision making” (Joosten, De Jong, De Weert-Van Oene, Sensky, & 
Van Der Staak, 2009), where patient and clinician formulate the focus of treatment 
together. This focus of treatment can change during treatment and can be subject of 
discussion. Perhaps, after a period of abstinence, a patient finds the TRP to be the 
largest burden. Clinicians should be aware of this and can make use of the PRISM as an 
aid in deciding which treatment goals will be the priority. This can be done by 
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administering the PRISM on a regular basis or at times when the treatment is not 
progressing.  
Studies on the efficacy of interventions are becoming more difficult to conduct 
in the Netherlands due to decreasing budgets and funding possibilities. Perhaps there is 
an opportunity here to cooperate more closely with general mental health care. 
Planning and executing well-designed studies on treatments for patients with comorbid 
disorders could be easier and more efficient this way. We have described a RCT 
protocol that evaluates the efficacy of Seeking Safety compared to an active outpatient 
SUD treatment. To our knowledge, this design has only been used once before (Boden 
et al., 2012). Results from the RCT will provide a solid base for making decisions about 
the implementation of Seeking Safety in the Netherlands. However, research on 
integrated treatments for PTSD should be continued, as other forms of treatment are 
emerging and show promising results (Najavits & Johnson, 2014; Nosen, Littlefield, 
Schumacher, Stasiewicz, & Coffey, 2014; Torchalla et al., 2012).  
As has been pointed out before (Najavits & Hien, 2013), it is also essential to 
attend to the clinicians that provide treatment for these complex patients. In the 
upcoming years, we expect that the focus of substance abuse treatment will be more on 
productivity and that there will be less time for reflection and multidisciplinary 
consultation as a result of budget cuts. In addition, funders are currently demanding 
from substance abuse treatment centers to focus more on substance use and less on 
other comorbid psychiatric disorders as these problems should be treated in other 
mental health care settings. This is actually a step back and will result in the return to a 
previous situation in which patients will be sent back and forth between general mental 
health care and SUD treatment. The upside of this is that in recent years there has been 
a small shift in other (regular health care) institutions recognizing the need for expertise 
on substance abuse and there are several initiatives in which integrated treatments are 
made available in the general mental health care. So, despite unfortunate 
developments, in time they may help to make integrated treatments become 
increasingly available. But these treatments will be of little use if trauma is not 
recognized and patients are not referred to them. The first step is always to recognize 
the problem, in this case the presence of PTSD or trauma. The importance of good 
screening instruments and assessment tools should thus not be underestimated.  
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A. NEDERLANDSE SAMENVATTING 
 
7.1 Inleiding 
 
De posttraumatische stress stoornis (PTSS) is een psychiatrische aandoening die 
voorafgegaan wordt door een traumatische gebeurtenis, zoals fysiek of seksueel 
geweld, of oorlogservaringen. Afhankelijkheid van psychoactieve middelen is een 
psychiatrische stoornis met een klinisch significante beperking in het dagelijks leven 
vanwege het voortdurend en dwangmatig gebruik van een middel, ondanks 
verscheidene negatieve consequenties. Uit onderzoek blijkt dat er een relatie is tussen 
middelenafhankelijkheid en het meemaken van een traumatische gebeurtenis. Patiënten 
met middelenafhankelijkheid komen in vergelijking met de algemene bevolking 
frequenter en met ernstiger traumatische gebeurtenissen in aanraking (bijvoorbeeld 
interpersoonlijk geweld, fysiek geweld, misbruik of verwaarlozing in de kindertijd) 
(Khoury, Tang, Bradley, Cubells, & Ressler, 2010). Ook is er een relatie tussen 
middelenafhankelijkheid en PTSS (Breslau, Davis, & Schultz, 2003; Jacobsen, Southwick, 
& Kosten, 2001; Leeies, Pagura, Sareen, & Bolton, 2010), waarvoor een aantal 
hypotheses bestaan: de zelfmedicatie hypothese (PTSS gaat vooraf aan 
middelenafhankelijkheid), de “high-risk” hypothese (middelenafhankelijkheid gaat vooraf 
aan PTSS) en een gedeelde kwetsbaarheid voor beide stoornissen. Deze hypotheses 
worden verder beschreven in het eerste hoofdstuk van dit proefschrift. 
 Het eerste onderwerp van dit proefschrift gaat over de prevalentie van trauma 
en PTSS in een populatie klinisch opgenomen patiënten met middelenafhankelijkheid in 
Nederland. Het doel was om te bepalen welke traumatische ervaringen het meest 
voorkomen, hoeveel patiënten voldoen aan de criteria voor PTSS en of deze aantallen 
vergelijkbaar zijn met eerdere resultaten van onderzoek uit de Verenigde Staten en 
andere Europese landen. Het tweede onderwerp richt zich op de psychometrische 
kwaliteiten van drie screeningsinstrumenten voor PTSS om te onderzoeken welke het 
beste gebruikt kan worden bij patiënten met middelenafhankelijkheid. Het derde 
onderwerp gaat over de klinisch relevante toegevoegde waarde van de Vragenlijst 
Belastende Ervaringen als toevoeging aan een vragenlijst voor PTSS symptomen. Het 
vierde onderwerp richt zich op het kwantificeren van ervaren lijdensdruk door PTSS en 
middelenafhankelijkheid zodat het mogelijk wordt om deze twee stoornissen hierop met 
elkaar te vergelijken. Het laatste doel was om een gedetailleerd onderzoeksprotocol te 
schrijven voor een gerandomiseerd gecontroleerd onderzoek (RCT) om de 
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werkzaamheid van een geïntegreerde groepstherapie te onderzoeken voor patiënten 
met middelenafhankelijkheid en PTSS/trauma: “Seeking Safety”. In dit hoofdstuk zal een 
samenvatting gegeven worden van de belangrijkste bevindingen van dit proefschrift, 
gevolgd door de beperkingen, suggesties voor toekomstig onderzoek en de implicaties 
voor de praktijk. 
 
7.2 Belangrijkste bevindingen 
 
7.2.1 Prevalentie van trauma/PTSS in patiënten met middelenafhankelijkheid 
Om de prevalentie van PTSS in een klinisch opgenomen populatie patiënten met 
middelenafhankelijkheid te bepalen, zijn 197 patiënten onderzocht op PTSS toen ze 
minimaal vier weken abstinent waren. PTSS is vastgesteld door gebruik te maken van 
het Klinisch Interview voor PTSS (KIP), een klinisch interview dat als gouden standaard 
wordt gezien voor het vaststellen van PTSS. De prevalentie van huidige PTSS was 25,4% 
en 46,2% van de patiënten heeft in de levensloop minimaal één episode van PTSS 
gehad (Kok et al., 2012; hoofdstuk 2). De meest genoemde traumatische gebeurtenis 
was fysiek geweld (56,3%), gevolgd door plotseling en onverwacht overlijden van een 
naaste (54,3%), en een verkeersongeluk (41,6%). Bij 25,4% is er sprake geweest van 
seksueel geweld en 3% van de patiënten is blootgesteld aan oorlogservaringen.  
 De prevalentie van (huidig) PTSS bij patiënten met middelenafhankelijkheid is in 
verschillende andere studies beschreven. De gevonden percentages variëren van 8% in 
een ambulante populatie van patiënten die cocaïne misbruiken (Najavits et al., 2007) tot 
50% in een klinische populatie met voornamelijk patiënten met alcoholafhankelijkheid 
(Read, Brown, & Kahler, 2004). In Nederland zijn er lang geen prevalentiecijfers 
beschikbaar geweest. Recent zijn een aantal studies uitgevoerd in ambulante settings 
waarin hoge percentages werden gevonden van comorbide middelenafhankelijkheid en 
PTSS: 37% (Gielen, Havermans, Tekelenburg, & Jansen, 2012), 17% (Langeland, Draijer, 
& van den Brink, 2004) en 15% (van Dam, Ehring, Vedel, & Emmelkamp, 2013). Hierbij 
moet worden opgemerkt dat in de studie van Gielen et al. geen klinisch interview is 
gebruikt om de aanwezigheid van PTSS te bepalen. 
 Onze studie was de eerste die de prevalentie van PTSS in klinisch opgenomen 
patiënten met middelenafhankelijkheid in Nederland heeft onderzocht. De prevalentie 
van een huidige (25,4%) en life-time PTSS (46,2%) is vergelijkbaar met percentages die 
in eerdere studies in andere Europese landen (Reynolds et al., 2005; Schäfer & Najavits, 
2007) en in de Verenigde Staten (P. Brown, Recupero, & Stout, 1995; Jaycox, Ebener, 
171 
 
Damesek, & Becker, 2004; Kimerling, Trafton, & Nguyen, 2006) zijn gevonden. Deze 
bevindingen hebben twee belangrijke implicaties. Ten eerste, de hoge prevalentie in 
combinatie met het feit dat PTSS in de praktijk ondergediagnosticeerd wordt (Dansky & 
Roitzsch, 1997; Kimerling et al., 2006) geven het belang aan van consequent gebruik 
van betrouwbare screeners binnen de verslavingszorg, zodat het risico op het niet 
onderkennen van PTSS wordt geminimaliseerd. Ten tweede, een groot aantal patiënten 
zou kunnen profiteren van traumagerichte behandelinterventies, maar krijgt deze 
momenteel niet. Het is daarom van belang dat de verslavingszorg zich gaat richten op 
het ontwikkelen of implementeren van bestaande behandelingen voor PTSS voor deze 
populatie.  
 
7.2.2 Screenen op PTSS 
We hebben de betrouwbaarheid en bruikbaarheid van drie screeners voor PTSS 
bepaald en geconcludeerd dat de Zelfinventarisatielijst PTSS (ZIL) en de Depressie, 
Angst en Stress Schaal (DASS) goede screeners zijn voor PTSS bij patiënten met 
middelenafhankelijkheid. Vooral de DASS heeft klinische waarde omdat deze makkelijk 
is af te nemen, gratis te gebruiken, al veel gebruikt wordt in sommige Europese landen 
en het mogelijk is om tegelijkertijd te screenen op depressie en angstklachten. Een 
belangrijk nadeel is echter dat er in de DASS niet direct naar PTSS symptomen wordt 
gevraagd. De Mini International Neuropsychiatric Interview-plus (MINI-plus) was minder 
goed bruikbaar als screener.  
 Er zijn momenteel nog veel andere screeners beschikbaar, maar slechts een 
paar zijn ook gevalideerd in patiënten met middelenafhankelijkheid, bijvoorbeeld de 
Schok Verwerkingslijst (SVL) (Weiss & Marmar, 2004), de Zelfrapportage Lijst voor PTSS 
(Coffey, Dansky, Falsetti, Saladin, & Brady, 1998), de Primary Care PTSD screening 
vragenlijst (PC-PTSD) (Kimerling et al., 2006) of de Penn Inventory (Harrington & 
Newman, 2007). Sommige vragenlijsten zijn ook in het Nederlands vertaald, maar de 
meesten zijn niet gevalideerd, in ieder geval niet in populaties met 
middelenafhankelijkheid. In hoofdstuk 2 zijn twee van de hierboven genoemde 
screeners onderzocht op psychometrische kwaliteiten in een Nederlandse populatie van 
patiënten met middelenafhankelijkheid: de ZIL en het PTSS onderdeel van de MINI-plus. 
De MINI-plus is goed in het excluderen van vals-positieven, maar deze strenge 
screening resulteert uiteindelijk in een groot percentage patiënten met PTSS dat gemist 
wordt (hoge specificiteit, maar lage sensitiviteit). De resultaten van de ZIL laten zien dat 
het een betrouwbare screener voor PTSS is. De optimale balans tussen sensitiviteit en 
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specificiteit bleek bij een afkappunt van 48 te zijn, waarmee een betrouwbare schatting 
gemaakt kan worden of een patiënt mogelijk PTSS heeft en of verder onderzoek 
middels een klinisch interview geïndiceerd is. Bij dit afkappunt was de sensitiviteit 0,80 
en de specificiteit 0,73.  
 De ZIL bevat geen verwijzing naar criterium A van PTSS en dit zou een 
probleem kunnen zijn omdat het aantal vals-positieven mogelijk toeneemt wanneer 
criterium A niet wordt uitgevraagd. Van het totale aantal van 197 patiënten, waren er 39 
vals-positieven als de ZIL werd gebruikt (19,8% van patiënten). Nader onderzoek van de 
data liet zien dat 4 van deze patiënten niet voldeden aan criterium A in het KIP. 
Wanneer deze patiënten correct zouden zijn geclassificeerd als niet-PTSS, bijvoorbeeld 
doordat er een extra vraag naar criterium A aan de ZIL zou worden toegevoegd, zou 
de totale effectiviteit van de vragenlijst met 1,2% toenemen. Een nadeel van het 
toevoegen van een dergelijke vraag is dat het risico op vals-negatieven wordt 
verhoogd, zoals te zien is in de resultaten van de MINI-plus. Daar leidt het gebruik van 
een strakke formulering wat betreft criterium A tot het uitsluiten van veel patiënten die 
eigenlijk wel voldoen aan de criteria voor PTSS. Desondanks is verder onderzoek nodig 
om de voordelen en nadelen van het toevoegen van een vraag over de traumatische 
gebeurtenis toe te voegen (zie 7.4). 
 In hoofdstuk 3 zijn de psychometrische kwaliteiten onderzocht van een andere 
screener: de Depressie, Angst en Stress Schaal (DASS). Deze vragenlijst is gekozen 
omdat het een aantal voordelen heeft in vergelijking met de eerder beschreven ZIL. De 
DASS is een vragenlijst die al standaard gebruikt wordt in veel instellingen voor 
verslavingszorg in Nederland en een aantal andere Europese landen, zoals Duitsland. Er 
zijn geen kosten verbonden aan het gebruik van de vragenlijst en het is een bredere 
screener, dat wil zeggen, deze kan gebruikt worden om te screenen op depressie- en 
angstklachten. Hoewel de DASS niet ontworpen is als een PTSS screener, is er wel een 
grote overlap tussen PTSS symptomen en depressie of angst symptomen (Borsboom, 
Cramer, Schmittmann, Epskamp, & Waldorp, 2011). We hebben onderzocht of de DASS 
samenhing met de aanwezigheid van PTSS omdat het een standaard gebruikte 
vragenlijst is in onze intake en die van de meeste andere instellingen voor 
verslavingszorg in Nederland. De DASS is bij een deel van de patiënten afgenomen 
tijdens de intake (n=58) en later bij alle deelnemende patiënten wanneer ze minimaal 
vier weken in behandeling waren en minimaal zo lang abstinent. De classificatie voor 
PTSS is ook vier weken na de opname in de kliniek met het KIP vastgesteld. We hebben 
gevonden dat de DASS sterk samenhing met PTSS, zowel tijdens de intake als later 
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tijdens de behandeling. De DASS die tijdens de intake was afgenomen liet iets betere 
resultaten zien (sensitiviteit: 0,79; specificiteit: 0,80) dan de DASS die na een periode van 
abstinentie was afgenomen (sensitiviteit: 0,78; specificiteit; 0,70) (Kok, de Haan, van der 
Meer, Najavits, & De Jong, 2015; chapter 3). Deze uitkomst was verrassend, omdat het 
tegenovergestelde verwacht werd: namelijk dat het beter is om onderzoek naar PTSS te 
doen wanneer er sprake is van een periode van abstinentie. Het laat echter zien dat het 
mogelijk is om de aanwezigheid van PTSS in een vroeg stadium te ontdekken. Dit is 
belangrijk omdat ontwenning en de eerste stappen richting abstinentie erg moeilijk 
kunnen zijn voor patiënten met PTSS, omdat de PTSS symptomen gedurende deze 
periode kunnen verergeren (Jacobsen et al., 2001). Het is eveneens een bevestiging van 
de eerdere vondst van Najavits (2004) dat een periode van abstinentie niet nodig is om 
PTSS te onderzoeken, in tegenstelling tot andere psychiatrische stoornissen die verward 
kunnen worden met symptomen van middelenafhankelijkheid of vroege 
ontwenningsklachten.  
 Eerder onderzoek heeft aangetoond dat alleen een trauma niet voorspellend is 
voor de verslavingsernst. Vooral bij mannen is een vroegkinderlijk trauma niet direct 
gerelateerd aan middelengebruik (Hyman et al., 2008; Widom, Marmorstein, & Raskin 
White, 2006; Widom, Weiler, & Cottler, 1999). Bij vrouwen wordt vaker een verband 
gevonden, maar dit verband wordt bijna altijd (grotendeels) gemedieerd door andere 
factoren. De belangrijkste factor is de aanwezigheid van PTSS, maar ook andere zoals 
stressvolle “life events” als volwassene, crimineel gedrag en depressie (Khoury et al., 
2010; Ullman, Relyea, Peter-Hagene, & Vasquez, 2013; White & Widom, 2008). Onze 
studie heeft verder gebouwd op eerder onderzoek door zich te richten op verschillende 
trauma variabelen (leeftijd van trauma, aantal traumatische gebeurtenissen en het soort 
trauma) als voorspellers, en huidige verslavingsernst als uitkomstvariabele. We vonden 
geen duidelijk verband tussen de traumavariabelen en huidige verslavingsernst wanneer 
er gecontroleerd werd voor huidige PTSS klachten. Alleen voor de ernst van 
alcoholverslaving was er een significante relatie met de leeftijd van het trauma, waarbij 
patiënten die op een jongere leeftijd getraumatiseerd zijn, ernstigere alcohol-
gerelateerde problemen ervaarden. We hebben geconcludeerd dat het onvoldoende is 
om te screenen op traumatische ervaringen, zonder ook te screenen op PTSS 
symptomen (Tim Kok, de Haan, van der Meer, Najavits, & de Jong, 2015; hoofdstuk 4). 
 Er wordt in de literatuur, maar ook in de klinische praktijk, uitgebreid 
gediscussieerd in hoeverre een trauma en/of PTSS zou moeten worden uitgevraagd 
tijdens de intake of tijdens een vroeg stadium van de behandeling. De klinische indruk is 
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dat patiënten soms terughoudend zijn om dit onderwerp te bespreken, zelfs wanneer 
de behandelaar empathisch en uitnodigend is om het te bespreken. De patiënt is 
misschien onwillig om pijnlijke traumatische gebeurtenissen te bespreken die gevoelens 
van schaamte en schuld oproepen. Desondanks is het altijd belangrijk om aandacht te 
besteden aan een mogelijk trauma en PTSS. In alle gezondheidszorginstellingen in de 
Verenigde Staten wordt met “Trauma-informed care” gewerkt, zoals geadviseerd door 
de SAMHSA National Center for Trauma Informed Care (http://www.samhsa.gov/nctic). 
Trauma-informed care betekent dat elke instelling zich bewust moet zijn van de 
prevalentie van een trauma, moet kunnen herkennen hoe een trauma mensen binnen 
de instelling beïnvloedt en hoe ze met het probleem om moeten gaan door kennis in 
de praktijk te brengen. Ook verslavingszorginstellingen moeten dus op de hoogte zijn 
van de prevalentie en de invloed van trauma’s en PTSS.  
 Het spreekt voor zich dat het belangrijk is om patiënten met 
middelenafhankelijkheid zo snel als mogelijk de best mogelijke behandeling te bieden. 
Het screenen op trauma en PTSS is van groot belang bij het plannen van de 
behandeling. Wanneer een patiënt een geschiedenis van traumatische ervaringen en 
trauma/PTSS gerelateerde klachten heeft, dan heeft dat gevolgen voor de diagnostische 
–en behandelfase. Voor het screenen op PTSS kan gebruikt gemaakt worden van een 
korte screener die de symptomen van PTSS inventariseert, of zelfs meer algemene 
symptomen van angst en depressie. Tijdens welke behandelfase een 
traumageschiedenis moet worden uitgevraagd is afhankelijk van de inschatting van de 
behandelaar. Het moment en hoe gedetailleerd, zal echter ook moeten worden 
besproken met de patiënt, waarmee twee doelen worden nagestreefd. Ten eerste, de 
patiënt zal zich realiseren dat het onderwerp bespreekbaar is. Dat is een belangrijke 
boodschap omdat dit het probleem van het niet durven bespreken doorbreekt waarvan 
vaak sprake is bij een trauma. Ten tweede, de patiënt zal hierdoor een gevoel van 
controle hebben. Het gevoel van controle hebben is vaak voor een groot deel 
aangetast bij patiënten die getraumatiseerd zijn. De uiteindelijke boodschap zal moeten 
zijn dat er op een zeker moment tijdens de behandeling aandacht moet worden 
besteed aan trauma’s, omdat het onmogelijk is om trauma en verslaving als twee 
verschillende entiteiten te beschouwen.  
 
7.2.3 Subjectief lijden door trauma gerelateerde problemen en verslaving gerelateerde 
problemen 
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In hoofdstuk 5 hebben we het concept van subjectief lijden door trauma gerelateerde 
problemen (TRP) en verslaving gerelateerde problemen (VRP) besproken en hoe dit kan 
worden gemeten met de PRISM. Lijden is gedefinieerd als de ervaren omvang van de 
dreiging van een ziekte of symptomen op het gevoel van het “Zelf” (Cassell, 1982). We 
hebben gevonden dat subjectief lijden door TRP het hoogst was bij de patiënten met 
PTSS. Verder zijn we de eersten geweest die hebben ontdekt dat deze groep patiënten 
vond dat hun TRP meer lijden veroorzaakte dan hun VRP. Dit bleek niet het geval te zijn 
in de groep met partiële PTSS of de patiënten die alleen een trauma hadden 
meegemaakt, maar vervolgens geen PTSS hadden ontwikkeld; een klinisch relevante 
vondst. Patiënten met PTSS of partiële PTSS verschillen wat betreft lijden door VRP niet 
van degenen die alleen een trauma hadden meegemaakt zonder significante PTSS 
symptomen. Omdat we gebruik hebben gemaakt van het concept lijden, was het 
mogelijk om twee verschillende condities met elkaar te vergelijken. Dit is een andere 
manier om naar de ernst van een stoornis te kijken, vergeleken met het gebruik van 
meetinstrumenten die gebruik maken van de aanwezigheid of ernst van DSM(-IV) 
symptomen om de ernst van een stoornis te bepalen.  
 Een sterk punt van deze studie is dat de ernst in de mate van lijden van de 
verschillende condities met elkaar vergeleken kunnen worden. Een dergelijke directe 
vergelijking is niet mogelijk wanneer gebruik wordt gemaakt van symptoom 
vragenlijsten. Uit de resultaten hebben we kunnen concluderen dat een groot deel van 
de patiënten, voornamelijk zij die aan de criteria voor PTSS voldoen, meer lijdensdruk 
ervaren door trauma’s dan verslaving. Deze groep patiënten zal mogelijk beter van een 
behandeling profiteren wanneer er traumagerichte interventies beschikbaar zijn tijdens 
de verslavingsbehandeling. Verder is de PRISM een instrument dat bruikbaar kan zijn in 
andere settings met patiënten met comorbide stoornissen (bijv. angst, depressie). In veel 
gevallen zal het moeilijk zijn om de focus van de behandeling te bepalen en, binnen de 
grenzen van professionele hulpverlening, is het belangrijk om rekening te houden met 
de visie van de patiënt. De PRISM kan bijdragen om te achterhalen welk probleem of 
stoornis de patiënt als het meest intrusief ervaart, of het meest dichtbij het “Zelf” op dat 
moment. De recente onderzoeken over “Samen Beslissen”, waarbij de patiënt en het 
behandelend team samenwerken om behandeldoelen en prioriteiten te stellen, hebben 
laten zien dat het effectief is om de ideeën en wensen van de patiënt mee te nemen in 
het plannen van de behandeling. De PRISM is voor dit doel een veelbelovend 
instrument.  
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7.2.4 Onderzoeksprotocol voor een gerandomiseerd gecontroleerd onderzoek 
Het is van groot belang dat er methodologisch sterke, pragmatische en klinisch 
relevante studies worden gedaan om het effect van behandelingen voor de dubbele 
diagnose middelenafhankelijkheid en PTSS te onderzoeken (Najavits & Hien, 2013; 
Torchalla, Nosen, Rostam, & Allen, 2012). Er zijn verschillende behandelinterventies 
ontwikkeld, maar slechts een beperkt aantal is systematisch onderzocht. Een van de 
meest onderzochte behandelingen is het Seeking Safety protocol, ontwikkeld door 
Najavits (2002). In hoofdstuk 6 hebben we een gedetailleerd voorstel beschreven voor 
een RCT om het effect van Seeking Safety te onderzoeken in een Nederlandse 
populatie patiënten met middelenafhankelijkheid met een minimaal aantal PTSS 
symptomen met behulp van een poliklinische behandeling (Kok, de Haan, van der Meer, 
Najavits, & DeJong, 2013). In de RCT zal een wekelijkse cognitieve gedragstherapie 
(CGT) in groepsverband worden vergeleken met Seeking Safety. CGT is een evidence-
based, geprotocolleerde behandeling waarbij de focus ligt op het verminderen van 
middelengebruik. Het bevat terugvalpreventie en motiverende gespreksvoering waarbij 
positieve bekrachtiging en het versterken van self-efficacy de belangrijkste onderdelen 
zijn. De primaire uitkomstmaat zal de verslavingsernst aan het eind van de behandeling 
en drie maanden na het einde van de behandeling zijn. Secundaire uitkomstmaten zijn 
trauma gerelateerde en PTSS symptomen, trek in middelen en de algemene 
gezondheidstoestand. Om een vergelijking te maken tussen de twee behandelingen 
zullen de kosten van de behandelingen (totale kosten van personeel en materieel) 
gerelateerd worden aan de voordelen van de behandeling door een kosten-
effectiviteitsanalyse te doen.  
 Er zijn een aantal redenen voor het uitvoeren van dit onderzoek. Ten eerste, 
het bewijs voor de werkzaamheid van Seeking Safety komt voort uit studies die 
overwegend in de Verenigde Staten zijn uitgevoerd. Wat betreft achtergrondkenmerken 
zijn patiënten met middelenafhankelijkheid in de Verenigde Staten en Europa of 
Nederland grotendeels gelijk aan elkaar. Echter, communicatiestijlen verschillen tussen 
landen vanwege culturele verschillen. Het is daarom belangrijk om de Nederlandse 
vertaling van het behandelprotocol te onderzoeken omdat deze verschillen invloed 
kunnen hebben op de manier waarop patiënten Seeking Safety ervaren en zich aan 
deze behandeling verbinden. Tot nu toe hebben alle onderzoeken die buiten de VS zijn 
uitgevoerd positieve resultaten gevonden wat betreft (klinische) uitkomstmaten en 
tevredenheid (Barrett et al., 2015; Daoust et al., 2012; Daoust, Najavits, Juéry, Biyong, & 
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Krause, 2014; Freyd-Harleaux & Strentz, 2014; Schäfer et al., 2010) en we verwachten 
daarom vergelijkbare resultaten voor deze studie. 
 Ten tweede, het grootste deel van de eerdere studies heeft zich gericht op 
vrouwelijke patiënten met middelenafhankelijkheid. Een overzicht van de huidige studies 
over Seeking Safety laat zien dat het in 65% van de studies om vrouwelijke patiënten 
gaat. Hoewel deze groep zeker baat kan hebben bij Seeking Safety, zijn er de afgelopen 
jaren steeds meer onderzoeken verschenen waarin zowel mannen als vrouwen 
geïncludeerd werden. Het eerste onderzoek met alleen mannen is in 2005 gepubliceerd 
(Najavits, Schmitz, Gotthardt, & Weiss, 2005) en het eerste met zowel mannen als 
vrouwen in 2006 (Cook, Walser, Kane, Ruzek, & Woody, 2006). In het algemeen is de 
prevalentie van middelenafhankelijkheid 2,5 keer zo hoog bij mannen als bij vrouwen 
(De Graaf, Ten Have, Van Gool, & Van Dorsselaer, 2012) en er zijn ongeveer tweemaal 
zo veel mannelijke patiënten als vrouwelijke patiënten in behandeling in de 
verslavingszorg (Brady & Randall, 1999). Er is een aantal pilot onderzoeken gedaan bij 
patiëntengroepen met zowel mannen als vrouwen en deze laten veelbelovende 
resultaten zien met betrekking tot trauma gerelateerde symptomen (Searcy & Lipps, 
2012) en middelengebruik (Daoust et al., 2012; Najavits et al., 2013). Het aantal 
deelnemers aan deze onderzoeken is echter klein en er waren geen controle groepen. 
Een RCT zou de positieve bevindingen van Seeking Safety kunnen bevestigen in een 
onderzoekspopulatie waar mannen in de meerderheid zijn en de groepssessies voor 
zowel mannen als vrouwen zijn. Het effect van geslacht op de behandeling voor PTSS is 
tot op heden nog niet systematisch onderzocht (Foa, Keane, Friedman, & Cohen, 2009). 
Daarom zal geslacht als mogelijke confounder of effectmodificator op het effect van 
Seeking Safety worden meegenomen in het huidige nog uit te voeren onderzoek. 
 Dit onderzoek zal dus een van de eerste RCT’s zijn die de werkzaamheid van 
Seeking Safety buiten de VS zal onderzoeken, en de eerste in Nederland. Er zijn pilot 
onderzoeken geweest in Duitsland (Schäfer et al., 2010), Canada (Daoust et al., 2012; in 
press), Australië (Barrett et al., 2015) en Frankrijk (Freyd-Harleaux & Strentz, 2014), maar 
die zijn uitgevoerd met een kleine sample size en zonder controle conditie. Het 
onderzoek zal zo veel mogelijk geïntegreerd worden in de reguliere behandeling en 
dagelijkse praktijk. Er is een sample size berekening gedaan om voldoende ‘power’ te 
verzekeren. Primaire uitkomstvariabelen zijn middelengebruik en PTSS symptomen, 
maar copingvaardigheden, gezondheidstoestand, trauma gerelateerde symptomen, 
therapietrouw en drop-out zullen ook worden onderzocht. Wanneer de interventie 
beter blijkt te zijn in het verminderen van middelengebruik en PTSS symptomen dan de 
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controle interventie, dan kan worden gesteld dat Seeking Safety het standaard 
behandelaanbod zou moeten zijn voor patiënten met middelenafhankelijkheid die ook 
trauma gerelateerde klachten hebben. Wanneer beide interventies even effectief blijken 
te zijn, zal er rekening gehouden moeten worden met de kosteneffectiviteit omdat een 
schaarste aan middelen een permanent probleem is van de geestelijke 
gezondheidszorg en de verslavingszorg in het bijzonder. 
 
7.3 Beperkingen 
 
Er zijn een aantal beperkingen aan het onderzoek die aanknopingspunten voor 
toekomstig onderzoek kunnen zijn (zie 7.4). In de eerste plaats bestond de steekproef in 
ons onderzoek uit patiënten met middelenafhankelijkheid die vrijwillig deelnamen. Een 
aantal patiënten weigerde deelname om verschillende redenen. Theoretisch gezien zou 
dit invloed kunnen hebben gehad op de resultaten wat betreft de prevalentiecijfers en 
de psychometrische kwaliteiten van de screeners. Echter, we hebben bij alle patiënten 
(dus ook de niet-deelnemende patiënten) data verzameld over PTSS symptomen met 
de ZIL en achtergrondkenmerken zoals leeftijd en geslacht. Een analyse van deze data 
liet geen significante verschillen zien. Vanwege de degelijke vergelijking tussen de 
deelnemende en niet-deelnemende patiënten zijn de resultaten makkelijker te 
generaliseren naar andere klinisch opgenomen patiëntpopulaties. 
 Ten tweede kleven er een aantal mogelijke nadelen aan het gebruik van 
zelfrapportage vragenlijsten, zoals overrapportage (Eaton, Neufeld, Chen, & Cai, 2000; 
Wilson & Keane, 2004), hoewel het gebruik ervan in het algemeen ook gezien wordt als 
een betrouwbare manier om informatie te verzamelen over gevoelige onderwerpen 
zoals misbruik en andere traumatische ervaringen. Om de prevalentie van PTSS te 
bepalen hebben we een klinisch interview afgenomen om het risico op over –of 
onderrapportage zo klein mogelijk te houden. Zelfrapportage vragenlijsten zijn alleen 
op een exploratieve manier gebruikt en als screener. De DSM-IV criteria voor 
middelenafhankelijkheid zijn ook onderzocht met een gestructureerd interview (CIDI-
SAM).  
 Ten derde, ons onderzoek is uitgevoerd binnen een steekproef van patiënten 
met middelenafhankelijkheid die in een gecontroleerde klinische setting verbleven. 
Hoewel verslaving een chronisch beloop heeft en gekenmerkt wordt door periodes van 
stabiliteit, afgewisseld met terugval en verslechtering van symptomen, vertonen 
patiënten die klinisch opgenomen zijn in het algemeen ernstiger symptomen en meer 
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bijkomende problemen dan patiënten die ambulant in behandeling zijn. Sommige 
resultaten (prevalentiecijfers en afkappunten voor de screeners) zijn daarom moeilijk te 
generaliseren naar alle patiënten met middelenafhankelijkheid. 
 Een andere beperking van dit onderzoek is dat de vragenlijsten afgenomen 
werden wanneer de patiënten minimaal vier weken opgenomen waren. Dit is gedaan 
om er zeker van te zijn dat de patiënten zo stabiel mogelijk waren en minimaal vier 
weken abstinent. De gemiddelde verblijfsduur van patiënten die voortijdig vertrekken uit 
de kliniek is 13,9 dagen (SD=7,2) (McKellar, Kelly, Harris, & Moos, 2006). Daar komt bij 
dat De Weert-Van Oene et al. (De Weert-Van Oene, Schippers, De Jong, & Schrijvers, 
2001) hebben gevonden dat 26% van de patiënten in een klinische behandeling binnen 
30 dagen uitvalt. Idealiter zou het screenen daarom zo vroeg mogelijk moeten 
gebeuren, zoals ook al benadrukt werd door andere auteurs (Mccauley, Killeen, Gros, 
Brady, & Back, 2012; Najavits, 2004), ook omdat effectieve geïntegreerde 
behandelingen voor comorbide PTSS en middelenafhankelijkheid steeds meer 
beschikbaar zijn (Ouimette & Read, 2013). Deze behandelingen zijn ook toepasbaar in 
een vroeg stadium van behandeling en kunnen een waardevolle bijdrage leveren aan 
het voorkomen van vroegtijdige uitval. Een replicatie van onze bevindingen bij 
patiënten in de eerste drie weken van behandeling kan inzicht bieden in de verdere 
validiteit van de screeners. We hebben dit voor een deel al gedaan in ons onderzoek 
met de DASS (hoofdstuk 3) die tijdens de intake was afgenomen, maar deze resultaten 
moeten met enige voorzichtigheid worden geïnterpreteerd omdat hiervoor slechts data 
van 58 patiënten beschikbaar was. 
 Tenslotte moet worden opgemerkt dat we alleen PTSS hebben onderzocht en 
geen andere As-I of As-II stoornissen. Het was daarom niet mogelijk om te controleren 
voor de invloed van deze stoornissen op de PTSS symptomen. As-II stoornissen komen 
vaak voor naast PTSS. De borderline persoonlijkheidsstoornis (BPS) komt bijvoorbeeld 
bij ongeveer 30% van de patiënten met PTSS voor (Pagura et al., 2010; Shea, Zlotnick, & 
Weisberg, 1999). Eén onderzoek liet zien dat de extra diagnose van BPS niet resulteerde 
in een ernstiger klinisch profiel of PTSS symptomen (Zlotnick, Franklin, & Zimmerman, 
2002b), maar wel een verhoogde neiging tot suïcide en impulsiviteit (Zlotnick et al., 
2003). Angst –en stemmingsstoornissen komen ook vaak naast PTSS voor en er bestaat 
een overlap wat betreft de symptomen. Vooral in het geval van de depressieve stoornis 
wordt er in de literatuur gediscussieerd over de interpretatie van de grote overlap van 
de symptomen. Op zijn minst een deel van de PTSS symptomen (emotionele verdoving, 
dysforie, slaapproblemen) lijkt sterk gerelateerd aan de symptomen van een depressieve 
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stoornis (Gros, Price, Magruder, & Frueh, 2012). Dat maakt het moeilijk om de PTSS 
symptomen als uniek voor PTSS te beschouwen en om PTSS symptomen te 
interpreteren zonder rekening te houden met eventuele stemmingsstoornissen. 
 
7.4 Aanbevelingen voor toekomstig onderzoek 
 
In deze paragraaf zal ik een aantal aanbevelingen voor toekomstig onderzoek 
beschrijven, gebaseerd op de bevindingen van het huidige onderzoek en de 
beperkingen ervan. Ten eerste, onze onderzoekspopulatie bestond uit patiënten die 
klinisch opgenomen waren omdat het belangrijk was om de patiënten te onderzoeken 
wanneer ze een periode abstinent waren. Het is echter een belangrijke volgende stap 
om de bevindingen te repliceren bij een populatie patiënten die ambulant in 
behandeling zijn, omdat het grootste gedeelte van de Nederlandse patiënten met 
middelenafhankelijkheid in ambulante behandeling is en dit waarschijnlijk een populatie 
is met minder ernstige symptomen op dat specifieke moment, vergeleken met patiënten 
die opgenomen zijn in een kliniek. We zijn er voor een deel in geslaagd om de 
resultaten te repliceren met de patiënten die ook onderzocht zijn tijdens de intake, maar 
omdat ze korte tijd later werden opgenomen impliceert dit mogelijk dat zij al in een fase 
zaten met ernstiger verslavingsproblemen. 
 Toekomstig onderzoek zal zich moeten richten op het gebruik van 
zelfrapportage vragenlijsten en het verbeteren ervan. Het is bijvoorbeeld interessant om 
te onderzoeken wat voor effect het heeft om een vraag over criterium A voor PTSS toe 
te voegen aan de ZIL. In het huidige onderzoek was de indruk dat patiënten geneigd 
waren om “nee” te antwoorden op een directe vraag over een traumatische 
gebeurtenis. Een mogelijke verklaring hiervoor is dat de vraag uit de MINI-plus alleen 
gaat over gebeurtenissen die te maken hebben met de dood of ernstige verwonding. 
Gebeurtenissen waarbij er sprake is van bedreiging van de lichamelijke integriteit, die 
wel onderdeel zijn van criterium A van PTSS in de DSM-IV, worden niet genoemd. Een 
andere verklaring zou kunnen zijn dat de vraag te lang is en daardoor niet goed wordt 
begrepen door patiënten. Tenslotte, het is mogelijk dat patiënten van sommige dingen 
die ze hebben meegemaakt niet het idee hebben dat dit “ernstig” was, omdat ze er 
mee hebben leren leven en het zijn gaan zien als een onderdeel van het leven. Het zal 
dus interessant zijn om te zien of de resultaten van de screener beter worden als 
criterium A wordt toegevoegd en wat de beste manier is om criterium A uit te vragen.  
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 Het zal ook interessant zijn om te onderzoeken welke specifieke symptomen, of 
welke items van de screeners (vooral de DASS), differentiëren tussen PTSS, 
stemmingsstoornissen, angststoornissen en intoxicatie –of ontwenningsklachten. Het is 
duidelijk dat tijdens het herstel van middelenafhankelijkheid symptomen van stress 
zowel kunnen toenemen als afnemen. Sommige items van de screeners zijn mogelijk 
gevoeliger voor deze factoren dan andere. Wanneer deze items kunnen worden 
geïdentificeerd, dan kunnen de psychometrische kwaliteiten van de screeners mogelijk 
verbeteren door deze items te verwijderen of aan te passen. 
 Binnen de geestelijke gezondheidszorg wordt het routinematig meten van 
behandeluitkomsten (ROM) steeds belangrijker. Het kan gebruikt worden om 
behandelingen te verbeteren door gebruik te maken van regelmatige feedback, terwijl 
de voortgang van de patiënt bijgehouden wordt. Voor dit doel is het efficiënt om korte 
vragenlijsten te gebruiken met een goede betrouwbaarheid en validiteit. In dit 
proefschrift heb ik de psychometrische kwaliteiten van een aantal korte screeners 
beschreven en sommigen zijn mogelijk bruikbaar als ROM instrument. Toekomstig 
onderzoek zal zich in deze context ook moeten richten op de DASS en de PRISM. 
Verder zullen er in toekomstig onderzoek ook andere uitkomstvariabelen meegenomen 
moeten worden dan verslavingsernst, zoals algemeen psychisch functioneren, sociaal 
functioneren en werkproblemen, omdat deze allemaal beïnvloed kunnen worden door 
een traumatische geschiedenis (Zlotnick, Franklin, & Zimmerman, 2002a). Deze 
variabelen kunnen ook gebruikt worden om de voortgang van de behandeling te 
volgen, want voor de ROM zouden niet alleen maar PTSS –of verslavingssymptomen 
moeten worden meegenomen. Zoals bleek uit hoofdstuk 5 laten deze symptomen niet 
altijd zien waar de ervaren lijdensdruk van patiënten ligt. Een veelbelovend instrument 
zoals de PRIM zal daarom ook als een mogelijk ROM instrument onderzocht moeten 
worden. 
 We hebben een onderzoeksprotocol voor een RCT beschreven om de 
werkzaamheid van Seeking Safety te onderzoeken in een Nederlandse populatie 
patiënten in ambulante behandeling. Wanneer het werkzaam blijkt, zal dit een 
belangrijke eerste stap zijn in de behandeling van patiënten met 
middelenafhankelijkheid en PTSS. Vervolgens zal echter nog bepaald moeten worden 
welke behandeling het best passend is voor welke specifieke patiënten. Voor sommige 
patiënten zal een op het heden gerichte behandeling onvoldoende zijn om op een 
acceptabel niveau van PTSS klachten te komen en is mogelijk toevoeging van een op 
het verleden gerichte behandeling (EMDR of Exposure) of medicatie nodig. Er zijn al een 
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aantal pogingen gedaan om deze behandelingen te integreren met veelbelovende 
resultaten (S. H. Brown, Gilman, Goodman, Adler-Tapia, & Freng, 2015; Hien et al., 
2015; Najavits et al., 2005). Toekomstig onderzoek zal voort moeten bouwen op deze 
onderzoeken en zal zich ook moeten richten op EMDR en medicamenteuze 
interventies. 
 
7.5 Klinische implicaties 
 
Onze resultaten laten zien dat de prevalentie van PTSS inderdaad hoog is bij patiënten 
met middelenafhankelijkheid en dat daar moet rekening mee worden gehouden. Het 
diagnosticeren van PTSS is erg belangrijk omdat het aanzienlijke implicaties kan hebben 
voor de behandeling wanneer een patiënt ook PTSS heeft (Mills et al., 2006; Ouimette, 
Finney, & Moos, 1999). Dansky et al. hebben al in de jaren ‘90 (Dansky & Roitzsch, 1997) 
en anderen recent (e.g., Gielen, Krumeich, Havermans, Smeets, & Jansen, 2014) laten 
zien dat veel behandelaren in de verslavingszorg de prevalentie van PTSS 
onderschatten en dat er onvoldoende expertise is op dat gebied. In de geestelijke 
gezondheidszorg laten behandelaren het vaak achterwege om middelenafhankelijkheid 
te onderzoeken en te behandelen. Omdat de prevalentie van PTSS wordt onderschat, 
wordt er vaak niet gedacht aan het uitvragen van trauma’s of PTSS. Het is ook mijn 
eigen indruk dat er in Nederland veel instellingen zijn waar weinig kennis is van 
specifieke behandelinterventies en dat geïntegreerde behandelingen niet worden 
geïmplementeerd vanwege een gebrek aan tijd, geld of bekwaamheid wat betreft 
implementatie. 
 Ons onderzoek heeft het nut laten zien van het gebruik van twee screeners 
voor PTSS: de ZIL en de DASS. Deze zijn beiden eenvoudig in gebruik en daardoor 
waarschijnlijk in veel verschillende settingen toepasbaar. Wat betreft screenen op PTSS 
in de verslavingszorg adviseren we het gebruik van de ZIL bij elke patiënt die zich 
aanmeldt voor behandeling, hoewel de DASS ook goed bruikbaar is. Allebei de 
instrumenten hebben ongeveer dezelfde sensitiviteit en specificiteit, vragen niet direct 
naar trauma’s en zijn ongeveer even lang. De uiteindelijke keuze voor welk instrument 
zal afhankelijk zijn van de beschikbare middelen en persoonlijke voorkeur. Het 
vaststellen van de ernst van de PTSS symptomen is waarschijnlijk voldoende om een 
snelle beslissing te kunnen maken om bepaalde vroege interventies in te zetten, zoals 
psychoeducatie en het trainen van copingvaardigheden om met PTSS symptomen om 
te gaan. Deze interventies kunnen een belangrijke rol spelen in het voorkomen van 
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vroegtijdige behandeluitval, wat van groot belang is in de behandeling van PTSS 
(Najavits, 2015). 
 Hoewel het een onderdeel is van “trauma-informed care” om al vroeg in de 
behandeling standaard te vragen naar trauma’s, zijn sommige patiënten terughoudend 
in het bespreekbaar maken van dit onderwerp vanwege gevoelens van schaamte en 
angst voor heftige emoties. Er kan daarom beter gekozen worden voor een snelle 
screening op PTSS symptomen dan een gedetailleerde beschrijving van de 
traumageschiedenis. Dit laatste is namelijk niet noodzakelijk voor het doorverwijzen van 
patiënten naar de eerdergenoemde behandelinterventies en het kost meer tijd om af te 
nemen. Helaas hebben we niet kunnen onderzoeken wat het effect van het moment 
van het uitvragen van trauma op behandeluitval of behandeluitkomsten was. Nadat 
screening heeft plaatsgevonden is het belangrijk om PTSS verder te onderzoeken om te 
bepalen of een patiënt aan de criteria voor PTSS voldoet en om eventuele andere DSM-
IV stoornissen te onderkennen. Dit is onder andere nodig omdat sommige 
behandelingsmogelijkheden niet beschikbaar zijn wanneer er geen formele DSM-IV 
diagnose gesteld is. Het diagnostisch onderzoek moet bestaan uit een onderzoek naar 
symptomen, gedachten, gevoelens en gedrag in combinatie met een gestructureerd 
interview. Voor ons onderzoek hebben we gekozen voor het KIP dat ook gevalideerd is 
voor gebruik in de klinische praktijk. Hoewel de afnametijd ruim een uur is, is het een 
waardevol meetinstrument voor een gestructureerde en betrouwbare classificatie van 
PTSS. In Nederland is er momenteel geen instrument beschikbaar dat voldoende 
gevalideerd is om het KIP voor dit doel te vervangen. Tijdens de diagnostische fase kan 
er een meer gedetailleerd overzicht worden gemaakt van de traumatische ervaringen 
van de patiënt met de Vragenlijst Belastende Ervaringen (VBE). Het voordeel van de VBE 
is dat het een uitgebreide lijst van mogelijk traumatische ervaringen bevat en een 
kwantitatieve maat van ervaren lijden door elk van de ervaringen. De VBE kan dan ook 
gebruikt worden als aanvulling op het KIP. 
 De resultaten van hoofdstuk 5 benadrukken het belang van een andere manier 
van kijken naar trauma gerelateerde problemen en hier aandacht voor te hebben. Het is 
opvallend dat patiënten met PTSS hun trauma gerelateerde problemen (TRP) als 
belangrijker ervaren (of dichter bij zichzelf) dan hun verslaving gerelateerde problemen 
(VRP). De focus van de behandeling zou daarom ter discussie moeten kunnen staan, 
mogelijk vanuit het idee van “Samen Beslissen” (Joosten, De Jong, De Weert-van Oene, 
Sensky, & Van der Staak, 2009), waarbij patiënt en behandelaar samen de 
behandelrichting vormgeven. Waar de focus van de behandeling op ligt, kan 
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gedurende de behandeling veranderen en kan daarom ook besproken worden. 
Misschien dat een patiënt na een periode van abstinentie de meeste lijdensdruk ervaart 
als gevolg van de TRP. Behandelaars moeten zich hier bewust van zijn en kunnen 
bijvoorbeeld gebruik maken van de PRISM als ondersteuning om te bepalen welke 
behandeldoelen op welk moment prioriteit hebben. Dit kan gedaan worden door de 
PRISM regelmatig af te nemen of op het moment wanneer de behandeling stagneert. 
 Onderzoeken naar de werkzaamheid van behandelinterventies worden in 
Nederland steeds moeilijker om uit te voeren vanwege afnemende financiële 
mogelijkheden en subsidies. Mogelijk ligt hier een kans voor een nauwere 
samenwerking met de reguliere geestelijke gezondheidszorg. Het plannen en uitvoeren 
van een goed opgezet onderzoek voor patiënten met comorbide stoornissen kan op 
die manier makkelijker en efficiënter worden. Wij hebben een onderzoeksprotocol voor 
een RCT beschreven om de werkzaamheid van Seeking Safety te onderzoeken 
vergeleken met een actieve ambulante verslavingsbehandeling. Voor zover we weten is 
deze onderzoeksopzet slechts een keer eerder gebruikt (Boden et al., 2012). De 
resultaten van de RCT zullen het mogelijk maken om op een gefundeerde manier 
keuzes te maken over de implementatie van Seeking Safety in Nederland. Desondanks 
zal het onderzoek naar geïntegreerde behandelingen voor PTSS voortgezet moeten 
worden omdat er ook steeds nieuwe behandelingen ontwikkeld worden die 
veelbelovende resultaten laten zien (Najavits & Johnson, 2014; Nosen, Littlefield, 
Schumacher, Stasiewicz, & Coffey, 2014; Torchalla et al., 2012). 
 Zoals al eerder is aangegeven (Najavits & Hien, 2013) is het ook van groot 
belang om aandacht te hebben voor de behandelaren die met deze groep complexe 
patiënten werken. In de komende jaren is de verwachting dat de nadruk in de 
verslavingszorg vanwege bezuinigingen steeds meer zal komen te liggen bij 
productiviteitscijfers en steeds minder bij tijd voor reflectie en multidisciplinair overleg. 
Daar komt bij dat zorgverzekeraars tegenwoordig van de verslavingszorg verwachten 
dat zij zich zo veel mogelijk op het middelengebruik richt en minder op de comorbide 
psychiatrische stoornissen omdat deze problemen in de reguliere GGZ zouden moeten 
worden behandeld. Feitelijk is dit een flinke stap terug en zal dit leiden tot een situatie 
die we kennen uit het verleden, namelijk dat patiënten heen en weer worden gestuurd 
tussen de verslavingszorg en de reguliere GGZ. Het voordeel van deze ontwikkeling is 
wel dat er in andere instellingen (reguliere GGZ) een kleine verandering wordt gezien 
waarbij de noodzaak voor expertise op het gebied van verslaving wordt onderkend en 
dat er een aantal initiatieven zijn om geïntegreerde behandelingen beschikbaar te 
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maken. Dus, ondanks de zorgelijke ontwikkelingen, zullen ze er op de lange termijn 
mogelijk toe leiden dat geïntegreerde behandelingen breder beschikbaar komen. Deze 
behandelingen zullen echter niet veel nut hebben wanneer een trauma niet onderkend 
wordt en patiënten dus niet zullen worden verwezen naar de juiste behandelingen. De 
eerste stap is altijd het onderkennen van het probleem, in dit geval de aanwezigheid 
van PTSS of een trauma. Het belang van goede screeners en diagnostische 
instrumenten mag niet worden onderschat.  
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